,PageNo,Text
0,page_1,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'NCT #NCT03920293', 'TITLE PAGE', 'Protocol Title:', 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled,', 'Multicenter Study to Evaluate the Safety and Efficacy of', 'Ravulizumab in Complement-Inhibitor-Na√Øv Adult Patients', 'With Generalized Myasthenia Gravis', 'Protocol Number:', 'ALXN1210-MG-306', 'Compound Number:', 'ALXN1210', 'USAN/INN:', 'Ravulizumab', 'Amendment Number:', '2', 'Short Title:', 'Safety and Efficacy Study of Ravulizumab in Adults With', 'Generalized Myasthenia Gravis', 'Sponsor Name', 'Alexion Pharmaceuticals, Inc. (Alexion)', 'Legal Registered', '121 Seaport Boulevard', 'Address:', 'Boston, MA 02210', 'USA', 'Regulatory Agency', 'IND: 140,115', 'Identifying Number:', 'EUDRACT: 2018-003243-39', 'Approval Date:', '25 Oct 2019', 'Page 1 of 109', 'Alexion Confidential']"
1,page_2,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Sponsor Signatory:', 'PPD', '10/28/2019', 'Date', 'Medical Monitor Name and Contact Information can be found in the Study Contact list', 'distributed to Study Sites.', '24-hour Emergency Contact:', 'PPD', 'Page 2 of 109', 'Alexion Confidential']"
2,page_3,"['Protocol', 'ALXN1210-MG-306 Amendment 2', ""INVESTIGATOR'S AGREEMENT"", 'I have read the ALXN1210-MG-306 study protocol and agree to conduct the study in accordance', 'with this protocol, all applicable government regulations, the principles of the ICH E6', 'Guidelines for Good Clinical Practice, and the principles of the World Medical Association', 'Declaration of Helsinki. I also agree to maintain the confidentiality of all information received or', 'developed in connection with this protocol.', 'Printed Name of Investigator', 'Signature of Investigator', 'Date', 'Page 3 of 109', 'Alexion Confidential']"
3,page_4,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 2', '25 Oct 2019', 'Amendment 1.2 (France)', '14 Oct 2019', 'Amendment 1.1 (Germany)', '27 Jun 2019', 'Amendment 1', '11 Dec 2018', 'Original Protocol', '16 Nov 2018', 'Amendment 2 (25 Oct 2019)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment', 'To revise secondary and exploratory endpoints, to decrease burden to patients by reduction in', 'assessment and visit frequency, to provide additional guidance for supplemental dosing, and to', 'clarify minor operational aspects of the protocol.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Title page', 'Updated legal registered address.', 'Sponsor Signatory', ""Removed sponsor signatory's personal contact"", 'Contact information is', 'information.', 'provided in the study contact', 'list provided to sites.', 'Section 1.1 and Section 3', 'Moved change from baseline in MG-QOL15r', 'To better characterize disease', 'Objectives and Endpoints', 'and Neuro-QOL Fatigue scores and MG-ADL', 'parameters associated with', 'and QMG responder from exploratory to', 'gMG and yield a clearer', 'secondary endpoints. PK/PD/ADA endpoints', 'assessment of the impact of', 'moved from under exploratory to new', 'study intervention.', 'independent subheading. Expanded', 'exploratory endpoints to include change from', 'baseline in MG-ADL and QMG', 'subcomponent scores as well as incidence of', 'hospitalizations/MG-related hospitalizations', 'and Clinical Deterioration/MG crisis. Clarified', 'that endpoints will be evaluated throughout', 'study.', 'Section 1.3 Schedule of', 'Removed evaluation of Myasthenia Gravis', 'Post-intervention status', 'Activities', 'Foundation of America-Post-Interventional', 'cannot be evaluated before', 'Status (MGFAPIS) on Day 1.', 'patients receive study', 'intervention.', 'Added serum pregnancy test at Day 183/ET.', 'To ensure patient safety.', 'Removed visits at Weeks 3, 8, 14, 22, and 40;', 'To reduce burden on patient.', 'reduced number of visits at which MG-', 'QOL15r, Neuro-QOL Fatigue, and EQ-5D-5L', 'are collected, including removal from Clinical', 'Deterioration visits; expanded visit window', 'and reduced/moved PK/Free C5 and ADA', 'collections during extension.', 'Page 4 of 109', 'Alexion Confidential']"
4,page_5,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Added body weight collection at all visits.', 'Needed to ensure that proper', 'dosage is administered.', 'Revised footnotes to specify data collected for', 'Clarifications', 'MG history and C-SSRS, assessments needed', 'at Clinical Deterioration visits, and', 'requirement for Properly Trained Clinical', 'Evaluator to perform QMC and MGC', 'assessments.', 'Section 2.3 Study Rationale', 'Added approval of eculizumab for the', 'Update.', 'treatment of neuromyelitis optica spectrum', 'disorder.', 'Section 4.1.1 Screening Period', 'Clarified MG history data collection,', 'To enable assessment of pre-', 'including 2-year hospitalization history.', 'study hospitalizations.', 'Removed incorrect statement about retaining a', 'Correction.', 'patient who experiences Clinical', 'Deterioration/MG crisis during the Screening', 'Period (inconsistent with Section 5.4).', 'Section 4.2.4 Responsibilities', 'Noted that MG-ADL must be performed first,', 'Clarification.', 'for Myasthenia Gravis', 'QMG second.', 'Assessments', 'Section 4.4 Justification for', 'Revised to reflect that the ravulizumab dosing', 'To inform on labeled dosing', 'Dose', 'regimen used in this study is approved for', 'recommendation.', 'adult patients with PNH.', 'Section 5.1 Inclusion Criteria', 'Revised IC#2 and IC#3 to clarify that MG', 'To further clarify entry', 'diagnosis must occur at least 6 months prior to', 'criteria for the investigator.', 'screening, and that eligibility is confirmed by', 'positive anti-AChR Ab test result at screening', 'and by abnormal neuromuscular transmission', 'test and/or improvement in MG signs with', 'oral cholinesterase inhibitor treatment either', 'historically or during screening.', 'Section 5.2 Exclusion Criteria', 'Revised EC#1 to permit treated patients with', 'To clarify entry criteria for', 'stage 1 or 2 thymoma other than thymic', 'patients with thymoma.', 'carcinoma and EC#2 to exclude', 'thymomectomy or any thymic surgery.', 'Added 3 new exclusion criteria for history of', 'To exclude enrollment of', 'unexplained infections, active infections', 'patients with active systemic', 'within 14 days of study drug administration,', 'infections.', 'or fever within 7 days of study drug', 'administration.', 'Section 6.1 Study Drug', 'Added instruction for action to be taken if a', 'Clarification.', 'Administration', ""patient's body weight drops below 40 kg"", 'during treatment.', 'Section 6.4 Concomitant', 'Added that MG-specific medication or therapy', 'Clarification regarding data', 'Therapy', '(eg, thymectomy, ISTs including', 'collection.', 'corticosteroids, IVIg, and PE/PP) within 2', 'years prior to screening will be recorded.', 'Page 5 of 109', 'Alexion Confidential']"
5,page_6,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 6.5.1.4 PE/PP/IVIg', 'In Table 7 and Table 8, applicable', 'To clarify timing of', 'supplemental dosing day range has been', 'supplemental dosing and to', 'added, and doses and corresponding diluent', 'maintain blind on Day 183.', 'and total volumes have been corrected in the', 'Placebo group Open Label Extension', 'associated with the Blinded ravulizumab', 'loading dose administered on Day 183. Details', 'in text on supplemental dose timing.', 'Section 6.5.1.5 Disallowed', 'Added chronic PE/PP and IVIg therapies.', 'To clarify that only acute', 'Medications and Therapies', 'treatment is permitted.', 'Section 8.1.1 Hospitalization', 'Reduced information to be collected to', 'To reduce burden on patients.', 'include only that required for meaningful', 'assessment.', 'Section 8.1.2 Clinical', 'Replaced text description of PK/PD sampling', 'Clarification. Specific order', 'Deterioration', 'during Clinical Deterioration with a figure that', 'of procedures is not required.', 'provides instructions more clearly. Changed', 'numbering to bullets.', 'Section 8.1.9 MGFA Clinical', 'Added new section describing Day 1', 'Correction.', 'Classification', 'assessment of MGFA Clinical Classification.', 'Section 8.1.10 MGFA Post-', 'Noted that modified version of MGFA-PIS', 'Clarification.', 'Intervention Status', 'does not include categories of Exacerbation or', 'Died of MG.', 'Section 8.2.3', 'Indicated that QT interval will be corrected for', 'Clarification.', 'Electrocardiogram', ""heart rate using Fridericia's formula."", 'Section 8.2.4.1 Urinalysis and', 'Removed statement regarding', 'Correction.', 'Urine Chemistry', 'protein:creatinine ratio, which will not be', 'performed in this study.', 'Section 8.2.5.1 Columbia-', 'Added timepoints (lifetime and past 1 year [12', 'To provide specific time', 'Suicidal Severity Rating Scale', 'months]) for assessing suicidal ideation and', 'points for data collection that', 'behaviors', 'have been implemented in the', 'eCRF.', 'Section 8.3.1 Time Period and', 'All adverse events that occur after the', 'To ensure appropriate', 'Frequency for Collecting', 'informed consent form (ICF) is signed must', 'collection of pretreatment', 'Adverse Event and Serious', 'be recorded in the adverse event case report', 'adverse events.', 'Adverse Event Information', 'form, not in the medical history form.', 'Section 8.8 Biomarkers', 'Noted that unused PK/PD/ADA/AChR', 'To allow for future studies to', 'samples may be stored for future biomarker', 'understand drug/disease', 'research.', 'mechanisms.', 'Section 8.9 Healthcare', 'Data collected will be the type of facility', 'To reduce data collection to', 'Resource Utilization', '(hospital, rehabilitation center, or hospice),', 'only those elements needed', 'whether the primary reason for admission was', 'for analysis.', 'related to MG, and the duration of', 'hospitalization.', 'Section 9 Statistical', 'Added description of plans for CSR', 'Clarification.', 'Considerations', 'preparation.', 'Section 9.1 Statistical', 'Re-ordered secondary and exploratory', 'To better characterize disease', 'Hypotheses', 'hypotheses and estimation of treatment effect', 'parameters associated with', 'to align with changes made in Section 1.1 and', 'gMG and yield a clearer', 'Section 3 Objectives and Endpoints.', 'assessment of the impact of', 'study intervention.', 'Section 9.4.5.4 Multiplicity', 'Added description of secondary hypothesis', 'To inform on statistical', 'Adjustment for Primary and', 'testing.', 'methods.', 'Secondary Endpoints', 'Page 6 of 109', 'Alexion Confidential']"
6,page_7,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9.4.6.4 Analysis of PK', 'Revised description of analyses to be', 'To inform on statistical', 'and PD', 'performed.', 'methods.', 'Section 10.1.3 Data Protection', 'Described storage of anonymized data.', 'To inform on data protection.', 'Section 10.2 Appendix 2:', 'Deleted creatinine and added leukocyte', 'Correction.', 'Clinical Laboratory Tests', 'esterase, ADA, and AChR Ab.', 'Section 10.8 Appendix 8', 'Replaced with updated image.', 'Correction.', 'Myasthenia Gravis Composite', 'Scale', 'Section 10.11 Appendix 11:', 'The last 3 questions of the Neurology Quality', 'Page 2 of the sample', 'Neurology Quality of Life', 'of Life Fatigue questionnaire were added to', 'document was missing in', 'Fatigue', 'Appendix 11.', 'prior versions of the protocol.', 'Section 10.12 Appendix 12:', 'MGFA clinical classification is added as', 'In this trial, MGFA', 'Myasthenia Gravis Foundation', 'Appendix 12.', 'classification is utilized to', 'of America Clinical', 'assess the MG clinical state', 'Classification', 'of patients. It was missing in', 'prior versions of the protocol.', 'Section 10.16 Appendix 16:', 'Expanded description of sample size', 'To inform on statistical', 'Statistical Considerations', 'determination.', 'methods.', 'Page 7 of 109', 'Alexion Confidential']"
7,page_8,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', ""INVESTIGATOR'S AGREEMENT"", '3', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '4', 'TABLE OF CONTENTS', '8', '1.', 'PROTOCOL SUMMARY', '15', '1.1.', 'Synopsis', '15', '1.2.', 'Schema', '19', '1.3.', 'Schedule of Activities', '20', '2.', 'INTRODUCTION', '26', '2.1.', 'Generalized Myasthenia Gravis', '26', '2.2.', 'Background', '26', '2.2.1.', 'Unmet Medical Need in Patients With Generalized Myasthenia Gravis', '26', '2.2.2.', 'Role of Complement in Myasthenia Gravis', '26', '2.3.', 'Study Rationale', '27', '2.4.', 'Benefit/Risk Assessment', '28', '2.4.1.', 'Identified and Potential Risks', '28', '2.4.1.1.', 'Identified Risk', '28', '2.4.1.2.', 'Potential Risks', '28', '3.', 'OBJECTIVES AND ENDPOINTS', '30', '4.', 'STUDY DESIGN', '31', '4.1.', 'Overall Design', '31', '4.1.1.', 'Screening Period (2 - 4 Weeks Prior to Day 1)', '32', '4.1.2.', 'Randomization', '32', '4.1.3.', 'Randomized Controlled Period (26 Weeks)', '32', '4.1.4.', 'Open-Label Extension Period', '33', '4.2.', 'Standard Protocol Definitions', '33', '4.2.1.', 'Clinical Deterioration', '33', '4.2.2.', 'Unscheduled Visits', '33', '4.2.3.', 'Properly Trained Clinical Evaluator', '33', '4.2.4.', 'Responsibilities for Myasthenia Gravis Assessments', '34', '4.3.', 'Scientific Rationale for Study Design', '34', 'Page 8 of 109', 'Alexion Confidential']"
8,page_9,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.4.', 'Justification for Dose', '35', '4.5.', 'End of Study Definition', '36', '5.', 'STUDY POPULATION', '37', '5.1.', 'Inclusion Criteria', '37', '5.2.', 'Exclusion Criteria', '38', '5.3.', 'Lifestyle Considerations', '39', '5.4.', 'Screen Failures', '39', '6.', 'STUDY DRUG', '40', '6.1.', 'Study Drugs Administered', '40', '6.2.', 'Preparation/Handling/Storage/Accountability.', '42', '6.2.1.', 'Study Drug Preparation', '42', '6.2.2.', 'Storage', '42', '6.2.3.', 'Packaging and Labeling', '43', '6.2.4.', 'Accountability', '43', '6.2.5.', 'Handling and Disposal', '43', '6.3.', 'Measures to Minimize Bias: Randomization and Blinding', '44', '6.3.1.', 'Randomization', '44', '6.3.2.', 'Blinding', '44', '6.4.', 'Concomitant Therapy', '45', '6.5.', 'Study Drug Compliance', '45', '6.5.1.', 'Allowed Medications', '45', '6.5.1.1.', 'Palliative and Supportive Care', '45', '6.5.1.2.', 'Cholinesterase Inhibitors', '45', '6.5.1.3.', 'Immunosuppressive Agents', '46', '6.5.1.4.', 'Plasma Exchange/Plasmapheresis/Intravenous Immunoglobulin', '46', '6.5.1.5.', 'Disallowed Medications and Therapies', '49', '6.5.2.', 'Rescue Therapy', '49', '6.6.', 'Intervention After the End of the Study', '49', '7.', 'DISCONTINUATION OF STUDY INTERVENTION AND PATIENT', 'DISCONTINUATION/WITHDRAWAL', '50', '7.1.', 'Discontinuation of Study Intervention', '50', '7.2.', 'Lost to Follow Up', '50', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', '52', 'Page 9 of 109', 'Alexion Confidential']"
9,page_10,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.1.', 'Efficacy Assessments', '52', '8.1.1.', 'Hospitalization', '52', '8.1.2.', 'Clinical Deterioration', '52', '8.1.3.', 'Myasthenia Gravis Activities of Daily Living Profile', '54', '8.1.4.', 'Quantitative Myasthenia Gravis Score', '54', '8.1.5.', 'Myasthenia Gravis Composite Score', '54', '8.1.6.', 'Euro Quality of Life 5D-5L', '54', '8.1.7.', 'Revised Myasthenia Gravis Qualify of Life-15 Scale', '54', '8.1.8.', 'Neurological Quality of Life Fatigue', '55', '8.1.9.', 'Myasthenia Gravis Foundation of America Clinical Classification', '55', '8.1.10.', 'Myasthenia Gravis Foundation of America Post-Intervention Status', '55', '8.2.', 'Safety Assessments', '55', '8.2.1.', 'Physical Examination', '55', '8.2.2.', 'Vital Signs and Pulse Oximetry', '55', '8.2.3.', 'Electrocardiogram', '55', '8.2.4.', 'Clinical Safety Laboratory Assessments', '56', '8.2.4.1.', 'Urinalysis and Urine Chemistry', '56', '8.2.4.2.', 'Virus Serology', '56', '8.2.4.3.', 'Immunogenicity Assessments', '56', '8.2.5.', 'Suicidal Risk Monitoring', '56', '8.2.5.1.', 'Columbia-Suicidal Severity Rating Scale', '56', '8.3.', 'Adverse Events and Serious Adverse Events', '57', '8.3.1.', 'Time Period and Frequency for Collecting Adverse Event and Serious', 'Adverse Event Information', '57', '8.3.2.', 'Method of Detecting Adverse Events and Serious Adverse Events', '57', '8.3.3.', 'Follow-up of Adverse Events and Serious Adverse Events', '57', '8.3.4.', 'Regulatory Reporting Requirements for Serious Adverse Events', '58', '8.3.5.', 'Pregnancy', '58', '8.3.6.', 'Vaccine and Antibiotic Prophylaxis', '58', '8.3.7.', 'Study Drug Administration Reactions', '59', '8.3.7.1.', 'Local and Systemic Reactions', '59', '8.3.7.2.', 'Infusion-Associated Reactions', '59', '8.4.', 'Adverse Events of Special Interest', '59', 'Page 10 of 109', 'Alexion Confidential']"
10,page_11,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.5.', 'Pharmacokinetics', '59', '8.6.', 'Pharmacodynamics', '60', '8.7.', 'Genetics', '60', '8.8.', 'Biomarkers', '60', '8.9.', 'Healthcare Resource Utilization', '60', '9.', 'STATISTICAL CONSIDERATIONS', '61', '9.1.', 'Statistical Hypotheses', '61', '9.1.1.', 'Primary Hypothesis', '61', '9.1.2.', 'Secondary Hypotheses', '61', '9.1.3.', 'Hypotheses Related to Exploratory Efficacy Objectives', '62', '9.1.4.', 'Estimation of Treatment Effect for Secondary and Exploratory Hypotheses', '62', '9.2.', 'Sample Size Determination', '63', '9.3.', 'Populations for Analyses', '63', '9.4.', 'Statistical Analyses', '63', '9.4.1.', 'Enrollment and Disposition', '63', '9.4.2.', 'Demographics, Baseline Characteristics, Inclusion and Exclusion Criteria,', 'and Protocol Deviations', '64', '9.4.3.', 'Medical/Surgical History, Physical Examination, and Myasthenia Gravis', 'History', '64', '9.4.4.', 'Prior and Concomitant Medications', '64', '9.4.5.', 'Efficacy Analyses', '64', '9.4.5.1.', 'Primary Efficacy Analysis', '64', '9.4.5.2.', 'Sensitivity Analyses for Primary Endpoint', '65', '9.4.5.3.', 'Analyses of Secondary and Exploratory Endpoints', '65', '9.4.5.4.', 'Multiplicity Adjustment for Primary and Secondary Endpoints', '65', '9.4.5.5.', 'Per Protocol Analyses for Primary and Secondary Endpoints', '66', '9.4.6.', 'Safety Analyses', '66', '9.4.6.1.', 'Analysis of Adverse Events', '66', '9.4.6.2.', 'Analysis of Clinical Laboratory Parameters, Vital Sign Measurements and', 'Electrocardiogram Parameters', '66', '9.4.6.3.', 'Other Safety Analyses', '66', '9.4.6.4.', 'Analysis of Pharmacokinetics and Pharmacodynamics', '66', '9.4.6.5.', 'Analysis of Immunogenicity', '67', 'Page 11 of 109', 'Alexion Confidential']"
11,page_12,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '9.4.6.6.', 'Analysis of Exploratory Biomarkers', '67', '9.5.', 'Interim Analyses', '67', '9.6.', 'Data Monitoring Committee', '67', '10.', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '68', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '68', '10.1.1.', 'Regulatory and Ethical Considerations', '68', '10.1.2.', 'Informed Consent Process', '68', '10.1.3.', 'Data Protection', '69', '10.1.4.', 'Dissemination of Clinical Study Data', '69', '10.1.5.', 'Data Quality Assurance', '69', '10.1.6.', 'Source Documents', '70', '10.1.7.', 'Study and Site Closure', '70', '10.1.8.', 'Publication Policy', '71', '10.2.', 'Appendix 2: Clinical Laboratory Tests', '72', '10.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '73', '10.3.1.', 'Adverse Event', '73', '10.3.2.', 'Serious Adverse Event', '74', '10.3.3.', 'Suspected Unexpected Serious Adverse Reactions', '74', '10.3.4.', 'Recording and Follow-Up of Adverse Event and/or Serious Adverse Event', '75', '10.3.5.', 'Reporting of Serious Adverse Events', '76', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '78', '10.4.1.', 'Contraception Guidance', '78', '10.4.2.', 'Pregnancy Testing', '78', '10.4.3.', 'Collection and Reporting of Pregnancy Information', '79', '10.5.', 'Appendix 5: Management of Potential Infusion-Associated Adverse Events', 'During Study Drug Administration', '80', '10.6.', 'Appendix 6: Myasthenia Gravis Activities of Daily Living Profile', '82', '10.7.', 'Appendix 7: Quantitative Myasthenia Gravis Score for Disease Severity', '83', '10.8.', 'Appendix 8: Myasthenia Gravis Composite Scale', '84', '10.9.', 'Appendix 9: Euro Quality of Life Questionnaire', '85', '10.10.', 'Appendix 10: Myasthenia Gravis Quality-of-Life 15r Scale', '88', 'Page 12 of 109', 'Alexion Confidential']"
12,page_13,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.11.', 'Appendix 11: Neurology Quality of Life Fatigue', '89', '10.12.', 'Appendix 12: Myasthenia Gravis Foundation of America Clinical', 'Classification', '91', '10.13.', 'Appendix 13: Myasthenia Gravis Foundation of America Post-Interventional', 'Status', '92', '10.14.', 'Appendix 14: Columbia-Suicide Severity Rating Scale - Baseline/Screening', '(Version 1/14/09)', '93', '10.15.', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last Visit', '(Version 1/14/09)', '96', '10.16.', 'Appendix 16: Statistical Considerations', '99', '10.16.1.', 'Additional Details on Sample Size Determination', '99', '10.16.2.', 'Additional Details on Sensitivity Analysis for Primary Endpoint', '99', '10.16.2.1. Placebo-based Sensitivity Analysis', '99', '10.16.2.2. Tipping Point Sensitivity Analysis', '99', '10.17.', 'Appendix 17: Abbreviations', '101', '10.18.', 'Appendix 18: Protocol Amendment History', '104', '11.', 'REFERENCES', '107', 'LIST OF TABLES', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-', 'Controlled Period', '20', 'Table 2:', 'Schedule of Activities: Extension Period', '23', 'Table 3:', 'Myasthenia Gravis Assessments and Responsibilities', '34', 'Table 4:', 'Ravulizumab Weight-Based Dosing', '35', 'Table 5:', 'Study Drug Administered', '40', 'Table 6:', 'Reference Chart for Weight-Based Dosing', '41', 'Table 7:', 'Supplemental Dose When Plasmapheresis/Plasma Exchange is Administered', 'as Rescue Therapy on Nonscheduled Dosing Visits', '47', 'Table 8:', 'Supplemental Dose When Intravenous Immunoglobulin is Administered as', 'Rescue Therapy on Nonscheduled Dosing Visits', '48', 'Table 9:', 'Study ALXN1210-MG-306: Analysis Sets', '63', 'Table 10: Protocol-Required Safety Laboratory Assessments', '72', 'Table 11: List of Abbreviations and Definitions of Terms', '101', 'Page 13 of 109', 'Alexion Confidential']"
13,page_14,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'LIST OF FIGURES', 'Figure 1: Ravulizumab Every 8 Weeks Dosage Regimen Versus Eculizumab Every', '2 Weeks Dosage Regimen', '28', 'Figure 2: PK/PD/ADA Sampling for Clinical Deterioration', '53', 'Page 14 of 109', 'Alexion Confidential']"
14,page_15,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.', 'PROTOCOL SUMMARY', '1.1.', 'Synopsis', 'Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study', 'to Evaluate the Safety and Efficacy of Ravulizumab in', 'Complement-Inhibitor-Na√Øve Adult Patients With Generalized Myasthenia', 'Gravis', 'Short Title: Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia', 'Gravis', 'Rationale: Ravulizumab (ALXN1210) was engineered from eculizumab (h5G1.1-mAb)', 'humanized monoclonal antibody that specifically binds with high affinity to the human terminal', 'complement component (C5), inhibiting C5 enzymatic cleavage and thereby preventing the', 'generation of the proinflammatory/prothrombotic complement activation products, C5a, and the', 'cytolytic and proinflammatory/prothrombotic membrane attack complex, C5b-9, which are', 'responsible for the antibody-mediated destruction of the neuromuscular junction (NMJ), loss of', 'acetylcholine receptors, and failure of neuromuscular transmission associated with generalized', 'myasthenia gravis (gMG). Eculizumab is approved for the treatment of gMG, paroxysmal', 'nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome in many countries', 'worldwide, including Japan, the USA, and countries in the European Union under the trade name', 'Soliris', 'Ravulizumab preserves immediate and complete C5 inhibition while providing sustained', 'complement inhibition throughout a prolonged dosing interval; it was specifically designed (and', 'has subsequently been proven) to have an increased half-life relative to eculizumab. Therefore,', 'ravulizumab requires less frequent (once every 8 weeks [q8w]) infusions than eculizumab (once', 'every 2 weeks [q2w] infusions). Given that gMG is a chronic disease with a significant treatment', 'burden, the relative convenience of the ravulizumab dosing regimen may increase patient', 'satisfaction and treatment adherence, and ultimately, lead to improved health outcomes.', 'Ravulizumab was designed based on comprehensive modelling and simulation analyses to', 'maintain efficacious concentrations across an extended dosing interval. The enhanced', 'pharmacokinetic (PK)/pharmacodynamic profile of ravulizumab, with fewer PK troughs than', 'eculizumab, has the potential to improve therapeutic efficacy while maintaining a safety profile', 'similar to that of eculizumab. Furthermore, the q8w dosing regimen minimizes the risk of', 'incomplete complement inhibition.', 'Page 15 of 109', 'Alexion Confidential']"
15,page_16,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Study ALXN1210-MG-306 Objectives and Enppoints', 'Objectives', 'Enppoints', 'Primary', 'To assess the efficacy of ravulizumab compared with', 'Change from Baseline in MG-ADL total score at', 'placebo in the treatment of gMG based on the', 'Week 26 of the Randomized-Controlled Period.', 'improvement in the Myasthenia Gravis-Activities of', 'Daily Living (MG-ADL) profile.', 'Secondary', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in QMG total score at', 'with placebo in the treatment of gMG based on', 'Week 26.', 'the improvement in the Quantitative Myasthenia', 'Gravis (QMG) total score.', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in the Revised', 'with placebo in the treatment of gMG based on', '15-Component Myasthenia Gravis Quality of Life', 'the improvement in quality of life measures.', '(MG-QOL15r) score at Week 26.', 'Change from Baseline in Neuro-QOL Fatigue', 'score at Week 26.', 'To assess the efficacy of ravulizumab compared', 'Improvement of at least 3 points in the MG-ADL', 'with placebo in the treatment of gMG based on', 'total score from Baseline at Week 26.', 'other efficacy endpoints.', 'Improvement of at least 5 points in the QMG total', 'score from Baseline at Week 26.', 'Exploratory', 'To assess the efficacy of ravulizumab in the', 'Change from Baseline in the Myasthenia Gravis', 'treatment of gMG based on other efficacy', 'Composite (MGC) score at Week 26.', 'endpoints throughout the study.', 'Myasthenia Gravis Foundation of America', '(MGFA) Post-Intervention Status (PIS) at', 'Week 26.', 'Change from Baseline in Euro Quality of Life', '(EQ-5D-5L) at Week 26.', 'Change from baseline in MG-ADL subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Change from baseline in QMG subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Incidence of hospitalizations/MG-related', 'hospitalizations.', 'Incidence of Clinical Deterioration/MG crisis.', 'PK/PD/Immunogenicity', 'To evaluate the PK/PD and immunogenicity of', 'Change in serum ravulizumab concentration over', 'ravulizumab in the treatment of gMG throughout', 'time.', 'the study.', 'Change in serum free C5 concentration over time.', 'Incidence of treatment-emergent antidrug', 'antibodies over time.', 'Safety', 'To characterize the overall safety of ravulizumab in', 'Incidence of adverse events and serious adverse', 'the treatment of gMG.', 'events over time.', 'Changes from Baseline in vital signs and', 'laboratory assessments.', 'The above endpoints will be evaluated over time throughout the study.', 'Page 16 of 109', 'Alexion Confidential']"
16,page_17,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Overall Design:', 'This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter', 'study to evaluate the safety and efficacy of ravulizumab for the treatment of patients with gMG.', 'Approximately 160 eligible patients will be stratified by region (North America, Europe,', 'Asia-Pacific, and Japan) and randomized 1:1 to 1 of 2 treatment groups: (1) ravulizumab', 'infusion or (2) placebo infusion. There will be 3 periods in this study: Screening Period,', 'Randomized-Controlled Period, and an Open-Label Extension (OLE) Period.', 'Eight weeks after the final dose of study drug is administered, all enrolled patients will return for', 'an End of Study (EOS) Visit (Visit 25) at Week 132, during which final study assessments will', 'be conducted. If a patient withdraws from the study or completes the study early because', 'ravulizumab has become registered or approved (in accordance with country-specific', 'regulations) prior to Visit 24, the patient will be encouraged to return for an Early Termination', 'Visit, 8 weeks after the last dose of study drug was administered, during which final planned', 'safety assessments will be conducted. Attempts should be made to follow all patients for safety', ""for 8 weeks following the patient's last dose of study drug."", 'Patients being treated with an immunosuppressive therapy (IST) at the time of the Screening', 'Visit may continue to receive ISTs throughout the Randomized-Controlled and OLE Periods.', 'However, the dosage of IST must not be changed and no new ISTs may be added during the', 'Randomized-Controlled Period of the study, unless deemed by the Investigator to be medically', 'necessary.', 'Throughout the study, rescue therapy (eg, high-dose corticosteroids, plasmapheresis/plasma', 'exchange, or intravenous immunoglobulin) will be allowed if a patient experiences Clinical', 'Deterioration, as defined by the study protocol. The rescue therapy used for a particular patient', 'will be at the discretion of the Investigator.', 'The primary endpoint for this study will be measured at Week 26. Endpoints will be measured', 'and analyzed irrespective of rescue therapy. For those patients who complete the study, as', ""defined in the protocol, the EOS Visit is defined as patient's last visit in the (up to) 2-year OLE"", ""Period. Including the 8-week safety follow-up, which begins after the patient's last dose of study"", 'drug is administered, the overall study-duration for an individual patient is estimated to take up', 'to 132 weeks (from enrollment through the end of the Safety Follow-up). The period of active', 'patient-participation is estimated to take up to 132 weeks (from enrollment through the EOS', 'Visit).', 'Number of Patients:', 'Patients will be screened until enough patients have been enrolled to achieve an estimated total', 'of 160 patients, with approximately 80 patients per group.', 'Intervention Groups and Duration:', 'At the time of randomization, all patients will be reassessed for eligibility based on the study', 'inclusion and exclusion criteria. All patients who meet the inclusion criteria and none of the', 'exclusion criteria, have been vaccinated against Neisseria meningitidis, within the timeframe', 'specified in the inclusion criteria, and have been cleared for randomization by the Investigator', 'will be randomized 1:1 to 1 of 2 treatment groups: (1) ravulizumab infusion or (2) placebo', 'Page 17 of 109', 'Alexion Confidential']"
17,page_18,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'infusion. Patients will be centrally randomized using interactive response technology. The', 'randomization will be stratified by region (North America, Europe, Asia-Pacific, and Japan).', 'Patients randomized to the ravulizumab group will receive a blinded loading dose of', 'ravulizumab on Day 1, followed by blinded maintenance doses of ravulizumab on Day 15', '(Week 2) and q8w thereafter, for a total of 18 weeks of treatment. Patients randomized to', 'placebo will receive a blinded dose of placebo on Day 1, followed by blinded doses of placebo', 'on Day 15 (Week 2) and q8w thereafter, for a total of 18 weeks. Both ravulizumab and placebo', 'will be administered by intravenous infusion.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'dose at Week 28 (Day 197). Starting at Week 28, all patients will begin open-label ravulizumab', 'maintenance doses q8w.', 'The OLE Period for each patient will commence when the patient receives a dose of ravulizumab', 'on Week 26 (Day 183) and will continue for up to 2 years or until the product is registered or', 'approved (in accordance with country-specific regulations), whichever occurs first.', 'Data Monitoring Committee: No.', 'Page 18 of 109', 'Alexion Confidential']"
18,page_19,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.2.', 'Schema', 'Study ALXN1210-MG-306 Schematic', 'Screening', 'Randomized-Controlled Period', 'Open-Label Extension Period', '(up to 4 weeks)', '(26 weeks)', '(up to 2 years)', 'Ravulizumab IV¬π (N=80)', 'Meningococcal', 'vaccination required', 'Receiving standard of care2', 'for all patients prior', 'No previous treatment with a', 'to administration of', 'complement-inhibitor', 'study drug', 'Placebo IV(N=80)', '1 Ravulizumab dosage regimen:', 'LOADING DOSE (Day 1) =', '2400 mg for patients weighing 40 kg to < 60 kg', '2700 mg for patients weighing > 60 kg to < 100 kg', '3000 mg for patients weighing > 100 kg', 'MAINTENANCE DOSE (Day 15 and every 8 weeks [q8w] thereafter) =', '3000 mg for patients weighing > 40 kg to < 60 kg', '3300 mg for patients weighing > 60 kg to < 100 kg', '3600 mg for patients weighing > 100 kg', '2', 'Standard of care treatment to remain stable throughout the Randomized-Controlled Period', 'Abbreviations: IV = intravenous; N = number [of patients]', 'Page 19 of 109', 'Alexion Confidential']"
19,page_20,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.3.', 'Schedule of Activities', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period', 'Clinical', 'Period/Phase', 'Screening', 'Randomized-Controlled Period', 'Deterioration', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET2', 'Study Day', 'D1', 'D8', 'D15', 'D29', 'D71', 'D85', 'D127', 'D183', 'Window (day)', '2', ' 2', ' 2', ' 2', ' 2', '2', '+2', 'Weeks', '-4 to -2 W', 'W1', 'W2', 'W4', 'W10', 'W12', 'W18', 'W26', 'Informed Consent', 'X', 'Assessment of Inclusion/', 'X', 'X', 'Exclusion Criteria', 'Medical History', 'X', 'MG History¬≥', 'X', 'MGFA Clinical Classification4', 'X', 'X', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Height', 'X', 'HIV-(1 and 2) testing', 'X', 'Vital Signs & Pulse Oximetry5', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical Examination', 'X', 'X', 'X', 'Abbreviated Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Examination6', 'Concomitant Medication', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Non-Drug Therapy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG Therapy Status', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hospitalization Status', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Adverse Event', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG-ADL4,7', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'QMG4,8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG-QOL15r', 'X', 'X', 'X', 'X', 'X', 'X', 'Neuro-QOL Fatigue', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5L', 'X', 'X', 'X', 'X', 'X', 'X', 'MGC4,8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MGFA-PIS4', 'X', 'X', 'X', 'X', 'C-SSRS Baseline/Screening', 'X', 'Version9', 'C-SSRS Since Last Visit', 'X', 'X', 'Version', 'ECG', 'X', 'X', 'AChR Ab', 'X', 'X', 'X', 'X', 'Page 20 of 109', 'Alexion Confidential']"
20,page_21,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period (Continued)', 'Clinical', 'Period/Phase', 'Screening', 'Randomized-Controlled Period', 'Deterioration¬π', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET2', 'Study Day', 'D1', 'D8', 'D15', 'D29', 'D71', 'D85', 'D127', 'D183', 'Window (day)', '+2', '2', ' 2', '+ 2', '2', '+ 2', ' 2', 'Weeks', '-4 to -2 W', 'W1', 'W2', 'W4', 'W10', 'W12', 'W18', 'W26', 'Clinical Lab Tests10', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy Test 11', 'X', 'X', 'X', 'X', 'X', 'X', 'PK, Free C512', 'B/P', 'T/P', 'T/P', 'T/P', 'T', 'X', 'ADA 13', 'X', 'X', 'X', 'X', 'X', 'N meningitidis Vaccine1', 'X', 'Patient Safety Information', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Card14', 'Randomization15', 'X', 'Study Drug Infusion¬π 16', 'X', 'X', 'X', 'X', '1', 'Evaluation of Clinical Deterioration must be performed as soon as possible, within 48 hours of notification to the Investigator of symptom onset. If Clinical', 'Deterioration occurs between scheduled visits, only the assessments for the Clinical Deterioration visit are needed. If Clinical Deterioration', 'occurs', 'on', 'a', 'scheduled visit, all scheduled assessments should be performed for that visit as well as for the evaluation of Clinical Deterioration.', 'Additional', 'evaluation', 'visits', 'may be scheduled at the discretion of the Investigator.', '2', 'If a patient withdraws early from the study during the Randomized-Controlled Period, an Early Termination Visit will be', 'performed.', '3', 'MG history will include diagnosis date; initial MG clinical presentation (oMG or gMG); time to gMG, if initial clinical presentation was oMG; maximum', 'MGFA classification since diagnosis; ventilatory support since diagnosis; dates of MG exacerbation or crisis since diagnosis and prior to Day 1; and any MG-', 'related hospitalizations in 2 years prior to screening. MG-specific medication or therapy taken within 2 years prior to screening will be recorded.', '4', 'Refer to Section 4.2.4.', '5', 'Vital signs and pulse oximetry will include systolic and diastolic blood pressure (millimeters of mercury [mmHg]), pulse oximetry (oxygen saturation [SO2]),', 'heart rate (beats/minute), and temperature (degrees Celsius [¬∞C] or degrees Fahrenheit [¬∞F]). On dosing days, vital signs will be taken before study drug', 'administration and after the patient has been resting for at least 5 minutes.', ""6 To be performed, if necessary, on the basis of the patient's health status and the clinical judgment of the Investigator."", '7 The MG-ADL is required to be performed first, followed by the QMG. The MG-activities of daily living (MG-ADL) assessment should be performed by a', 'Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same evaluator, throughout the study. The recall period for MG-ADL is', 'the preceding 7 days or since the last visit if the visit interval is less than 7 days.', '8', 'The QMG and MGC assessments should be performed by a Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same', 'evaluator, throughout the study. If a patient is taking a cholinesterase inhibitor, the dose must be withheld for at least 10 hours prior to the assessment.', '9', 'C-SSRS will be assessed for both lifetime and past 1 year (12 months).', '10 Clinical laboratory tests will be performed at the central laboratory.', 'Page 21 of 109', 'Alexion Confidential']"
21,page_22,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period (Continued)', '11', 'Pregnancy tests must be performed on all patients of child-bearing potential at the specified time points. Serum pregnancy test will be performed at Screening', 'and Day 183/ET; urine pregnancy tests will be performed locally at all other required time points. A negative urine test result performed locally is required', 'prior to administering ravulizumab to patients of childbearing potential at the indicated visits. Additional pregnancy tests (urine or serum) may also be', ""performed at any visit at the Investigator's discretion."", '12 Baseline (B) and trough (T) blood samples for serum PK, free C5 (PD), and ADA will be collected predose (within 30 minutes prior to the start of infusion of', 'study drug). Peak (P) blood samples for serum PK/PD samples are to be taken within the 30 minutes following completion of study drug infusion. The T', 'samples may be drawn through the venous access created for the dose infusion, prior to administration of the dose. The P samples will be drawn from the', ""patient's opposite, noninfused arm. On Day 183 (Week 26), the T sample is considered a Randomized-Controlled Period assessment and the P sample is"", 'considered an Extension Period assessment. All collection times will be recorded in eCRF. In the event of Clinical Deterioration, blood samples for serum', 'PK/PD and ADA analyses will be collected if supplemental dosing is provided (see Section 8.1.2).', '13 To reduce the risk of meningococcal infection (N meningitidis), all patients must be vaccinated against meningococcal infections within 3 years prior to, or at', 'the time of, initiating study drug. Patients who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment', 'with appropriate prophylactic antibiotics until 2 weeks after vaccination.', '14 Patients will be given a Patient Safety Information Card prior to the first dose of study drug. At each visit throughout the study, the study staff will ensure that', 'the patient has the Patient Safety Information Card.', '15 All patients that continue to meet all inclusion criteria and none of the exclusion criteria and have been cleared for randomization by the Investigator will be', 'centrally randomized through interactive response technology (IRT).', '16', 'Study drug will be administered intravenously via infusion after completion of all other tests and procedures, excluding the peak blood sampling for PK/PD,', 'free C5, and ADA.', 'Abbreviations: AChR Ab = acetylcholine receptor antibody; ADA = antidrug antibody; B = baseline sample; C5 = complement component 5;', 'C-SSRS = Columbia-Suicide Severity Rating Scale; D = day; ECG = electrocardiogram; EQ-5D-5L=Euro Quality of Life; ET = Early Termination;', 'HIV = Human Immunodeficiency Virus; MG = Myasthenia Gravis; MG-ADL = Myasthenia gravis Activities of Daily Living profile; MGC = Myasthenia gravis', 'Composite score; MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = MGFA-Post-Intervention Status; N meningitidis = Neisseria meningitidis;', 'P', '= peak sample; PK/PD = = pharmacokinetic(s)/pharmacodynamic(s); QMG = Quantitative Myasthenia Gravis score for disease severity; QoL = quality of life;', 'T = trough sample; W = week(s).', 'Page 22 of 109', 'Alexion Confidential']"
22,page_23,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period', 'Clinical', 'Period', 'Open-Label Extension', 'Deterioration¬π', 'Study Visit', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', 'D925/', 'ET¬≥/', 'Study Days¬≤', 'D183', 'D197', 'D211', 'D253', 'D267', 'D309', 'D365', 'D421', 'D477', 'D533', 'D589', 'D645', 'D701', 'D757', 'D813', 'D869', 'EOS', 'W', 'Weeks', 'W26', 'W28', 'W30', 'W36', 'W38', 'W44', 'W52', 'W60', 'W68', 'W76', 'W84', 'W92', 'W100', 'W108', 'W116', 'W124', '132', 'Window (day)', '3', '7', '+ 7', '7', '7', ""+' 7"", '7', '7', '7', ""' 7"", '7', '7', '7', '+ 7', '7', '7', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs &', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pulse Oximetry4', 'Physical', 'X', 'Examination', 'Abbreviated', 'Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Examination5', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Medication', 'Non-Drug', 'X', 'X', 'X', 'X', 'Therapy', 'MG Therapy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Status', 'Hospitalization', 'X', 'X', 'X', 'Status', 'Adverse Events', 'X', 'X', 'X', 'MG-ADL6,1', 'X', 'X', 'QMG6, 8', 'X', 'X', 'X', 'X', 'X', 'MG-QOL15r', 'X', 'Neuro-QOL', 'X', 'Fatigue', 'EQ-5D-5L', 'X', 'MGC6,', 'X', 'X', 'X', 'X', 'MGFA-PIS6', 'C-SSRS Since', 'Last Visit', 'X', 'X', 'X', 'X', 'Version', 'ECG', 'AChR Ab', 'X', 'X', 'X', 'Clinical Lab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Tests9', 'Page 23 of 109', 'Alexion Confidential']"
23,page_24,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period (Continued)', 'Clinical', 'Period', 'Open-Label Extension', 'Deterioration¬π', 'Study Visit', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', 'D925/', 'ET¬≥/', 'Study Days¬≤', 'D183', 'D197', 'D211', 'D253', 'D267', 'D309', 'D365', 'D421', 'D477', 'D533', 'D589', 'D645', 'D701', 'D757', 'D813', 'D869', 'EOS', 'W', 'Weeks', 'W26', 'W28', 'W30', 'W36', 'W38', 'W44', 'W52', 'W60', 'W68', 'W76', 'W84', 'W92', 'W100', 'W108', 'W116', 'W124', '132', 'Window (day)', '3', '7', '+ 7', '7', '7', '7', '+ 7', '+ 7', '7', '+7', '7', '7', '7', '+ 7', '7', '7', 'Pregnancy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Test10', 'PK, Free C511', 'P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T/P', 'T', 'X', 'ADA11', 'X', 'X', 'X', 'Patient Safety', 'Information', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Card12', 'Ravulizumab', '13', 'X', 'X', 'X', 'Infusion¬π', '1 Evaluation of Clinical Deterioration must be performed as soon as possible, within 48 hours of notification to the Investigator of symptom onset.', 'If', 'Clinical', 'Deterioration occurs between scheduled visits, only the assessments for the Clinical Deterioration visit are needed. If Clinical Deterioration occurs on a', 'scheduled visit, all scheduled assessments should be performed for that visit as well as for the evaluation of Clinical Deterioration. Additional', 'evaluation', 'visits', 'can be scheduled at the discretion of the Investigator.', '2', 'Extension Period begins at the start of Day 183 (Week 26) dosing.', '3 If a patient withdraws early from the study during the Extension Period an Early Termination Visit will be performed.', '4 Vital signs and pulse oximetry will include systolic and diastolic blood pressure (millimeters of mercury [mmHg]), pulse oximetry (oxygen saturation [SO2]),', 'heart rate (beats/minute), and temperature (degrees Celsius [¬∞C] or degrees Fahrenheit [¬∞F]). On dosing days, vital signs will be taken before study drug', 'administration and after the patient has been resting for at least 5 minutes.', ""5 To be performed, if necessary, on the basis of the patient's health status and the clinical judgment of the Investigator."", '6', 'Refer to Section 4.2.4.', '7 The MG-ADL is required to be performed first, followed by the QMG. The MG-ADL should be performed by a Properly Trained Clinical Evaluator (as', 'defined in the study protocol), preferably the same evaluator, throughout the study. The recall period for MG-ADL is the preceding 7 days or since the last visit', 'if the visit interval is less than 7 days.', '8', 'The QMG and MGC assessments should be performed by a Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same', 'evaluator, throughout the study. If a patient is taking a cholinesterase inhibitor, the dose must be withheld for at least 10 hours prior to the assessment.', '9 Clinical laboratory tests will be performed at the central laboratory.', '10', 'Pregnancy tests must be performed on all patients of child-bearing potential at the specified time points. Serum pregnancy tests will be performed at', 'Day 925/ET/EOS; urine pregnancy tests will be performed locally at all other required time points. A negative urine test result performed locally is required', 'prior to administering ravulizumab to patients of childbearing potential at the indicated visits. Additional pregnancy tests (urine or serum) may also be', ""performed at any visit at the Investigator's discretion."", 'Page 24 of 109', 'Alexion Confidential']"
24,page_25,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period (Continued)', ""l'Trough (T) blood samples for serum PK, free C5 (PD), and ADA will be collected predose (within 30 minutes prior to the start of infusion of study drug). Peak"", '(P) blood samples for serum PK/PD are to be taken within the 30 minutes following completion of study drug infusion. The T samples may be drawn through', ""the venous access created for the dose infusion, prior to administration of the dose. The P samples will be drawn from the patient's opposite, noninfused arm."", 'On Day 183 (Week 26), the T sample is considered a Randomized-Controlled Period assessment and the P sample is considered an Extension Period', 'assessment. All collection times will be recorded in eCRF. In the event of Clinical Deterioration, a blood sample for serum PK/PD and ADA analyses will be', 'collected if supplemental dosing is provided (see Section 8.1.2).', '12Patients will be given a Patient Safety Information Card prior to the first dose of study drug. At each visit throughout the study, staff will ensure that the patient', 'has the Patient Safety Information Card.', '13Ravulizumab will be administered intravenously via infusion after completion of all other tests and procedures, excluding the peak blood sampling for PK,', 'free C5, and ADA.', 'Abbreviations: AChR Ab = Acetylcholine receptor antibody; ADA = Antidrug antibody B = Baseline sample; C5 = Complement component 5;', 'C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; EOS=End of Study; EQ-5D-5L = Euro Quality of Life; ET = Early Termination;', 'ICU = Intensive Care Unit; MG = Myasthenia Gravis; MG-ADL = MG Activity of Daily Living profile; MGC = Myasthenia Gravis Composite score;', 'MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = MGFA-Post-Intervention Status; N meningitidis = Neisseria meningitidis; P = peak sample;', 'PK/PD = pharmacokinetics/pharmacodynamics; QMG = Quantitative Myasthenia Gravis score for disease severity; QoL = quality of life; T = trough sample.', 'Page 25 of 109', 'Alexion Confidential']"
25,page_26,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '2.', 'INTRODUCTION', '2.1.', 'Generalized Myasthenia Gravis', 'Generalized myasthenia gravis (gMG) is a rare disorder, which based on studies conducted in', 'Europe, has an estimated prevalence between 145 to 278 per million inhabitants (Cetin, 2012;', 'Fang, 2015; Heldal, 2009). Patients with gMG suffer from a devastating inflammatory', 'neuromuscular disorder with limited therapeutic options.', 'Generalized myasthenia gravis patients differ from the ocular myasthenia gravis (MG)', 'population in that neuromuscular inflammation and the resultant clinical findings are not just', 'limited to the ocular muscles, but involve all voluntary muscle groups: the bulbar, respiratory,', 'head, neck, trunk, or peripheral muscles with or without involvement of the eyes. Profound', 'weakness and devastating consequences, including slurred speech, dysarthria, dysphagia,', 'disorienting vision, shortness of breath (both with activity and at rest), weakness of the upper and', 'lower extremities, impaired mobility, marked reductions in the ability to perform activities of', 'daily living (ADLs), extreme fatigue, and episodes of pulmonary failure requiring mechanical', 'ventilation are hallmarks of gMG. Compared with patients with isolated ocular MG, patients', 'with gMG have a greater incidence of morbidities and a higher burden of disease (Engel-Nitz,', '2018).', 'Hospitalizations for gMG exacerbations are common, with the need for respiratory support,', 'including mechanical ventilation secondary to respiratory failure (eg, myasthenic crisis) and', 'gastrointestinal tube placement for nutritional support and prevention of dysphagia-associated', 'aspiration. Patients with more advanced gMG have been reported to experience increased', 'mortality of up to 40% at 10 years following diagnosis (Christensen, 1998).', '2.2.', 'Background', '2.2.1.', 'Unmet Medical Need in Patients With Generalized Myasthenia Gravis', 'In difficult-to-control cases, patients with gMG experience unrelenting inflammation, tissue', 'destruction, and consequent severe morbidities including profound muscle weakness, impaired', 'mobility, shortness of breath, pulmonary failure, extreme fatigue, risk for aspiration, and', 'markedly impaired ADLs (Sahashi, 1978; Silvestri, 2014; Suh, 2013). These patients are', 'typically diagnosed in the prime of their adult lives, with a median age of onset ranging from', '36 to 60 years (Suh, 2013). As a result of the morbidities associated with gMG, many patients', 'cannot work or have diminished work-capacity, experience difficultly caring for themselves and', 'others, and require assistance speaking, eating, ambulating, breathing, and performing ADLs.', '2.2.2.', 'Role of Complement in Myasthenia Gravis', 'Uncontrolled terminal complement activation has been implicated in animal models of', 'experimental autoimmune gMG (Sahashi, 1978; Fitch, 1999; Dalakas, 2004; Keshavjee, 2005;', 'Patel, 2005) as well as in other forms of autoimmune neuropathy in humans. Autoantibodies', 'recognize targeted neural or muscle tissues, including the acetylcholine receptor (AChR), leading', 'to uncontrolled terminal complement activation at the neural or muscle surface (Ha, 2015).', 'Page 26 of 109', 'Alexion Confidential']"
26,page_27,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Autoantibody-driven uncontrolled terminal complement activation with membrane attack', 'complex MAC)-dependent lysis and activation, and C5a-dependent inflammation at the', 'neuromuscular junction (NMJ) causes AChR loss and failure of neuromuscular transmission.', 'Consistent with this model, both complement component (C) 3 (C3a and C3b) fragments and the', 'MAC C5b-9 have been found in NMJs of MG patients (Sahashi, 1978).', 'Taken together, the data support that uncontrolled terminal complement activation at the NMJ', 'plays a role in the destruction of post-synaptic structure. Rapid, complete, and sustained', 'inhibition of terminal complement activation is a biologically rational approach to prevent the', 'damage caused in patients with gMG.', '2.3.', 'Study Rationale', 'Ravulizumab (ALXN1210) was engineered from eculizumab (h5G1.1-mAb), a humanized', 'monoclonal Ab (mAb) that specifically binds with high affinity to the human terminal C5,', 'inhibiting C5 enzymatic cleavage and thereby preventing the generation of the', 'proinflammatory/prothrombotic mediators, such as MAC C5b-9, which are responsible for the', 'inflammatory consequences of terminal complement activation. Eculizumab is approved for the', 'treatment of gMG, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic', 'syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD) in many countries', 'worldwide under the trade name Soliris', 'Ravulizumab preserves immediate and complete C5 inhibition while providing sustained', 'complement inhibition throughout a prolonged dosing interval; it was specifically designed (and', 'has subsequently been proven) to have an increased half-life relative to eculizumab. Therefore,', 'ravulizumab requires less frequent (once every 8 weeks [q8w]) infusions relative to eculizumab', '(once every 2 weeks [q2w] infusions). Given that gMG is a chronic disease with a significant', 'treatment burden, the relative convenience of the ravulizumab dosing regimen may increase', 'patient satisfaction, increase treatment adherence, and ultimately, lead to improved health', 'outcomes.', 'Ravulizumab was designed based on comprehensive modelling and simulation analyses to', 'maintain efficacious concentrations across a longer dosing interval. The enhanced', 'pharmacokinetic (PK)/pharmacodynamic (PD) profile of ravulizumab, with fewer PK troughs,', 'than eculizumab, has the potential to improve therapeutic efficacy while maintaining a safety', 'profile similar to that of eculizumab. Furthermore, the q8w dosing regimen minimizes the risk of', 'incomplete complement inhibition. The infusion frequency is relatively low (6 infusions per', 'year) (Figure 1), which offers the potential for improved quality of life (QoL) through fewer', 'missed days of work or school, better treatment adherence, and improved accessibility.', 'Page 27 of 109', 'Alexion Confidential']"
27,page_28,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Figure 1:', 'Ravulizumab Every 8 Weeks Dosage Regimen Versus Eculizumab Every', '2 Weeks Dosage Regimen', 'wo', 'W2', 'W10', 'W18', 'W26', 'W34', 'W42', 'Ravulizumab', 'Eculizumab', 'Ravulizumab offers a convenient dosing and immediate onset of action with effective and', 'complete terminal complement inhibition at the end of the first infusion. Additionally, the dose', 'regimen of ravulizumab has been optimized to reduce the exposure differences across the adult', 'body-weight range by utilizing a weight-based dosing paradigm that provides immediate,', 'complete, and sustained C5 inhibition over the entire dosing interval. Therefore, ravulizumab', 'minimizes the risk of inflammation, including C5a recruitment and activation of inflammatory', 'cells as well as direct MAC-complex induced damage of the motor neural endplate (Kusner,', '2008).', 'The proposed rationale for the ravulizumab posology for the gMG indication is highly consistent', 'with the approach used in dose-selection for eculizumab in the aHUS and gMG indications.', '2.4.', 'Benefit/Risk Assessment', 'Ravulizumab provides patients and physicians with an option for less frequent dosing, which', 'allows greater access to care for those patients who may not initiate treatment on eculizumab,', 'may discontinue eculizumab due to frequency of dosing, or who are currently receiving', 'eculizumab every 2 weeks.', '2.4.1.', 'Identified and Potential Risks', '2.4.1.1.', 'Identified Risk', '2.4.1.1.1. Neisseria meningitidis', 'Increased susceptibility to infection caused by Neisseria meningitidis (N meningitidis) is a', 'known risk associated with complement inhibition. The main risk associated with ravulizumab is', 'the risk of meningococcal infections. Specific risk mitigation measures are in place to address', 'this risk, as described in Section 8.3.6.', '2.4.1.2.', 'Potential Risks', '2.4.1.2.1. Immunogenicity', 'Administration of any therapeutic protein, including ravulizumab, may induce an immunogenic', 'response potentially resulting in antidrug antibodies (ADA). The spectrum of potential clinical', 'Page 28 of 109', 'Alexion Confidential']"
28,page_29,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'consequences may include severe hypersensitivity-type reactions and decrease in efficacy (PK', 'and/or PD neutralization) due to development of neutralizing ADA (Casadevall, 2002; Li, 2001).', 'Of the 261 patients with PNH who were treated with ravulizumab in the ravulizumab IV clinical', 'studies, 1 patient developed a treatment-emergent ADA. Treatment-emergent ADAs have been', 'observed in 3 healthy subjects treated with ravulizumab subcutaneous (SC) and 1 healthy subject', 'treated with ravulizumab IV in Study ALXN1210-HV-104. All ADA positive titer values were', 'low and negative for eculizumab cross-reactivity. There was no apparent impact of', 'immunogenicity on the PK or PD of ravulizumab. More information about the immunogenicity', ""of ravulizumab may be found in the current edition of the Investigator's Brochure (IB)."", 'Monitoring of immunogenicity for this study will be conducted as described in Section 1.3 and', 'Section 8.2.4.3.', '2.4.1.2.2. Local and Systemic Reactions', 'Protein therapies administered IV have the potential risk of causing local (infusion-site reactions)', 'and systemic reactions (infusion-associated reactions). Infusion-site reactions are those localized', 'to the site of IV drug administration and may include reactions such as erythema, pruritus, and', 'bruising. Infusion-associated reactions are those which are systemic in nature and which may be', 'immune or nonimmune-mediated, generally occurring within hours of drug administration.', 'Immune-mediated reactions may include allergic reactions (eg, anaphylaxis), while', 'nonimmune-mediated reactions are nonspecific (eg, headache, dizziness, nausea). Monitoring for', 'these reactions will be conducted as part of routine safety assessments for this study', '(Section 8.3.7).', '2.4.1.2.3. Pregnancy Exposure', 'No studies of ravulizumab have been conducted in pregnant women. Pregnant or nursing patients', 'will be excluded from the clinical study. Patients enrolled in the study, and their', 'spouses/partners, will use a highly effective or acceptable method of contraception as required in', 'Section 10.4 (Appendix 4). In the event of a pregnancy, the patient will be discontinued from', 'study drug (Section 7).', 'More detailed information about the known and expected benefits and risks and reasonably', 'expected adverse events of ravulizumab may be found in the IB.', 'Page 29 of 109', 'Alexion Confidential']"
29,page_30,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '3.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Enppoints', 'Primary', 'To assess the efficacy of ravulizumab compared with', 'Change from Baseline in MG-ADL total score at', 'placebo in the treatment of gMG based on the', 'Week 26 of the Randomized-Controlled Period.', 'improvement in the Myasthenia Gravis-Activities of', 'Daily Living (MG-ADL) profile.', 'Secondary', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in QMG total score at', 'with placebo in the treatment of gMG based on', 'Week 26.', 'the improvement in the Quantitative Myasthenia', 'Gravis (QMG) total score.', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in the Revised', 'with placebo in the treatment of gMG based on', '15-Component Myasthenia Gravis Quality of Life', 'the improvement in quality of life measures.', '(MG-QOL15r) score at Week 26.', 'Change from Baseline in Neuro-QOL Fatigue', 'score at Week 26.', 'To assess the efficacy of ravulizumab compared', 'Improvement of at least 3 points in the MG-ADL', 'with placebo in the treatment of gMG based on', 'total score from Baseline at Week 26.', 'other efficacy endpoints.', 'Improvement of at least 5 points in the QMG total', 'score from Baseline at Week 26.', 'Exploratory', 'To assess the efficacy of ravulizumab in the', 'Change from Baseline in the Myasthenia Gravis', 'treatment of gMG based on other efficacy', 'Composite (MGC) score at Week 26.', 'endpoints throughout the study.', 'Myasthenia Gravis Foundation of America', '(MGFA) Post-Intervention Status (PIS) at', 'Week 26.', 'Change from Baseline in Euro Quality of Life', '(EQ-5D-5L) at Week 26.', 'Change from baseline in MG-ADL subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Change from baseline in QMG subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Incidence of hospitalizations/MG-related', 'hospitalizations.', 'Incidence of Clinical Deterioration/MG crisis.', 'PK/PD/Immunogenicity', 'To evaluate the PK/PD and immunogenicity of', 'Change in serum ravulizumab concentration over', 'ravulizumab in the treatment of gMG throughout', 'time.', 'the study.', 'Change in serum free C5 concentration over time.', 'Incidence of treatment-emergent antidrug', 'antibodies over time.', 'Safety', 'To characterize the overall safety of ravulizumab in', 'Incidence of adverse events and serious adverse', 'the treatment of gMG.', 'events over time.', 'Changes from Baseline in vital signs and', 'laboratory assessments.', 'The above endpoints will be evaluated over time throughout the study.', 'Page 30 of 109', 'Alexion Confidential']"
30,page_31,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.', 'STUDY DESIGN', '4.1.', 'Overall Design', 'This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter', 'study to evaluate the safety and efficacy of ravulizumab for the treatment in patients with gMG.', 'Approximately 160 eligible patients will be stratified by region (North America, Europe,', 'Asia-Pacific, and Japan) and randomized 1:1 to 1 of 2 treatment groups: (1) ravulizumab', 'infusion or (2) placebo infusion. There will be 3 periods in this study: Screening Period,', 'Randomized-Controlled Period, and an Open-Label Extension (OLE) Period.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg. Starting Week 28, all', 'patients will begin open-label ravulizumab maintenance doses q8w. For patients in the', 'ravulizumab group, a blinded ravulizumab dose of 900 mg was chosen to ensure maintenance of', 'complete C5 inhibition until the next scheduled maintenance dose at Week 28 (Day 197).', 'Eight weeks after the final dose of study drug is administered, all enrolled patients will return for', 'an End of Study (EOS) Visit (Visit 25) at Week 132 during which final study assessments will', 'be conducted. If a patient withdraws from the study, or completes the study early (prior to', 'Visit 24; Week 124), the patient will be encouraged to return for an Early Termination (ET)/EOS', 'Visit, 8 weeks after the day the last dose of study drug was administered, during which final', 'planned safety assessments will be conducted (see Section 4.5 for further details regarding end of', 'study and study completion). Attempts should be made to follow all patients for safety for', '8 weeks from the day the last dose of study drug is administered.', 'Patients who are being treated with an immunosuppressive therapy (IST) at the time of the', 'Screening Visit may continue taking their baseline ISTs throughout the Randomized-Controlled', 'and OLE Periods. However, the dosage of IST must not be changed and no new ISTs may be', 'added or discontinued during the Randomized-Controlled Period of the study, unless deemed by', 'the Investigator to be medically necessary.', 'Throughout the study, rescue therapy (eg, high-dose corticosteroid, plasmapheresis (PP)/plasma', 'exchange (PE), or intravenous immunoglobulin [IVIg]) will be allowed if a patient experiences', 'Clinical Deterioration as defined in this protocol (Section 4.2.1). The rescue therapy used for a', 'particular patient will be at the discretion of the Investigator.', 'The primary endpoint for this study will be measured at Week 26 (Day 183), irrespective of', 'rescue therapy.', 'Including the 8-week safety follow-up, which begins after the last dose of study drug is', 'administered, the overall study duration for an individual patient is estimated to take up to', '132 weeks (from enrollment through the end of the Safety Follow-up). The period of active', 'patient-participation is estimated to take up to 132 weeks (from enrollment through the EOS', 'Visit). Schedules of Activities (SOA) for the Randomized-Controlled Period and the OLE Period', 'are provided in Table 1 and Table 2, respectively.', 'Page 31 of 109', 'Alexion Confidential']"
31,page_32,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.1.1.', 'Screening Period (2 - 4 Weeks Prior to Day 1)', 'At the screening visit, after obtaining informed consent, the patient will be screened for study', 'eligibility through medical history review, demographic data, and laboratory assessments. The', 'medical history review will include MG diagnosis date; initial MG clinical presentation (ocular', 'MG [oMG] or gMG); time to gMG, if initial clinical presentation was oMG; maximum MGFA', 'classification since diagnosis; ventilatory support since diagnosis; dates of MG exacerbation or', 'crisis since diagnosis and prior to Day 1; and any MG-related hospitalizations in 2 years prior to', 'screening. MG-specific medication or therapy (eg, thymectomy, ISTs including corticosteroids,', 'IVIg, and PE/PP) within 2 years prior to screening will be recorded.', 'If all inclusion criteria and none of the exclusion criteria are met, patients will be vaccinated', 'against N meningitidis, if not already vaccinated within the 3 years prior to their enrollment in', 'the study. Patients who initiate study drug treatment less than 2 weeks after receiving a', 'meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until', '2 weeks after vaccination.', 'If a patient experiences a Clinical Deterioration or MG Crisis during the Screening Period, the', 'Sponsor must be notified.', '4.1.2.', 'Randomization', 'At the time of randomization, all patients will be reassessed for eligibility based on the study', 'inclusion and exclusion criteria. All patients who are vaccinated, continue to meet all of the', 'inclusion criteria and none of the exclusion criteria at Randomization [Day 1]), and have been', 'cleared for randomization by the Investigator, will be randomized 1:1 to the ravulizumab group', 'or the placebo group. Patients will be centrally randomized using interactive response technology', '(IRT). The randomization will be stratified by region (North America, Europe, Asia-Pacific, and', 'Japan).', '4.1.3.', 'Randomized Controlled Period (26 Weeks)', 'Throughout the study, rescue therapy (eg, high-dose corticosteroid, PE/PP, or IVIg) will be', ""allowed when a patient's health would be in jeopardy if rescue therapy was not administered (eg,"", 'emergent situations), or if a patient experiences Clinical Deterioration as defined in this protocol.', 'The rescue therapy used for a particular patient will be at the discretion of the Investigator.', 'Patients must be informed of potential signs and symptoms of Clinical Deterioration or MG', 'Crisis and instructed to contact the Investigator to be evaluated within 48 hours of notification of', 'the Investigator of the symptom onset. At the evaluation visit, the Investigator or the', ""Investigator's designee will perform the assessments as specified by this protocol. The"", 'Investigator or designee will determine whether or not the patient meets the definition of Clinical', 'Deterioration as defined by this protocol in Section 4.2.1 and treat the patient accordingly.', 'The primary endpoint for this study will be measured at Week 26 (Day 183), irrespective of', 'rescue therapy.', 'See the SOA for further details regarding visit procedures throughout the study (Section 1.3).', 'Page 32 of 109', 'Alexion Confidential']"
32,page_33,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.1.4.', 'Open-Label Extension Period', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'dose at Week 28 (Day 197). Starting at Week 28, all patients will begin open-label ravulizumab', 'maintenance doses q8w.', 'The OLE Period for each patient will commence when the patient receives a dose of ravulizumab', 'on Week 26 (Day 183) and will continue for up to 2 years or until the product is registered or', 'approved (in accordance with country-specific regulations), whichever occurs first.', '4.2.', 'Standard Protocol Definitions', '4.2.1.', 'Clinical Deterioration', 'For this protocol, Clinical Deterioration is defined as any of the following:', '1. Patients who experience an MG Crisis, which is defined as weakness from MG that is severe', 'enough to necessitate intubation or to delay extubation following surgery. The respiratory', 'failure is due to weakness of respiratory muscles. Severe bulbar (oropharyngeal) muscle', 'weakness often accompanies the respiratory muscle weakness, or may be the predominant', 'feature in some patients; or,', '2. Significant symptomatic worsening to a score of 3 or a 2-point worsening from Baseline on', 'any one of the individual MG-Activities of Daily Living (MG-ADL) items other than double', 'vision or eyelid droop; or,', '3. Administration of rescue therapy to a patient whose, in the opinion of the Investigator or', 'Investigator-designated physician, health would be in jeopardy, if rescue therapy were not', 'given (eg, emergent situations).', '4.2.2.', 'Unscheduled Visits', 'Under exceptional circumstances, additional (unscheduled) visits outside the specified visits are', 'permitted at the discretion of the Investigator. Procedures, tests, and assessments will be', 'performed at the discretion of the Investigator and efforts will be made to map the corresponding', 'data to the appropriate visit as described in the electronic case report form (eCRF) completion', 'guidelines and training materials.', '4.2.3.', 'Properly Trained Clinical Evaluator', 'Properly Trained Clinical Evaluators are study staff that have been certified in administering the', 'MG-ADL, QMG, and Myasthenia Gravis Composite (MGC) assessments. Only Properly', 'Trained Clinical Evaluators may administer these assessments. A Properly Trained Clinical', 'Evaluator may be a neurologist, physical therapist, or other study team member delegated by the', 'Investigator. Only the Investigator or a neurologist may perform the manual muscle test (MMT),', 'components of the MGC, the Myasthenia Gravis Foundation of America-Post-Interventional', 'Status (MGFA-PIS), and Myasthenia Gravis Foundation of America (MGFA) Classification.', 'Page 33 of 109', 'Alexion Confidential']"
33,page_34,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Clinical Evaluator training and certification for this protocol will take place either at the', ""Investigator's Meeting or via the Sponsor's designated on-line training portal."", '4.2.4.', 'Responsibilities for Myasthenia Gravis Assessments', 'Responsibilities for MG assessments are listed in Table 3. Throughout the study, MG', 'assessments should be performed at approximately the same time of day by a Properly Trained', 'Clinical Evaluator, and preferably the same evaluator. The MG-ADL should always be', 'performed first, followed by the QMG.', 'Table 3:', 'Myasthenia Gravis Assessments and Responsibilities', 'Assessment', 'Evaluator', 'MG-ADL', 'Properly Trained Clinical Evaluator', 'QMG', 'Properly Trained Clinical Evaluator', 'MGC', 'Properly Trained Clinical Evaluator', 'MGC (MMT Components)', 'Investigator or Neurologist', 'MGFA-PIS (modified version)', 'Investigator or Neurologist', 'MGFA Classification', 'Investigator or Neurologist', 'Abbreviations: MG-ADL = Myasthenia Gravis Activities of Daily Living Profile; MGC = Myasthenia Gravis', 'Composite scale; MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = Myasthenia Gravis', 'Foundation of America Post-Intervention Status; MMT = manual muscle test; QMG = Quantitative Myasthenia', 'Gravis score for disease severity.', '4.3.', 'Scientific Rationale for Study Design', 'Published data support the MG-ADL profile as an established, sensitive, and objective', 'assessment of treatment response over time in patients with gMG (Howard, 2017).', 'The safety parameters being evaluated are commonly used in clinical studies per International', 'Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use', '(ICH) and Good Clinical Practice (GCP) guidance.', 'Placebo was selected as the control and patients will be allowed to continue stable therapy with', 'standard of care therapy (ie, ISTs) throughout the course of the study, which thereby allows for', 'comparison of the safety and efficacy of ravulizumab when administered in addition to the', ""patient's standard of care treatment to current standard of care therapies in patients with gMG."", 'Given the heterogeneity of the disease and fluctuation in the severity of symptoms, there is no', '1 international standard of care accepted, and targeted treatment with complement-inhibitor', 'drugs, such as the recently introduced eculizumab, is not yet widely available to patients', 'worldwide and is not yet considered standard of care for all patients with gMG. A', 'placebo-controlled study allows for the evaluation of treatment effect and allows for a', 'double-blind design; an important study condition to be maintained when considering endpoints', 'that includes neurological scales, which are known to be especially prone to placebo effects. The', 'placebo-controlled part of the study will be limited to 26 weeks, after which time all patients will', 'transition to open-label treatment with ravulizumab for up to 2 years during the OLE Period. At', 'all points throughout the study, physicians will be encouraged to prioritize patient safety, and if', 'patients experience Clinical Deterioration, the full range of rescue therapies will be permitted.', 'Page 34 of 109', 'Alexion Confidential']"
34,page_35,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.4.', 'Justification for Dose', 'The ravulizumab dosage regimen for this study (Table 4) was approved for the treatment of adult', 'patients with PNH based on comprehensive modelling and simulation analyses of Phase 1 and 2', 'PK/PD data in healthy volunteers and PK/PD/efficacy (lactate dehydrogenase) and safety data in', 'patients with PNH. This regimen is considered optimal for achieving immediate, complete,', 'sustained inhibition of terminal complement activity within each dosing interval and for the', 'entire treatment course in adult patients.', 'Table 4:', 'Ravulizumab Weight-Based Dosing', 'Weight (kg)', 'Loading Dose (mg)', 'Maintenance Dose (mg)', '(administered q8w)', '40 to < 60', '2400', '3000', '> 60 to < 100', '2700', '3300', '> 100', '3000', '3600', 'Abbreviation: q8w = every 8 weeks.', 'Consistent with approved eculizumab labeling for treating adult and pediatric patients with', 'aHUS and adult patients with gMG, supplemental dosing of ravulizumab in the amount of 50%', '(rounded up if not in integral of 300 mg due to vial configuration) will be given in the setting of', 'concomitant PE/PP rescue therapy. For adult patients with gMG, supplemental dosing of', 'ravulizumab (in the amount of 600 mg) will be given in the setting of concomitant IVIg rescue', 'therapy. The 600 mg supplemental ravulizumab dose has been selected based on PK simulations', 'considering the published data describing the impact of co-administration of IVIg on eculizumab', 'PK/PD (Fitzpatrick, 2011) (see Table 7 and Table 8).', 'Supplemental study drug (or placebo) dosing is required if PE/PP or IVIg rescue therapy is', 'provided on non-dosing days; no supplemental study drug (or placebo) dosing is required if', 'PE/PP or IVIg infusion is provided on a dosing day, but it must occur prior to study drug', 'administration. If PE/PP or IVIg is administered on scheduled dosing visits, regular dosing will', 'be started within 60 minutes after the completion of PE/PP or IVIg. If PE/PP or IVIg is', 'administered on non-scheduled dosing visits, for patients receiving PE/PP: supplemental dose', 'administration will be started within 4 hours after the PE/PP session is completed; for patients', 'receiving IVIg: supplemental dose administration will be started within 4 hours after the last', 'continuous session(s) of IVIg is completed (see Section 6.5.1.4).', 'The favorable benefit/risk profiles of ravulizumab from the Phase 3 studies in patients with PNH', 'have confirmed immediate (after the first dose or loading dose), complete (free C5 <0.5 g/mL)', 'and sustained (throughout entire active treatment course) terminal complement inhibition under', 'the above investigated dosage regimen. Based on the totality of PK, PD, ADA, efficacy, and', 'safety data obtained from the ravulizumab development program, the above body weight-based', 'dosage regimen for treating adult patients with PNH may also be beneficial in treating patients', 'with gMG.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'Page 35 of 109', 'Alexion Confidential']"
35,page_36,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'dose at Week 28 (Day 197). Starting at Week 28 (Day 197), all patients will begin open-label', 'ravulizumab maintenance doses q8w.', 'The proposed q8w dosage regimen will facilitate studying a range of PK drug exposures useful', 'in assessing ravulizumab exposure-response relationships in patients with gMG. Safety and', 'tolerability of ravulizumab have been established over a wide range of PK exposures, including', 'those expected under the proposed gMG dosage regimens, in healthy volunteers and patients.', '4.5.', 'End of Study Definition', 'A patient is considered to have completed the study if:', 'The patient has completed all periods of the study including the last visit of the OLE', 'Period, or', 'In the event the study is completed early, the patient has completed all applicable', 'periods of the study including the EOS visit', 'The patient completes the study early (and completes the EOS Visit) because the', 'study drug has become registered or approved (in accordance with country-specific', 'regulations)', 'Measurement of the primary endpoints will be complete after the last visit of the last patient in', 'the Randomized-Controlled Period. The EOS is defined as the date of the last visit of the last', 'patient in the study or last scheduled procedure shown in the SoA (Section 1.3) for the last', 'patient in the study globally. The study completion date corresponds to the last visit when the', 'final patient in the study is examined or received an intervention for the primary or secondary', 'endpoints and AEs.', 'Page 36 of 109', 'Alexion Confidential']"
36,page_37,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '5.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as', 'protocol waivers are not allowed.', '5.1.', 'Inclusion Criteria', 'Patients are eligible to be included in the study only if all of the following criteria apply:', 'Age', '1. Male and female patients must be aged > 18 years of age at the time of signing the', 'informed consent', 'Type of Patient and Disease Characteristics', '2. Diagnosed with MG at least 6 months (180 days) prior to the date of the Screening Visit', '3. Confirmation of eligibility by:', 'a.', 'Positive serologic test for anti-AChR Abs as confirmed at screening, and', 'b. One of the following (either historical or during screening):', 'Abnormal neuromuscular transmission test demonstrated by single-fiber', 'electromyography or repetitive nerve stimulation', 'Positive anticholinesterase test (eg, edrophonium chloride test)', 'Demonstrated improvement in MG signs on oral cholinesterase inhibitors, as', 'assessed by the treating physician', '4. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at', 'screening', '5. MG-ADL profile must be > 6 at screening and randomization (Day 1)', '6. Patients receiving treatment with any of the following must have been receiving', 'treatment and on a stable dose for the time periods specified below prior to the date of the', 'Screening Visit:', 'Azathioprine (AZA): Must have been on AZA for > 6 months (180 days) and', 'have been on a stable dose for > 2 months (60 days)', 'Immunosuppressive therapies (ie, mycophenolate mofetil [MMF], methotrexate', '[MTX], cyclosporine [CYC], tacrolimus [TAC], or cyclophosphamide [CY]),', 'must have been on the IST for > 3 months (90 days) and have been on a stable', 'dose for > 1 month (30 days)', 'Oral corticosteroids, must have been on a stable dose for > 4 weeks (28 days)', 'A cholinesterase inhibitor, at the time of the Screening Visit, must have been on', 'a stable dose for > 2 weeks (14 days)', '7. To reduce the risk of meningococcal infection (N meningitidis), all patients must be', 'vaccinated against meningococcal infections within the 3 years prior to, or at the time of,', 'initiating study drug. Patients who initiate study drug treatment less than 2 weeks after', 'Page 37 of 109', 'Alexion Confidential']"
37,page_38,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'receiving a meningococcal vaccine must receive treatment with appropriate prophylactic', 'antibiotics until 2 weeks after vaccination', 'Weight', '8. Body weight > 40 kg at the time of screening', 'Pregnancy and Contraception', '9. Patients of childbearing potential and patients with partners of childbearing potential must', 'follow protocol-specified contraception guidance (Section 10.4, Appendix 4) for avoiding', 'pregnancy while on treatment and for 8 months after last dose of study drug', 'Informed Consent', '10. Capable of giving signed informed consent as described in Section 10.1, Appendix 1,', 'which includes compliance with the requirements and restrictions listed in the informed', 'consent form (ICF) and in this protocol', '5.2.', 'Exclusion Criteria', 'Patients are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Any active or untreated thymoma or history of thymic carcinoma or thymic malignancy', 'Note: Treated patients with history thymoma other than thymic carcinoma corresponding', 'to clinical stage 1 and 2 with no evidence of recurrence as defined by a recent negative', 'imaging study (CT scan with IV contrast or MRI scan within 6 months of randomization)', 'are eligible for enrollment.', '2. History of thymectomy, thymomectomy, or any thymic surgery within the 12 months', 'prior to screening', '3. History of hypersensitivity to any ingredient contained in the study drug, including', 'hypersensitivity to murine proteins', '4. History of N meningitidis infection', '5. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody', 'titer)', '6. Known medical or psychological condition(s) or risk factor that, in the opinion of the', ""Investigator, might interfere with the patient's full participation in the study, pose any"", 'additional risk for the patient, or confound the assessment of the patient or outcome of the', 'study', '7. History of hospitalization for > 24 hours, for any reason, within the 4 weeks (28 days)', 'prior to screening', '8. Clinical features that, in the opinion of the Investigator, consistent with MG', 'crisis/exacerbation or Clinical Deterioration, at the time of the Screening Visit or at any', 'time prior to randomization', '9. Female patients who plan to become pregnant or are currently pregnant or breastfeeding', 'Page 38 of 109', 'Alexion Confidential']"
38,page_39,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10. Female patients who have a positive pregnancy test result at screening or on Day 1', 'Prior/Concomitant Therapy', '11. Use of the following within the time period specified below:', 'IVIg within the 4 weeks (28 days) prior to randomization (Day 1)', 'Use of PE within the 4 weeks (28 days) prior to randomization (Day 1)', 'Use of rituximab within the 6 months (180 days) prior to screening', '12. Patients who have received previous treatment with complement-inhibitors', '(eg, eculizumab)', 'Prior/Concurrent Clinical Study Experience', '13. Participation in another interventional treatment study or use of any experimental therapy', 'within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives', 'of the study drug, whichever is greater', 'Additional Medical Conditions', '14. History of unexplained infections', '15. Active systemic bacterial, viral, or fungal infection within 14 days prior to study drug', 'administration on Day 1', '16. Presence of fever > 38¬∞C (100.4¬∞F) within 7 days prior to study drug administration on', 'Day 1', '5.3.', 'Lifestyle Considerations', 'No restrictions are required in this study.', '5.4.', 'Screen Failures', 'Screen failures are defined as patients who consent to participate in the clinical study but are not', 'subsequently randomized to a treatment group. A minimal set of screen failure information is', 'required to ensure transparent reporting of screen failure patients to meet the Consolidated', 'Standards of Reporting Trials publishing requirements and to respond to queries from regulatory', 'authorities. Minimal information includes demography, screen failure details, eligibility criteria,', 'and any serious adverse event (SAE).', 'Individuals who do not meet the criteria for participation in this study (screen failure) may be', 'rescreened once based on discussion and agreement between the Investigator and the Medical', 'Monitor.', 'A patient who experiences a gMG Clinical Deterioration or exacerbation/crisis during the', 'Screening Period will be considered a screening failure. Such patients may be rescreened with', 'Sponsor approval once they are treated and medically stable, in the opinion of the Investigator.', 'At least 28 days of clinical stability must exist prior to enrollment. The patient must meet all of', 'the inclusion criteria and none of the exclusion criteria at the time of rescreening in order to enter', 'the study.', 'Page 39 of 109', 'Alexion Confidential']"
39,page_40,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.', 'STUDY DRUG', '6.1.', 'Study Drugs Administered', 'Ravulizumab is formulated at pH 7.0 and is supplied in 30 mL single-use vials. Each vial of', 'ravulizumab contains 300 mg of ravulizumab (10 mg/mL) in 10 mM sodium phosphate, 150 mM', 'sodium chloride, 0.02% polysorbate 80, and water for injection. The comparator product is', 'formulated as a matching sterile, clear, colorless solution with the same buffer components, but', 'without active ingredient. Additional details are presented in Table 5.', 'Table 5:', 'Study Drug Administered', 'Product Name', 'Ravulizumab', 'Placebo', 'Dosage Form', 'Concentrated sterile, preservative-free', 'Sterile, preservative-free aqueous', 'aqueous solution (10 mg/mL) in', 'solution in single-use 30 mL vials', 'single-use 30 mL vials', 'Route of Administration', 'Intravenous infusion', 'Intravenous infusion', 'Dosing Instructions', 'Refer to pharmacy manual for dosing', 'Refer to pharmacy manual for dosing', 'instructions', 'instructions', 'Packaging and Labeling', 'Glass vials and stoppered with a butyl', 'Glass vials and stoppered with a butyl', 'rubber stopper with an aluminum', 'rubber stopper with an aluminum', 'overseal and a flip-off cap. Study drug', 'overseal and a flip-off cap. Study drug', 'will be supplied in kits.', 'will be supplied in kits.', 'Physical Description', 'Liquid solution practically free from', 'Liquid solution practically free from', 'particles', 'particles', 'Manufacturer', 'Alexion Pharmaceuticals, Inc. or', 'Alexion Pharmaceuticals, Inc. or', 'Contracted Manufacturing', 'Contracted Manufacturing', 'Organization', 'Organization', 'Source: product specifications', 'Study drug will be administered as indicated in Table 6.', 'During the Randomized-Controlled Period, patients in the ravulizumab or placebo treatment', 'groups will receive a weight-based loading dose of ravulizumab or placebo, respectively, on', 'Day 1 (Visit 2). At Visit 4 (Week 2), patients in the ravulizumab or placebo treatment groups', 'will receive weight-based maintenance doses or ravulizumab or placebo, respectively, q8w', 'through the completion of the Randomized-Controlled Period. After the completion of the', 'Randomized-Controlled Period, patients will enter the OLE Period.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'dose at Week 28 (Day 197). Starting at Week 28, all patients will begin open-label ravulizumab', 'maintenance doses q8w.', 'Page 40 of 109', 'Alexion Confidential']"
40,page_41,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 6:', 'Reference Chart for Weight-Based Dosing', 'Study Period', 'Ravulizumab or Placebo', 'Body Weight', 'Ravulizumab', 'Ravulizumab', 'Placebo', 'Diluent (0.9%', 'Total', 'Dosing', '(kg¬π', 'Dose', 'Volume (mL)', 'Volume', 'Sodium', 'Volume', '(mg)', '(mL)', 'Chloride)', '(mL)', 'Volume', '(mL)', 'Ravulizumab Group', 'Randomized-Controlled', 'Loading dose', '40 to < 60', '2400', '240', '0', '240', '480', '(Day 1)', '60 to < 100', '2700', '270', '0', '270', '540', '100', '3000', '300', '0', '300', '600', 'Maintenance dose', '40 to < 60', '3000', '300', '0', '300', '600', '(Days 15, 71, 127)', '60 to < 100', '3300', '330', '0', '330', '660', '100', '3600', '360', '0', '360', '720', 'Open-Label Extension', 'Blinded dose¬≤', '40 to < 60', '900', '90', '150', '240', '480', '(Day 183)', '60 to < 100', '900', '90', '180', '270', '540', '100', '900', '90', '210', '300', '600', 'Open-label maintenance dose', '40 to < 60', '3000', '300', '0', '300', '600', '(Days 197 to 869 q8w)', '60 to < 100', '3300', '330', '0', '330', '660', '100', '3600', '360', '0', '360', '720', 'Placebo Group', 'Randomized-Controlled', 'Loading dose', ' 40 to < 60', '0', '0', '240', '240', '480', '(Day 1)', '60 to < 100', '0', '0', '270', '270', '540', '100', '0', '0', '300', '300', '600', 'Maintenance dose', '40 to < 60', '0', '0', '300', '300', '600', '(Days 15, 71, 127)', '60 to < 100', '0', '0', '330', '330', '660', '100', '0', '0', '360', '360', '720', 'Open-Label Extension', 'Blinded loading dose¬≥', '40 to < 60', '2400', '240', '0', '240', '480', '(Day 183)', '60 to < 100', '2700', '270', '0', '270', '540', '100', '3000', '300', '0', '300', '600', 'Open-label maintenance dose', '40 to < 60', '3000', '300', '0', '300', '600', '(Days 197 to 869, q8w)', '> 60 to < 100', '3300', '330', '0', '330', '660', '> 100', '3600', '360', '0', '360', '720', ""1 Dose regimen will be based on the patient's most recently recorded body weight from a previous study/screening visit. Contact the Alexion medical"", 'monitor', 'if', 'a', ""patient's weight drops below 40 kg during the treatment period."", '2 Blinded dose on Day 183 (Week 26) for patients who were randomized to the ravulizumab group and are entering into the Open-Label Extension Period.', '3 Blinded loading dose on Day 183 (Week 26) for patients who were randomized to the placebo group and are entering into the Open-Label Extension Period.', 'Page 41 of 109', 'Alexion Confidential']"
41,page_42,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.2.', 'Preparation/Handling/Storage/Accountability', 'Study drug will be released to the site upon receipt of all required essential documents based', 'upon federal, state, and local regulations.', 'Only patients enrolled in the study may receive study drug and only authorized site staff may', 'supply or administer study drug. All study drug must be stored in a secure, environmentally', 'controlled, and monitored (manual or automated) area in accordance with the labeled storage', 'conditions with access limited to the Investigator and authorized site staff.', 'The Investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study intervention accountability, reconciliation, and record maintenance (ie,', 'receipt, reconciliation, and final disposition records).', '6.2.1.', 'Study Drug Preparation', 'Study drug will be prepared and administered by a trained member of the site study team. Study', 'drug is to be administered only to enrolled patients who are confirmed eligible for participation.', 'Preparation of ravulizumab and placebo doses must be performed in accordance with study', 'center-specific local standards by qualified and study-trained pharmacy personnel.', 'The handling and preparation of materials used to prepare and administer the study drug must be', 'carried out using aseptic techniques for sterile products.', 'All study patients, investigative-site personnel, Sponsor staff, Sponsor designees, and all staff', 'directly associated with the conduct of the study will be blinded to patient treatment assignments.', 'Further details on preparation and dose administration of study drug, as well as disposal of study', 'drug, can be found in the pharmacy manual.', '6.2.2.', 'Storage', 'The Investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study drugs received and that any discrepancies are reported and', 'resolved before use of the study drug.', 'Upon arrival at the investigative site, the study drug should be promptly removed from the', 'shipping cooler and stored in refrigerated conditions at 2¬∞C to 8¬∞C (36¬∞F to 46¬∞F). The', 'pharmacist should immediately record the receipt of the study drug and notify the distributor if', 'vials are damaged and/or if temperature excursions have occurred during transportation. Study', 'drug must be stored in a secure, limited-access storage area and temperature must be monitored', 'daily.', 'Diluted solutions of study drug may be stored at 2¬∞C to 8¬∞C (36¬∞F to 46¬∞F) for up to 24 hours', 'prior to administration. The solution should be allowed to warm to room temperature prior to', 'administration.', 'The admixed drug product should be at room temperature prior to administration. The material', 'must not be heated (eg, by using a microwave or other heat source) other than by ambient air', 'temperature.', 'Page 42 of 109', 'Alexion Confidential']"
42,page_43,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Please consult the pharmacy manual for further information regarding the storage conditions of', 'reconstituted ravulizumab.', '6.2.3.', 'Packaging and Labeling', 'The primary packaging of ravulizumab consists of a 30-mL vial (Type I borosilicate glass) with', 'a stopper and a seal. The secondary packaging consists of a single vial carton. Both primary', '(vial) and secondary (carton) packaging include a booklet label with relevant information.', 'Additional details are presented in Table 5 and in the Pharmacy Manual. The placebo will have', 'an identical appearance to that of ravulizumab.', '6.2.4.', 'Accountability', 'When a drug shipment is received at the site, the pharmacist should verify the contents, sign the', 'packing invoice provided with the shipment, and maintain the original copy for review by the', 'site monitor in the pharmacy binder. Additionally, study drug receipt (as well as condition of the', 'study drug at the time of receipt) must be reported to the IRT system to allow drug', 'randomization, resupply, estimations, and drug expiration control.', 'Unless notified otherwise, empty vials and vials with residual materials should be kept for', 'inspection and accountability by the study monitor prior to their destruction or handled per local', 'pharmacy standard operating procedures for clinical study drugs. Destruction of used and unused', 'vials, either locally or centrally, must be properly documented. Drug accountability will be', 'managed through the IRT system and detailed instructions on managing the IRT drug', 'accountability module will be included in the IRT User Guide. The IRT module will perform', 'accountability in two stages, where site personnel will complete an initial accountability entry in', 'the system followed by confirmation by the Study Monitor that the site has correctly entered the', 'appropriate status for all study drug. The pharmacist or designee must maintain accurate records', 'demonstrating dates and amount of study drug received, to whom dispensed (patient-by-patient', 'accounting), and accounts of any study drug accidentally or deliberately destroyed. These drug', 'accountability records must be readily available upon request, and will be reviewed throughout', 'the study.', 'Each kit will have a label and a place for the pharmacist to record the patient number and initials.', 'The study monitor will examine the inventory during the study. Additionally, the inventory', 'records must be readily available to regulatory authorities, the local regulatory agency, or an', ""independent auditor's inspection at any time."", 'Refer to the Pharmacy Manual for additional information.', '6.2.5.', 'Handling and Disposal', 'All clinical study material provided to the Investigator will be stored in a secure place, and', 'allocated and dispensed by appropriately trained personnel. Detailed records of the amounts of', 'the study drug received, dispensed, and destroyed will be maintained.', 'To satisfy regulatory requirements regarding drug accountability, all remaining ravulizumab', 'inventory will be reconciled and destroyed or returned to Alexion at the end of the study', 'according to applicable regulations.', 'Page 43 of 109', 'Alexion Confidential']"
43,page_44,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Refer to the Pharmacy Manual for further information.', '6.3.', 'Measures to Minimize Bias: Randomization and Blinding', '6.3.1.', 'Randomization', 'Patients will be randomized on Day 1 after the Investigator has verified that they are eligible.', 'Patients will be stratified by region (North America, Europe, Asia-Pacific, and Japan) and', 'randomized 1:1 either to ravulizumab IV infusion or to placebo IV infusion. Patients will be', 'centrally randomized using IRT.', '6.3.2.', 'Blinding', 'All investigative site personnel, Sponsor staff, Sponsor designees, staff directly associated with', 'the conduct of the study, and all patients will be blinded to patient treatment assignments. The', 'double-blind will be maintained by using identical study drug kits and labels for ravulizumab and', 'placebo. The placebo will have an identical appearance to that of ravulizumab. The', 'randomization code will be maintained by the IRT provider. After the 26-Week Randomized-', 'Controlled Period and assessments on Day 183 (Week 26), patients in the placebo group will', 'receive a blinded loading dose of ravulizumab and patients in the ravulizumab group will receive', 'a blinded ravulizumab dose of 900 mg. Starting at Week 28, all patients will begin open-label', 'ravulizumab maintenance doses q8w. For patients in the ravulizumab group, a blinded', 'ravulizumab dose of 900 mg was chosen to ensure maintenance of complete C5 inhibition until', 'the next scheduled maintenance dose at Week 28 (Day 197).', 'Unblinding should only be considered for the safety of the patient. If unblinding is deemed', 'necessary by the Investigator, the Investigator should make a reasonable attempt to contact the', 'Sponsor to discuss possible unblinding. After a reasonable attempt has been made, the', ""Investigator can unblind the patient's treatment allocation using an IRT. The Investigator must"", 'note the date, time, and reason for unblinding. The Investigator should also inform the Medical', 'Monitor that the patient was unblinded; however, they should not reveal to the Medical Monitor', ""the patients' treatment allocation."", 'When an adverse event (AE) is an unexpected or related and serious, the blind will be broken for', 'that specific patient only. The blind will be maintained for persons responsible for the ongoing', 'conduct of the study (such as the management, monitors, Investigators, etc.) and those', 'responsible for data analysis and interpretation of results, such as biometrics personnel.', 'Unblinded information will only be accessible to those who need to be involved in the safety', 'reporting to Health Authorities, Independent Ethics Committees (IECs), and/or Institutional', 'Review Boards (IRBs).', 'Any patient who is unblinded during the Randomized-Controlled Period will be discontinued', 'from the study.', 'Investigators will receive only blinded information unless unblinded information is judged', 'necessary for safety reasons.', 'Page 44 of 109', 'Alexion Confidential']"
44,page_45,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.4.', 'Concomitant Therapy', 'Prior medications (including vitamins and herbal preparations), including those discussed in the', 'exclusion criteria (Section 5.2) and procedures (any therapeutic intervention, such as', 'surgery/biopsy or physical therapy) the patient takes or undergoes within 28 days prior to the', ""start of screening until the first dose of study drug, will be recorded in the patient's eCRF. In"", 'addition, history of meningococcal vaccination must be collected for the 3 years prior to first', 'dose of study drug. MG-specific medication or therapy (eg, thymectomy, ISTs including', 'corticosteroids, IVIg, and PE/PP) within 2 years prior to screening will be recorded.', ""All medication use and procedures undertaken during the study will be recorded in the patient's"", 'source document/medical chart and eCRF. This record will include all prescription drugs, herbal', 'products, vitamins, minerals, over-the-counter medications, and any other current medications.', 'Concomitant medications will be recorded from the first infusion of study drug through 8 weeks', ""after the patient's last dose of study drug. Any changes in concomitant medications also will be"", ""recorded in the patient's source document/medical chart and eCRF. Any concomitant medication"", ""deemed necessary for the patient's standard of care during the study, or for the treatment of any"", 'AE, along with any other medications, other than those listed as prohibited medications in', 'Section 6.5.1.5 may be given at the discretion of the Investigator. However, it is the', 'responsibility of the Investigator to ensure that details regarding all medications are recorded', 'in', ""full in the patient's source document/medical chart and eCRF."", '6.5.', 'Study Drug Compliance', 'Study drug will be administered in a controlled setting under the supervision of the Investigator', 'or designee, thereby ensuring compliance with study drug administration.', '6.5.1.', 'Allowed Medications', '6.5.1.1.', 'Palliative and Supportive Care', 'Palliative and supportive care is permitted during the course of the study for underlying', 'conditions.', 'The medications described in the following sections are allowed under certain circumstances and', 'restrictions.', '6.5.1.2.', 'Cholinesterase Inhibitors', 'For patients who enter the study receiving a cholinesterase inhibitor at screening, the dose and', 'schedule of their cholinesterase inhibitor should be maintained stable throughout the entire', 'Randomized-Controlled and OLE Periods, unless there is compelling medical need. Increases in', 'cholinesterase therapy that are required as a result of intercurrent illness or other medical cause', 'of deterioration are permitted, but dosing should be returned to dosing levels at study entry as', 'soon as feasible and the Sponsor should be notified of the change.', '1.', 'Cholinesterase inhibitor treatment must be withheld for at least 10 hours prior to', 'administration of the QMG and MGC tests.', '2. If a decrease in cholinesterase inhibitor is considered based on clinical evaluation,', 'Sponsor approval must be obtained prior to the change in dose.', 'Page 45 of 109', 'Alexion Confidential']"
45,page_46,"['Protocol', 'ALXN1210-MG-30‚Ç¨ Amendment 2', '6.5.1.3.', 'Immunosuppressive Agents', 'The following immunosuppressive agents are allowed during the study: corticosteroid, AZA,', 'MMF, MTX, TAC, CYC, or CY. The immunosuppressive agent(s) and its appropriate dose level', 'to be used for an individual patient will be at the discretion of the treating physician/Investigator.', '1. Corticosteroid: for patients who enter the study receiving oral corticosteroid, eg,', 'prednisone, the dose/schedule may not be changed during the entire double-blind study', 'period (ie, the Randomized-Controlled Period). If a decrease or taper in steroid dose is', 'considered during the Randomized-Controlled Period based on clinical evaluation,', 'Sponsor approval must be obtained prior to the change in order for the patient to remain', 'on study. If the dose level subsequently must be increased, the dose level increase cannot', 'be above the dose level reported at the baseline (at the start of randomized treatment).', '2. High-dose steroid should be reserved for patients that experience Clinical Deterioration', 'as defined by this protocol. Every effort should be made to notify the Sponsor within', '24 hours of administration should a patient require rescue therapy for Clinical', 'Deterioration.', '3. AZA, MMF, MTX, TAC, CYC, or CY: for patients who enter the study receiving above', 'mentioned immunosuppressive agents, the dosing regimen of the immunosuppressive', 'agent may not be changed during the entire Randomized-Controlled Period. If a change', 'in the dosing regimen is considered due to known toxicity or side effects associated with', 'the given immunosuppressive agent, Sponsor approval must be obtained prior to the dose', 'change. A different immunosuppressive agent cannot be added or substituted during the', '26-week Randomized-Controlled Period.', '6.5.1.4. Plasma Exchange/Plasmapheresis/Intravenous Immunoglobulin', 'Use of PE/PP or IVIg (acute use only) will be allowed for patients who experience a Clinical', 'Deterioration as defined by this protocol. The rescue therapy used for a particular patient will be', 'at the discretion of the Investigator. Every effort should be made to notify the Sponsor within', '24 hours should a patient require rescue therapy.', 'Supplemental study drug (or placebo) dosing is required if PE/PP or IVIg rescue therapy is', 'provided on nondosing days; if PE/PP or IVIg infusion is provided on a dosing day, it must occur', 'prior to study drug administration.', '1. If PE/PP or IVIg is administered on nonscheduled dosing visits:', 'a.', 'Patients receiving PE/PP: supplemental dose administration will be started within', '4 hours after the PE/PP session is completed (Table 7)', 'b. Patients receiving IVIg: supplemental dose administration will be started within', '4 hours after the last continuous session(s) of IVIg is completed (Table 8)', '2. If PE/PP or IVIg is administered on scheduled dosing visits:', 'a.', 'Regular dosing will be started within 4 hours after the completion of PE/PP or IVIg', '3. No gap is required between a supplemental dose and the regular scheduled dose.', 'Page 46 of 109', 'Alexion Confidential']"
46,page_47,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 7:', 'Supplemental Dose When Plasmapheresis/Plasma Exchange is Administered as Rescue Therapy on', 'Nonscheduled Dosing Visits', 'Body Weight', 'Volume (mL)', 'Previous', 'Next Applicable', 'Used for Most', 'Ravulizumab', 'Diluent', 'Ravulizumab or', 'Supplemental', 'Study Period', 'Recent', 'Dose', 'Placebo Scheduled', '(0.9%', 'Dosing Day', 'Ravulizumab', 'Placebo', 'Total', 'Scheduled', '(mg)', 'sodium', 'Dosing Visit', 'Range', 'Dose (kg¬π', 'chloride)', 'Ravulizumab Group', 'Randomized-', 'Loading dose', 'Days 2 to 14', '> 40 to < 60', '1200', '120', '0', '120', '240', 'Controlled', '(Day 1)', '> 60 to < 100', '1500', '150', '0', '150', '300', '> 100', '1500', '150', '0', '150', '300', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '1500', '150', '0', '150', '300', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '1800', '180', '0', '180', '360', 'Days 128 to 182', '100', '1800', '180', '0', '180', '360', 'Open-Label', 'Blinded dose¬≤', 'Days 184 to 196', '40 to < 60', '600', '60', '60', '120', '240', 'Extension', '(Day 183)', '> 60 to < 100', '600', '60', '90', '150', '300', '100', '600', '60', '90', '150', '300', 'Open-label', 'On intervals', '> 40 to < 60', '1500', '150', '0', '150', '300', 'maintenance dose', 'between', '> 60 to < 100', '1800', '180', '0', '180', '360', '(Days 197 to 869 q8w)', 'scheduled visits', '> 100', '1800', '180', '0', '180', '360', 'Placebo Group', 'Randomized-', 'Loading dose', 'Days 2 to 14', '> 40 to < 60', '0', '0', '120', '120', '240', 'Controlled', '(Day 1)', '60 to < 100', '0', '0', '150', '150', '300', '100', '0', '0', '150', '150', '300', 'Maintenance dose', 'Days 16 to 70,', '> 40 to < 60', '0', '0', '150', '150', '300', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '0', '0', '180', '180', '360', 'Days 128 to 182', '> 100', '0', '0', '180', '180', '360', 'Open-Label', 'Blinded loading dose¬≥', 'Days 184 to 196', '> 40 to < 60', '1200', '120', '0', '120', '240', 'Extension', '(Day 183)', '60 to < 100', '1500', '150', '0', '150', '300', '> 100', '1500', '150', '0', '150', '300', 'Open-label', 'On intervals', '> 40 to < 60', '1500', '150', '0', '150', '300', 'maintenance dose', 'between', '> 60 to < 100', '1800', '180', '0', '180', '360', '(Days 197 to 869,', 'scheduled visits', '> 100', '1800', '180', '0', '180', '360', 'q8w)', ""1 Supplemental dose will be based on the patient's body weight used to determine the most recently administered scheduled dose."", '2 Blinded dose on Day 183 (Week 26) for patients who were randomized to the ravulizumab group and are entering into the Open-Label Extension Period.', '3 Blinded loading dose on Day 183 (Week 26) for patients who were randomized to the placebo group and are entering into the Open-Label Extension Period.', 'Page 47 of 109', 'Alexion Confidential']"
47,page_48,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 8:', 'Supplemental Dose When Intravenous Immunoglobulin is Administered as Rescue Therapy on Nonscheduled', 'Dosing Visits', 'Body Weight', 'Volume (mL)', 'Previous', 'Next Applicable', 'Used for Most', 'Ravulizumab', 'Diluent', 'Ravulizumab or', 'Supplemental', 'Study Period', 'Recent', 'Dose', 'Placebo Scheduled', '(0.9%', 'Dosing Day', 'Ravulizumab', 'Placebo', 'Total', 'Scheduled Dose', '(mg)', 'sodium', 'Dosing Visit', 'Range', '(kg¬π', 'chloride)', 'Ravulizumab Group', 'Loading dose', 'Days 2 to 14', '40 to < 60', '600', '60', '0', '60', '120', '(Day 1)', '60 to < 100', '600', '60', '0', '60', '120', 'Randomized-', '100', '600', '60', '0', '60', '120', 'Controlled', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '600', '60', '0', '60', '120', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '600', '60', '0', '60', '120', 'Days 128 to 182', '100', '600', '60', '0', '60', '120', 'Blinded dose¬≤', 'Days 184 to 196', '40 to < 60', '600', '60', '0', '60', '120', '> 60 to < 100', '600', '60', '0', '60', '120', '(Day 183)', '> 100', '600', '60', '0', '60', '120', 'Open-Label', 'Open-label', 'On intervals', '40 to < 60', '600', '60', '0', '60', '120', 'Extension', 'maintenance dose', 'between', '> 60 to < 100', '600', '60', '0', '60', '120', '(Days 197 to 869', 'scheduled visits', '> 100', '600', '60', '0', '60', '120', 'q8w)', 'Placebo Group', 'Loading dose', 'Days 2 to 14', '40 to < 60', '0', '0', '60', '60', '120', '(Day 1)', '60 to < 100', '0', '0', '60', '60', '120', 'Randomized-', '> 100', '0', '0', '60', '60', '120', 'Controlled', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '0', '0', '60', '60', '120', '(Days 15, 71, 127)', 'Days 72 to 126,', '60 to < 100', '0', '0', '60', '60', '120', 'Days 128 to 182', '> 100', '0', '0', '60', '60', '120', 'Days 184 to 196', '40 to < 60', '600', '60', '0', '60', '120', 'Blinded loading dose¬≥', '> 60 to < 100', '600', '60', '0', '60', '120', '(Day 183)', '> 100', '600', '60', '0', '60', '120', 'Open-Label', 'Extension', 'Open-label', 'On intervals', '40 to < 60', '600', '60', '0', '60', '120', 'maintenance dose', 'between', '> 60 to < 100', '600', '60', '0', '60', '120', '(Days 197 to 869,', 'scheduled visits', '> 100', '600', '60', '0', '60', '120', 'q8w)', ""1 Supplemental dose will be based on the patient's body weight used to determine the most recently administered scheduled dose."", '2 Blinded dose on Day 183 (Week 26) for patients who were randomized to the ravulizumab group and are entering into the Open-Label Extension Period.', '3 Blinded loading dose on Day 183 (Week 26) for patients who were randomized to the placebo group and are entering into the Open-Label', 'Extension', 'Period.', 'Page 48 of 109', 'Alexion Confidential']"
48,page_49,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.5.1.5.', 'Disallowed Medications and Therapies', 'The following concurrent medications are prohibited during the study:', 'Rituximab', 'Chronic PE/PP therapy', 'Chronic IVIg therapy', 'Eculizumab (or other complement-inhibitors)', 'Patient-use of rituximab or eculizumab (or other complement inhibitors) at any point during the', 'study will result in the patient being discontinued from the study.', '6.5.2.', 'Rescue Therapy', ""Rescue therapy (eg, high-dose corticosteroid, PE/PP, or IVIg) will be allowed when a patient's"", 'health would be in jeopardy if rescue therapy was not administered (eg, emergent situations) or,', 'if a patient experiences Clinical Deterioration as defined in this protocol. The rescue therapy', 'used for a particular patient will be at the discretion of the Investigator. The date and time of', 'rescue medication administration as well as the name and dosage regimen of the rescue', 'medication will be recorded.', 'Should a patient require rescue therapy, every effort should be made to notify the Sponsor within', '24 hours.', '6.6.', 'Intervention After the End of the Study', 'Patients will return to the care of their treating physician at the completion of study participation.', 'Page 49 of 109', 'Alexion Confidential']"
49,page_50,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '7.', 'DISCONTINUATION OF STUDY INTERVENTION AND', 'PATIENT DISCONTINUATION/WITHDRAWAI', '7.1.', 'Discontinuation of Study Intervention', 'A patient may withdraw from the study at any time at his/her own request, or may be withdrawn', 'at any time at the discretion of the Investigator for safety, behavioral, compliance, or', 'administrative reasons. If a patient discontinues treatment from the study, the Investigator will', 'attempt to perform (if the patient agrees) assessments specified for the ET Visit, or if not', 'possible, a follow-up phone call to be conducted 8 weeks after the last dose of study drug has', 'been administered (SoA, Section 1.3). Attempts should also be made to follow all patients for', 'safety for a total of 8 weeks from the day the last dose of study drug is administered. The', 'Sponsor and site monitor will be notified as soon as possible. If a patient is withdrawn from the', 'study or withdraws consent no further data will be collected. Patients who withdraw from the', 'study will not be replaced.', 'Patients should be discontinued from study drug if any of the following occur during the study:', '1. Serious hypersensitivity reaction (such as bronchospasm with wheezing or requiring', 'ventilator support or symptomatic hypotension, refer to Section 10.5 [Appendix 5]) or', 'serum sickness-like reactions manifesting 1 to 14 days after study drug administration;', '2. Severe uncontrolled infection;', '3. Pregnancy or planned pregnancy; or', '4. Sponsor or Investigator deems it is in the best interest of the patient.', '5. Use of rituximab, eculizumab (or other complement-inhibitors)', 'The Investigator should contact the Medical Monitor prior to discontinuing a patient from study', 'drug. If a patient discontinues from treatment, the patient should be encouraged to return for the', ""ET Visit (SoA, Section 1.3) 8 weeks after the patient's last dose of study drug."", 'The reason for the treatment discontinuation (ie, patient withdraws consent, patient withdrawal', 'from procedures, physician decision, AE, or other reason specified in eCRF) will be recorded in', 'the eCRF.', 'If a female patient is permanently discontinued from study drug due to pregnancy, the', 'Investigator will make a reasonable attempt to follow-up, in accordance with local laws and', 'regulations, until the outcome of the pregnancy is known (Section 10.4 [Appendix 4]).', 'If the patient withdraws consent for disclosure of future information, the Sponsor may retain and', 'continue to use all data collected before such a withdrawal of consent.', 'If a patient withdraws from the study, the patient may request destruction of any samples taken', 'and not tested, and the Investigator must document this in the site study records as well as inform', 'the site monitor and Sponsor.', '7.2.', 'Lost to Follow Up', 'A patient will be considered lost to follow-up if the patient repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'Page 50 of 109', 'Alexion Confidential']"
50,page_51,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The following actions must be taken if a patient fails to return to the clinic for a required study', 'visit:', '1. The site must attempt to contact the patient and reschedule the missed visit as soon as', 'possible and counsel the patient on the importance of maintaining the assigned visit', 'schedule and ascertain whether or not the patient wishes to and/or should continue in the', 'study.', '2. Before a patient is deemed lost to follow up, the Investigator or designee must make', 'every effort to regain contact with the patient (where possible, 3 telephone calls and, if', ""necessary, a certified letter to the patient's last known mailing address or local equivalent"", ""methods). These contact attempts should be documented in the patient's medical record."", '3. Should the patient continue to be unreachable, the patient will be considered to have', 'withdrawn consent and future missed visits will not be considered protocol deviations.', 'Page 51 of 109', 'Alexion Confidential']"
51,page_52,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', '8.1.', 'Efficacy Assessments', '8.1.1.', 'Hospitalization', 'Information related to all-cause hospitalization, including those that occurred within the last', '2 years prior to screening, will be collected through the OLE Period. Hospitalizations are defined', 'as all admissions to a healthcare facility (hospital, rehabilitation center, or hospice), irrespective', 'of the underlying relation to MG. Dates of admission/discharge, reasons for hospitalization,', 'relationship to MG, and other relevant information will be collected on the eCRF.', '8.1.2.', 'Clinical Deterioration', 'Information related to Clinical Deterioration, as defined in Section 4.2.1, will be collected from', 'patient signing of the ICF through the OLE Period. The evaluation visit for a Clinical', 'Deterioration must be performed as soon as possible, within 48 hours of notification to the', 'Investigator of the symptom onset. Additional Unscheduled Visits (Section 4.2.2) can be', 'scheduled at the discretion of the Investigator. The following tests and procedures will be', 'completed at this visit:', 'Measure vital signs and pulse oximetry, including assessments of systolic and blood', 'pressure (BP), temperature (¬∞C or ¬∞F), oxygen saturation (SO2), and heart rate (HR).', 'Record any new medications or changes to concomitant medications, including all', 'treatments for MG.', 'Evaluate and record any new AEs or changes in AEs since the previous visit.', 'Administer MG-ADL by a properly trained evaluator, preferably the same evaluator,', 'throughout the study. The recall period is the preceding 7 days or since the last visit', 'whichever occurs earlier.', 'Administer clinical assessments QMG and MGC; these should be performed at', 'approximately the same time of day by a properly trained evaluator, preferably the', 'same evaluator, throughout the study.', 'Collect blood sample for the AChR auto-Abs test.', 'Collect blood samples for clinical laboratory tests (see Section 10.2 [Appendix 2]).', 'If medically indicated for evaluation of Clinical Deterioration, additional tests may be', 'performed at the discretion of the Investigator.', 'PK/PD/ADA sampling at or during Clinical Deterioration Visit is described in', 'Figure 2.', 'Page 52 of 109', 'Alexion Confidential']"
52,page_53,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Figure 2:', 'PK/PD/ADA Sampling for Clinical Deterioration', 'Clinical Deterioration Evaluation occurs', 'on a scheduled study visit', 'Yes', 'No', 'Patient receives regular scheduled', 'No', 'No', 'Collect 1 blood sample', 'Patient receives PE/PP/IVIg requiring', 'for PK, free C5, and', 'dose of study drug', 'supplemental dose of study drug', 'ADA assays.', 'Yes', 'Collect 2 blood samples for', 'serum PK, free C5, and ADA:', '(1) within 30 minutes prior to', 'No', 'Patient receives PE/PP/IVIg prior to', 'Yes', 'the start of infusion of study', 'regular scheduled dose of study drug', 'drug and (2) within 30 minutes', 'following completion of study', 'Yes', 'drug infusion.', 'Collect 3 blood samples for PK and free C5: (1) within 90 minutes prior to', 'PE/PP/IVIg, (2) after completion of PE/PP/IVIg and before study drug infusion,', 'and (3) within 30 minutes following completion of study drug infusion. In', 'addition, a single ADA sample should be collected within 90 minutes prior to', 'PE/PP/IVIg only.', 'Abbreviations: ADA = antidrug antibody; IVIg = intravenous immunoglobulin; PD = pharmacodynamic(s); PE = plasma exchange; PK = pharmacokinetic(s);', 'PP = plasmapheresis', 'Page 53 of 109', 'Alexion Confidential']"
53,page_54,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.1.3.', 'Myasthenia Gravis Activities of Daily Living Profile', 'The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional', 'performance of ADL in patients with MG (Section 10.6 [Appendix 6]). The 8 items of the', 'MG-ADL questionnaire were derived from symptom-based components of the original 13-item', 'QMG scale to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory', '(1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this', 'functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of', 'total MG-ADL score is 0 - 24. The recall period for MG-ADL is the preceding 7 days. The MG-', 'ADL profile should be administered by a properly trained evaluator. For consistency, the same', 'evaluator should administer the questionnaire throughout the study.', '8.1.4.', 'Quantitative Myasthenia Gravis Score', 'The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items),', 'gross motor (6 items), axial (1 item), and respiratory (1 item); each graded 0 to 3, with 3 being', 'the most severe (Section 10.7 [Appendix 7]). The range of total QMG score is 0 - 39. The QMG', 'scoring system is considered to be an objective evaluation of therapy for MG and is based on', 'quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the', 'QMG score be used in prospective studies of therapy for MG (Benatar, 2012).', '8.1.5.', 'Myasthenia Gravis Composite Score', 'The MGC is a validated assessment tool for measuring clinical status of patients with MG. The', 'range of total MGC score is 0 - 50. The MGC assesses 10 important functional areas most', 'frequently affected by MG and the scales are weighted for clinical significance that incorporates', 'patient-reported outcomes (Burns, 2010) (Section 10.8 [Appendix 8]).', '8.1.6.', 'Euro Quality of Life 5D-5L', 'The Euro Quality of Life-5L (EQ-5D-5L) (Section 10.9 [Appendix 9]) is a self-assessed,', 'health-related QoL questionnaire. The scale measures QoL on a 5-component scale including', 'mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated', 'on a scale that describes the degree of problems in that area (ie, I have no problems walking', 'about, slight problems, moderate problems, severe problems, or unable to walk). This tool also', 'has an overall health scale where the rater selects a number between 1 - 100 to describe the', 'condition of their health, 100 being the best imaginable. Convergent validity was demonstrated', 'by a correlation between EQ-5D-5L and the dimensions of World Health Organization 5 Well', 'Being questionnaires, (r = 0.43, p < 0.001) (Janssen, 2013). The EQ-5D-5L approach is reliable,', 'average test-retest reliability using interclass coefficients with mean of 0.78 and 0.73 (Brooks,', '1996; Chaudhury, 2006).', '8.1.7.', 'Revised Myasthenia Gravis Qualify of Life-15 Scale', 'The revised Myasthenia Gravis Qualify of Life 15-item scale (MG-QOL15r) (Section 10.10', '[Appendix 10]) is a health-related QoL evaluative instrument specific to patients with MG. The', ""MG-QOL15r was designed to provide information about patients' perception of impairment and"", 'disability, determine the degree to which disease manifestations are tolerated, and to be', 'Page 54 of 109', 'Alexion Confidential']"
54,page_55,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'administered and interpreted easily (Burns, 2016). The MG-QOL15r will be completed by the', 'patient. Higher scores indicate greater extent of and dissatisfaction with MG-related dysfunction.', '8.1.8.', 'Neurological Quality of Life Fatigue', 'The Neuro-QOL Fatigue is a reliable and validated brief 19-item survey of fatigue, completed by', 'the patient (Cella, 2010). Higher scores indicate greater fatigue and greater impact of MG on', 'activities (Section 10.11 [Appendix 11]).', '8.1.9.', 'Myasthenia Gravis Foundation of America Clinical Classification', 'The MGFA Clinical Classification will be assessed on Day 1 (Section 10.12 [Appendix 12]).', '8.1.10.', 'Myasthenia Gravis Foundation of America Post-Intervention Status', 'The MG clinical state will be assessed using a modified version of the MGFA-PIS', '(Section 10.13 [Appendix 13]). Change in status categories of Improved, Unchanged, or Worse,', 'as well as the minimal manifestation (MM) will be assessed and recorded at the time points', 'indicated in the SoA (Section 1.3) by the Investigator or the same neurologist skilled in the', 'evaluation of patients with MG throughout the study. The subscores of MM, ie, MM-0, MM-1,', 'and MM-3, will not be used in this protocol.', '8.2.', 'Safety Assessments', '8.2.1.', 'Physical Examination', 'A physical examination will include assessments of the following body systems: general', 'appearance; skin; head, ear, eye, nose, throat; neck; lymph node; chest; heart; abdominal cavity;', 'limb; central nervous system; and musculoskeletal. An abbreviated physical examination', 'consists of a body-system relevant examination based upon Investigator judgment and patient', 'symptoms. For consistency, all efforts should be made to have the physical examination', 'performed by the same qualified study staff.', '8.2.2.', 'Vital Signs and Pulse Oximetry', 'Vital signs and pulse oximetry will be measured at every visit and will include assessments of', 'systolic and diastolic BP (mmHg), temperature (¬∞C or ¬∞F), SO2, and HR (beats per minute). Vital', 'signs will be obtained after the patient has been supine or seated for at least 5 minutes. Ideally,', ""each patient's BP should be measured using the same arm."", '8.2.3.', 'Electrocardiogram', 'Single 12-lead electrocardiogram (ECG) will be obtained as outlined in the SoA (Section 1.3)', 'using an ECG machine to obtain HR and measures of PR, QRS, QT, and QTc intervals. QT', ""interval will be corrected for heart rate using Fridericia's formula (QTcF). Patients must be"", 'supine for approximately 5 - 10 minutes before ECG collection and remain supine but awake', 'during ECG collection.', 'The Investigator or designee will be responsible for reviewing the ECG to assess whether the', 'ECG is within normal limits and determine the clinical significance of the results. These', 'assessments will be indicated on the eCRF.', 'Page 55 of 109', 'Alexion Confidential']"
55,page_56,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.2.4.', 'Clinical Safety Laboratory Assessments', 'Laboratory assessments will be tested at a central laboratory facility. Any clinically significant', 'abnormal results should be followed until resolution or stabilization.', 'All protocol-required laboratory assessments, as defined in Section 10.2 (Appendix 2), must be', 'conducted in accordance with the laboratory manual and the SoA (Section 1.3).', 'The Investigator must review the laboratory report, document this review, and record any', 'clinically relevant changes occurring during the study in the AE section of the eCRF. The', 'laboratory reports must be filed with the source documents.', 'Clinically significant abnormal laboratory findings associated with the underlying disease are not', 'considered AEs unless they are judged by the Investigator to be more severe than expected for', ""the patient's condition."", 'If such values do not return to normal/baseline within a period of time judged reasonable by the', 'Investigator, the etiology should be identified and the Sponsor notified.', '8.2.4.1.', 'Urinalysis and Urine Chemistry', 'Urine samples will be analyzed for the parameters listed in Section 10.2 (Appendix 2). A', 'microscopic examination of urine samples will be performed if the results of the macroscopic', 'analysis are abnormal.', '8.2.4.2.', 'Virus Serology', 'Human immunodeficiency virus testing for HIV-1 and HIV-2 is required of all patients prior to', 'enrollment. Patients who are HIV positive will not be enrolled.', '8.2.4.3.', 'Immunogenicity Assessments', 'Blood samples will be collected to test for presence of ADAs to ravulizumab in serum prior to', 'study drug administration. Further characterization of antibody responses may be conducted as', 'appropriate, including ADA titer, binding and neutralizing antibodies, PK/PD, safety, and', 'activity of ravulizumab. Antibodies to ravulizumab will be evaluated in serum samples collected', 'from all patients according to the SoA (Section 1.3). Serum samples will be screened for', 'antibodies binding to ravulizumab and the titer of confirmed positive samples will be reported.', 'The detection and characterization of antibodies to ravulizumab will be performed using a', 'validated assay by or under the supervision of the Sponsor.', 'Detailed instructions on the procedure for collecting, processing, storing, and shipping serum', 'samples for immunogenicity analysis will be provided in the laboratory manual.', '8.2.5.', 'Suicidal Risk Monitoring', '8.2.5.1.', 'Columbia-Suicidal Severity Rating Scale', 'The Columbia-Suicide Severity Rating Scale (C-SSRS; Section 10.14 [Appendix 14] and', 'Section 10.15 [Appendix 15]) is a validated questionnaire used extensively across primary care,', 'clinical practice, surveillance, research, and institutional settings to assess suicidal ideation and', 'behavior (Posner, 2011). The C-SSRS will be administered by the Investigator or a properly', 'Page 56 of 109', 'Alexion Confidential']"
56,page_57,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'trained designee. The C-SSRS will be assessed for both lifetime and past 1 year (12 months) as', 'specified in the SoA (Section 1.3). The C-SSRS is being implemented to ensure that patients', 'who are experiencing suicidal ideation or behavior are properly recognized and adequately', 'managed.', '8.3.', 'Adverse Events and Serious Adverse Events', 'Adverse events will be reported to the Investigator or qualified designee by the patient (or when', ""appropriate, by a caregiver, surrogate, or the patient's legally authorized representative)."", 'The Investigator or qualified designees are responsible for detecting, documenting, and recording', 'events that meet the definition of an AE or SAE, and remain responsible for following up events', 'that are serious, considered related to the study drug or study procedures; or that caused the', 'patient to discontinue the study drug (Section? 7).', 'Definitions and procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are', 'outlined in Section 10.3 (Appendix 3).', '8.3.1.', 'Time Period and Frequency for Collecting Adverse Event and Serious Adverse', 'Event Information', 'All AEs will be collected from the signing of the ICF until 8 weeks after the last dose of study', 'drug is administered.', 'Medical occurrences that begin before the start of study drug but after obtaining informed', 'consent must be recorded in the AE case report form (CRF) as AEs and not in the Medical', 'History/Current Medical Conditions CRF.', 'All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated', 'in Section 10.3 (Appendix 3). The investigator will submit any updated SAE data to the Sponsor', 'within 24 hours of awareness.', 'Investigators are not obligated to actively seek AEs or SAEs after the conclusion of study', 'participation. However, if the Investigator learns of any SAE, including a death, at any time after', 'a patient has been discharged from the study, regardless of whether or not the event is related to', 'the study drug, the Investigator must promptly notify the Sponsor.', 'The method of recording, evaluating, and assessing causality of AE and SAE and the procedures', 'for completing and transmitting SAE reports are provided in Section 10.3 (Appendix 3).', '8.3.2.', 'Method of Detecting Adverse Events and Serious Adverse Events', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and', 'nonleading verbal questioning of the patient is the preferred method to inquire about', 'AE occurrences.', '8.3.3.', 'Follow-up of Adverse Events and Serious Adverse Events', 'After the initial AE/SAE report, the Investigator is required to proactively follow each patient at', 'subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is', 'otherwise explained, or the patient is lost to follow-up (as defined in Section 7.2). Further', 'information on follow-up procedures is given in Section 10.3 (Appendix 3).', 'Page 57 of 109', 'Alexion Confidential']"
57,page_58,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.3.4.', 'Regulatory Reporting Requirements for Serious Adverse Events', 'The Investigator must notify the Sponsor of an SAE within 24 hours of the first awareness of', 'the event.', 'The Sponsor has a legal responsibility to notify both the local regulatory authority and other', 'regulatory agencies about the safety of a study drug under clinical investigation. The Sponsor', 'will comply with country-specific regulatory requirements relating to safety reporting to the', 'regulatory authority, IRB/IEC, and Investigators.', 'The Council for International Organizations of Medical Sciences (CIOMS) or MedWatch', 'reports must be prepared for suspected unexpected serious adverse reactions (SUSARs)', '(Section 10.3 [Appendix 3]) according to local regulatory requirements and Sponsor policy', 'and forwarded to Investigators as necessary. Alexion procedures for the reporting of', 'SUSARs are in accordance with United States Title 21 Code of Federal Regulations (CFR)', '312.32 and European Union Clinical Trial Directive 2001/20/EC and the associated detailed', 'guidance documents or national regulatory requirements in participating countries, as well as', 'IRBs/IECs where applicable.', 'An Investigator who receives an Investigator safety report describing an SAE or other', 'specific safety information (eg, summary or listing of SAEs) from the Sponsor will review', 'and acknowledge the report and notify the IRB/IEC, if appropriate, according to local', 'requirements.', '8.3.5.', 'Pregnancy', 'Contraception guidance that must be followed for the study duration is detailed in', 'Section 10.4 (Appendix 4).', 'For patients of childbearing potential, a serum pregnancy test (ie, beta-human chorionic', 'gonadotropin) will be performed at Screening and at the EOS/ET. Urine pregnancy tests will be', 'performed at all other required time points, as indicated in the SoA (Section 1.3). A negative', 'pregnancy test is required prior to administering ravulizumab to patients of childbearing', 'potential.', 'If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of', 'learning of the pregnancy and should follow the procedures outlined in', 'Section 10.4 (Appendix 4).', 'Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital', 'anomalies, and ectopic pregnancy) are considered SAEs and should be reported as described in', 'Section 10.3 (Appendix 3).', '8.3.6.', 'Vaccine and Antibiotic Prophylaxis', ""As with any terminal complement antagonist, the use of ravulizumab increases the patient's"", 'susceptibility to meningococcal infection (N meningitidis). To reduce the risk of meningococcal', 'infection, all patients must be vaccinated against meningococcal infections within the 3 years', 'prior to, or at the time of, initiating study drug. Patients who initiate study drug treatment less', 'than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate', 'prophylactic antibiotics until 2 weeks after vaccination.', 'Page 58 of 109', 'Alexion Confidential']"
58,page_59,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Vaccines against serotypes A, C, Y, W135, and B, where available, are recommended to prevent', 'common pathogenic meningococcal serotypes. Patients must be vaccinated or revaccinated', 'according to current national vaccination guidelines or local practice for vaccination use with', 'complement-inhibitors (eg, eculizumab).', 'Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be', 'given per official guidance and local practice on the appropriate use of antibacterial agents. All', 'patients should be monitored for early signs of meningococcal infection, evaluated immediately', 'if infection is suspected, and treated with appropriate antibiotics, if necessary.', 'To increase risk awareness and promote quick disclosure of any potential signs or symptoms of', 'infection experienced by the patients during the course of the study, patients will be provided a', 'safety card to carry with them at all times. Additional discussion and explanation of the potential', 'risks, signs, and symptoms will occur at each visit as part of the review of the patient safety card', 'as described in the SoA (Section 1.3). Vaccination(s) for N meningitidis will be recorded on the', ""patient's eCRF."", '8.3.7.', 'Study Drug Administration Reactions', '8.3.7.1.', 'Local and Systemic Reactions', 'Infusion-site reactions are those localized to the site of IV study drug administration and may', 'include those such as erythema, pruritus, and bruising. Infusion-associated reactions are those', 'which are systemic in nature and which may be immune or nonimmune-mediated generally', 'occurring within hours of study drug administration. Immune-mediated reactions may include', 'allergic reactions (eg, anaphylaxis), while nonimmune-mediated reactions are nonspecific (eg,', 'headache, dizziness, nausea). Monitoring for these reactions will be conducted as part of routine', 'safety assessments for this study.', '8.3.7.2.', 'Infusion-Associated Reactions', 'Infusion-associated reactions are defined as systemic AEs (eg, fever, chills, flushing, alterations', 'in HR and BP, dyspnea, nausea, vomiting, diarrhea, and generalized skin rashes) occurring', 'during or within 24 hours of the start of IV infusion that are assessed by the Investigator to be', 'possibly, probably, or definitely related to the study drug.', '8.4.', 'Adverse Events of Special Interest', 'Meningococcal infections will be collected as adverse events of special interest (AESI) for this', 'study.', '8.5.', 'Pharmacokinetics', 'Blood samples will be obtained to assess pre- and post-treatment serum ravulizumab', 'concentrations at the time points and within the windows indicated in the SoA (Section 1.3).', 'Samples obtained outside of the allotted windows will be considered protocol deviations. Unused', 'samples may be retained for a period of up to 5 years to perform additional assessments as', 'necessary.', 'Page 59 of 109', 'Alexion Confidential']"
59,page_60,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Additional details on sample collection, including blood volume requirements, are provided in', 'the laboratory manual.', '8.6.', 'Pharmacodynamics', 'Blood samples will be obtained to assess pre- and post-treatment serum free C5 at the time points', 'and within the windows indicated in the SoA Section 1.3). Samples obtained outside of the', 'allotted windows will be considered protocol deviations. Unused samples may be retained for a', 'period of up to 5 years to perform additional assessments as necessary.', 'Additional details on sample collection, including blood volume requirements, are provided in', 'the laboratory manual.', '8.7.', 'Genetics', 'Genetics will not be evaluated in this study.', '8.8.', 'Biomarkers', 'Blood samples for the assessment of AChR auto-Abs will be obtained at the time points', 'indicated in the SoA (Section 1.3).', 'Additional details on sample collection, including blood volume requirements, are provided in', 'the laboratory manual.', 'Remaining samples from PK, PD, immunogenicity, and biomarker testing may be stored for', 'future biomarker research. Analyses may be performed on biomarker variants thought to play a', 'role in gMG activity/progression or treatment response to ravulizumab. These samples may also', 'be used to develop methods, assays, prognostics, and/or companion diagnostics related to the', 'study drug target, disease process, pathways associated with disease state, and/or mechanism of', 'action of the study drug.', 'Samples may be stored for a maximum duration according to local regulations following the last', ""patient's last visit for the study, at a facility selected by the sponsor, to enable further analyses."", '8.9.', 'Healthcare Resource Utilization', 'Healthcare resource utilization data, associated with medical encounters, will be collected by the', 'Investigator or designee for all patients throughout the study. Data will be recorded in the eCRF.', 'The data collected may be used to conduct exploratory economic analyses and will include:', 'Whether patients were admitted to a hospital, rehabilitation center, or hospice', 'Whether the primary reason for admission was related to MG (yes/no)', 'Duration of hospitalization (admission and discharge dates)', 'Page 60 of 109', 'Alexion Confidential']"
60,page_61,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '9.', 'STATISTICAL CONSIDERATIONS', 'Statistical methods described in this section will be further elaborated in a separate SAP. The', 'SAP will be developed and finalized before database lock. The analyses will be performed using', 'the SASE statistical software system Version 9.4 or later. Statistical analyses will include', 'tabulations of summary data, inferential analyses, by-patient listings and figures. Inference from', 'efficacy analyses will be based on 2-sided Type I error (a) = 5%. Summary statistics for', 'continuous variables will minimally include n, mean, standard deviation, minimum, median, and', 'maximum. For categorical variables, frequencies and percentages will be presented.', 'The baseline value for analysis and reporting will be based on the last nonmissing measurement', 'on or prior to the first dose of study drug. The treatment groups for analysis and reporting will be', 'based on the conventions outlined in Table 9. A ""Total\' group will be formed to report', 'demographics, baseline characteristics and other prestudy information such as prestudy SAEs,', 'medical history, or prior medications. Details for imputation of efficacy data will be described in', 'the SAP. Missing safety data will not be imputed.', 'A clinical study report (CSR) will be produced based on efficacy, safety, PK, PD, and', 'immunogenicity data collected though the end of the 26-week Randomized-Controlled Period. A', 'final CSR to summarize long-term efficacy, safety, PK, PD, and immunogenicity parameters will', 'be produced at study completion.', '9.1.', 'Statistical Hypotheses', '9.1.1.', 'Primary Hypothesis', 'The primary hypothesis for this study is that ravulizumab is superior to placebo in improvement', 'of MG-ADL total score at Week 26.', 'The treatment effect based on the primary endpoint will be estimated by the difference in means', 'between the ravulizumab group and placebo group in the change from Baseline in MG-ADL', 'total score at Week 26 irrespective of rescue therapy¬π A lower value of the corresponding', 'estimate will indicate a beneficial treatment effect.', '9.1.2.', 'Secondary Hypotheses', 'The following secondary hypotheses will be included in study-wise multiplicity adjustment', '(provided the null hypothesis for primary endpoint is rejected) (Section 9.4.5.4):', '1. Ravulizumab is superior to placebo in improvement of QMG total score at Week 26.', '2. Ravulizumab is superior to placebo in QMG 5-point response (>5 point improvement', 'from baseline in QMG total score) at Week 26.', ""1 Rescue therapy includes high-dose corticosteroids, PE/PP or IVIg. It will be allowed when a patient's health is in"", 'jeopardy, if rescue therapy was not administered (eg, emergent situations), or if a patient experiences Clinical', 'Deterioration', 'Page 61 of 109', 'Alexion Confidential']"
61,page_62,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '3. Ravulizumab is superior to placebo in improvement of the MG-QOL15r total score at', 'Week 26.', '4. Ravulizumab is superior to placebo in improvement of Neuro-QOL Fatigue total', 'score at Week 26.', '5.', 'Ravulizumab is superior to placebo in MG-ADL 3-point response', '(>3 point improvement from baseline in MG-ADL total score) at Week 26.', '9.1.3.', 'Hypotheses Related to Exploratory Efficacy Objectives', '1. Ravulizumab is superior to placebo in improvement of MGC total score at Week 26.', '2. Ravulizumab is superior to placebo in MGFA-PIS at Week 26.', '3. Ravulizumab is superior to placebo in improvement of EQ-5D-5L index score at', 'Week 26.', '4. Ravulizumab is superior to placebo in improvement of MG-ADL subcomponent scores', '(bulbar, limbs, respiratory, and ocular) at Week 26.', '5. Ravulizumab is superior to placebo in improvement of QMG subcomponent scores', '(bulbar, limbs, respiratory, and ocular) at Week 26.', '6. Ravulizumab is superior to placebo in reducing incidence of hospitalizations/MG-related', 'hospitalizations.', '7. Ravulizumab is superior to placebo in reducing incidence of Clinical Deterioration/MG', 'crisis.', '9.1.4.', 'Estimation of Treatment Effect for Secondary and Exploratory Hypotheses', 'The treatment effect corresponding to the change from Baseline continuous endpoints will be', 'estimated similarly as the primary endpoint.', 'The treatment effect corresponding to the following dichotomous endpoints will be estimated by', 'the odds ratio (OR) of the proportions of the corresponding endpoint in the ravulizumab group', 'compared with the placebo group:', 'a.', 'MG-ADL 3-point response at Week 26 irrespective of rescue therapy', 'b. QMG 5-point response at Week 26 irrespective of rescue therapy', 'c. Incidence of hospitalization/MG-related hospitalizations irrespective of rescue', 'therapy', 'd. Incidence of Clinical Deterioration/MG crisis over 26 weeks irrespective of rescue', 'therapy', 'An estimate of OR < 1 corresponding to the hospitalization and Clinical Deterioration endpoint', 'will indicate a beneficial treatment effect, likewise an estimate of OR > 1 corresponding', 'responder endpoints will indicate a beneficial treatment effect.', 'Page 62 of 109', 'Alexion Confidential']"
62,page_63,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The treatment effect corresponding to the MGFA-PIS endpoint will be estimated by the', 'proportional OR of the cumulative proportions over the ordinal categories (starting from the best', 'outcome) of this endpoint in the ravulizumab group compared with the placebo group at', 'Week 26, irrespective of rescue therapy. An estimate of OR > 1 will indicate a beneficial', 'treatment effect.', '9.2.', 'Sample Size Determination', 'Approximately 160 patients will be randomly assigned to ravulizumab and placebo in a 1:1 ratio', '(ravulizumab:placebo stratified by region (North America, Europe, Asia-Pacific, and Japan) to', 'ensure at least 90% nominal power to reject the null hypotheses of no treatment difference for', 'the primary and secondary endpoints based on 2-sided Type I error (a) = 5%. Assumptions', 'related to statistical power calculations are based on Study ECU-MG-301. Details are provided', 'in Section 10.16 (Appendix 16).', '9.3.', 'Populations for Analyses', 'For purposes of analysis, the following analysis sets are defined in Table 9.', 'Table 9:', 'Study ALXN1210-MG-306: Analysis Sets', 'Population', 'Description', 'Randomized set', 'All randomized patients grouped by randomized treatment group (for', 'reporting disposition, demographics, and baseline characteristics).', 'PK Analysis Set (PKAS)', 'All ravulizumab treated patients with at leastl post-baseline PK concentration', 'available.', 'Full analysis set (FAS)', 'All randomized patients who received at least 1 dose of study drug grouped by', 'randomized treatment group (for reporting efficacy data).', 'Per protocol set (PPS)', 'Subset of FAS without any major protocol deviations¬π during', 'Randomized-Controlled Period grouped by randomized treatment group (for', 'reporting key efficacy data).', 'Safety set (SS)', 'All patients who received at least 1 dose of study drug grouped by treatment', 'actually received (for reporting exposure and safety data). For a patient to be', 'analyzed according to the treatment they actually received and not according', 'to the randomization schedule, they would have to receive that treatment for', 'the entire duration of Randomized-Controlled Period.', 'Open-label extension set', 'All patients who received at least 1 dose of ravulizumab starting from', 'Week 26 onward (for reporting all data from the OLE Period).', '1', 'Determination of applicable major protocol deviations for this purpose will be made prior to database lock and', 'study unblinding.', '9.4.', 'Statistical Analyses', '9.4.1.', 'Enrollment and Disposition', 'The number of patients screened, screen failures, and randomized patients will be presented.', 'Enrollment information will be presented grouped by stratification factor and treatment group.', 'Number of patients discontinued along with reasons from Randomized-Controlled Period, OLE', 'Period, and the overall study will be summarized.', 'Page 63 of 109', 'Alexion Confidential']"
63,page_64,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '9.4.2.', 'Demographics, Baseline Characteristics, Inclusion and Exclusion Criteria, and', 'Protocol Deviations', 'All demographic information and baseline characteristics will be reported by treatment group', 'and overall. No statistical test will be performed for homogeneity among treatment groups.', 'The number and percentage of patients not meeting specific inclusion or exclusion criterion will', 'be summarized. Similar summary will be provided for major protocol deviations based on', 'prespecified categories.', '9.4.3.', 'Medical/Surgical History, Physical Examination, and Myasthenia Gravis', 'History', 'The medical and surgical history will be summarized by the Medical Dictionary for Regulatory', '(MedDRA) Activities, Version 20.1, or later by System Organ Class (SOC) and Preferred Term.', 'Myasthenia gravis and abnormal physical examination will also be summarized.', '9.4.4.', 'Prior and Concomitant Medications', 'For analysis and reporting purpose, any medication started prior to first dose of study drug will', 'be considered as prior medication; and medications that started on or after the first dose of study', 'drug will be considered as concomitant medications. All prior and concomitant medications', 'including MG-specific medications and rescue therapy during the study, if any, will be', 'summarized.', '9.4.5.', 'Efficacy Analyses', '9.4.5.1.', 'Primary Efficacy Analysis', 'The Mixed-effects Model with Repeated Measures (MMRM) will be used for the primary', 'efficacy endpoint (change from Baseline in MG-ADL total score at Week 26) using all available', 'longitudinal data (either complete or partial) regardless of whether patients received a rescue', 'therapy¬≤. Missing data will not be imputed for the primary analysis. The model will include the', 'MG-ADL change from Baseline score at each prespecified time point as the response variable,', 'fixed categorical effects of treatment, study visit and treatment-by-study visit interaction, region;', 'as well as fixed covariate of baseline MG-ADL total score. The treatment effect will be', 'evaluated via contrast for the treatment-by-visit term at Week 26. An unstructured covariance', 'matrix will be used to model the correlations among repeated measurements within each patient.', 'Other covariance structures will be implemented if a convergence issue occurs (details to be', 'provided in SAP). The Kenward-Rogers method will be used to estimate the denominator', 'degrees of freedom.', ""2 Rescue therapy includes high-dose corticosteroids, PE/PP or IVIg. It will be allowed when a patient's health is in"", 'jeopardy, if rescue therapy was not administered (eg, emergent situations), or if a patient experiences Clinical', 'Deterioration', 'Page 64 of 109', 'Alexion Confidential']"
64,page_65,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '9.4.5.2.', 'Sensitivity Analyses for Primary Endpoint', 'Two sensitivity analyses will be performed for the primary efficacy endpoint to explore the', 'robustness of the MMRM results for the primary efficacy analysis:', '1. Placebo-based sensitivity analysis:', 'The placebo-based sensitivity analysis will consider the Missing Not At Random', '(MNAR) mechanism for the missing data, where it will be assumed that patients who', 'discontinue early from ravulizumab will follow the trajectory of outcomes similar to the', 'one in the placebo group after discontinuation of ravulizumab, taking into account', 'observed values prior to discontinuation.', '2. Tipping point sensitivity analysis:', 'This approach assumes that patients who discontinue from ravulizumab treatment', 'experience worsening defined by a prespecified adjustment in the primary efficacy', 'endpoint.', '9.4.5.3.', 'Analyses of Secondary and Exploratory Enppoints', 'All continuous secondary and exploratory endpoints related to change from Baseline will be', 'analyzed similarly as the primary endpoint.', 'The QMG 5-point and MG-ADL 3-point responder endpoints will be analyzed using a mixed', 'effect repeated measures model. The model will include response variable at each pre-specified', 'time point as the dependent variable, fixed categorical effects of treatment, study visit and', 'treatment-by-study visit interaction, and region; as well as fixed covariate of baseline QMG or', 'MG-ADL total score (depending on the response variable). The treatment effect will be', 'evaluated via contrast for the treatment-by-visit term at Week 26. An unstructured covariance', 'matrix will be used to model the correlations among repeated measurements within each patient.', 'Other covariance structures will be implemented if a convergence issue occurs (details to be', 'provided in SAP).', 'Clinical Deterioration/MG crisis and hospitalizations/MG-related hospitalizations will be', 'analyzed using a logistic regression model with treatment group, region.', 'The MGFA-PIS endpoint at Week 26 will be considered as an ordinal scale. A logistic regression', 'of the cumulative odds (cumulated over the categories starting from best outcome) will be', 'performed using treatment as fixed categorical effect and adjusting for region.', 'Long-term efficacy data will be summarized descriptively based on OLE set.', '9.4.5.4.', 'Multiplicity Adjustment for Primary and Secondary Enppoints', 'The study is designed to strongly control the overall 2-sided Type I error of a = 0.05. The', 'primary null hypothesis will be tested first at a = 0.05. If statistically significant, 5 secondary', 'hypotheses will be tested for superiority using a closed-testing procedure with the following', 'order:', '1. Change from Baseline in QMG total score at Week 26', 'Page 65 of 109', 'Alexion Confidential']"
65,page_66,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '2. Proportion of patients with improvement of at least 5 points in the QMG total score from', 'Baseline at Week 26', '3. Change from Baseline in MG-QOL15r at Week 26', '4. Change from Baseline in Neuro-QOL Fatigue at Week 26', '5. Proportion of patients with improvement of at least 3 points in the MG-ADL total score', 'from Baseline at Week 26', 'The testing will proceed from (#1) to (#5) and if statistical significance is not achieved (p<0.05),', 'then subsequent endpoints will not be considered to be statistically significant. Estimates and', 'confidence intervals will be computed for all these secondary endpoints regardless of the', 'outcome of the closed testing procedure.', '9.4.5.5.', 'Per Protocol Analyses for Primary and Secondary Enppoints', 'Supplemental per protocol analyses for primary and secondary endpoints will be performed', 'based on per protocol set (PPS) in the same manner as done for FAS.', '9.4.6.', 'Safety Analyses', 'The safety and tolerability of ravulizumab will be assessed based on adverse events, clinical', 'laboratory findings, vital sign findings, and ECG abnormalities. Safety analyses will be', 'performed on the Safety Population and OLE set based on the study period under consideration.', '9.4.6.1.', 'Analysis of Adverse Events', 'Analysis and reporting for AEs will be based on treatment-emergent adverse events (TEAEs),', 'including treatment-emergent serious adverse events (TESAEs) defined as an AE with onset on', 'or after first dose of ravulizumab in the Randomized-Controlled Period. Treatment-emergent', 'AEs and TESAEs will be summarized by MedDRA SOC and Preferred Term, by severity, and', 'by relationship to the study drug. Patient-years adjusted event rates will be generated to', 'characterize long-term safety profile.', '9.4.6.2.', 'Analysis of Clinical Laboratory Parameters, Vital Sign Measurements and', 'Electrocardiogram Parameters', 'Laboratory measurements as well as their changes from Baseline at each visit and shift from', 'baseline, if applicable, will be summarized descriptively. ECG, vital sign, and pulse oximetry', 'findings will also be summarized using descriptive analyses.', '9.4.6.3.', 'Other Safety Analyses', 'The number and percentage of patients in each of the C-SSRS categories and shift analyses will', 'be produced. Results from pregnancy tests will be summarized.', '9.4.6.4.', 'Analysis of Pharmacokinetics and Pharmacodynamics', 'Individual serum concentration data for all patients who receive at least 1 dose of ravulizumab', 'and who have evaluable PK data will be used to derive PK parameters for ravulizumab.', 'Page 66 of 109', 'Alexion Confidential']"
66,page_67,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Pharmacokinetic parameters such as peak and trough serum ravulizumab concentrations will be', 'reported and summarized.', 'Graphs of mean serum concentration-time profiles will be constructed. Graphs of serum', 'concentration-time profiles for individual patients may also be provided. Descriptive statistics', 'will be calculated for serum concentration data at each sampling time, as appropriate.', 'Population-PK will be performed with this data but will be described in a separate report.', 'Pharmacodynamic analyses will be performed for all patients who receive at least 1 dose of', 'ravulizumab and who have evaluable PD data.', 'Descriptive statistics will be presented for all ravulizumab PD endpoints at each sampling time', '(Section 1.3). The PD effects of ravulizumab administered IV will be evaluated by assessing the', 'absolute values and changes from baseline in free C5 serum concentrations over time, as', 'appropriate. Assessments of ravulizumab PK/PD relationships may be explored using data from', 'this study or in combination with data from other studies.', '9.4.6.5.', 'Analysis of Immunogenicity', 'The presence of ADAs in serum ravulizumab will be assessed over the duration of the study.', 'Immunogenicity results will be analyzed by summarizing the number and percentage of patients', 'who develop detectable ADA. The association of ADA with ravulizumab concentration, PD', 'parameters, efficacy, and TEAEs may be evaluated.', '9.4.6.6.', 'Analysis of Exploratory Biomarkers', 'Acetylcholine receptor antibody titer levels as well as their changes from Baseline at each visit', 'will be summarized descriptively.', '9.5.', 'Interim Analyses', 'No interim analysis is planned for Study ALXN1210-MG-30 during the', 'Randomized-Controlled Period. The primary analysis will be conducted when the last patient', 'completes the Randomized-Controlled Period, the database is locked, and the study', 'randomization schedule is unblinded. Periodic analysis and reporting will be performed during', 'the OLE Period based on regulatory requirement. Final analysis and reporting will be conducted', 'at the conclusion of the study.', '9.6.', 'Data Monitoring Committee', 'No independent Data Monitoring Committee is planned for Study ALXN1210-MG-306.', 'Page 67 of 109', 'Alexion Confidential']"
67,page_68,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight', 'Considerations', '10.1.1.', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with the following:', '-', 'Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and CIOMS International Ethical Guidelines', '- Applicable ICH-GCP Guidelines', '- Applicable laws and regulations', 'The protocol, protocol amendments, ICF, IB, and other relevant documents (eg,', 'advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and', 'approved by the IRB/IEC before the study is initiated.', 'The IRB/IEC and relevant regulatory authority must be notified of any significant', 'amendment to the protocol, as applicable. Necessary approvals must be given before changes', 'are implemented.', 'The Investigator will be responsible for the following:', '- Providing written summaries of the status of the study to the IRB/IEC annually or', 'more frequently in accordance with the requirements, policies, and procedures', 'established by the IRB/IEC', '- Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures', '- Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC,', 'European regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', '10.1.2.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to the patient or', 'his/her legally authorized representative and answer all questions regarding the study.', 'Patients must be informed that their participation is voluntary. Patients or their legally', 'authorized representative will be required to sign a statement of informed consent that meets', 'the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance', 'Portability and Accountability Act requirements, where applicable, and the IRB/IEC or study', 'center.', 'Page 68 of 109', 'Alexion Confidential']"
68,page_69,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The medical record must include a statement that written informed consent was obtained', 'before the patient was enrolled in the study and the date the written consent was obtained.', 'The authorized person obtaining the informed consent must also sign the ICF.', 'Patients must be reconsented to the most current version of the ICF(s) during their', 'participation in the study. A copy of the ICF(s) must be provided to the patient.', 'The Investigator must retain the original version of the signed ICF(s). A copy of the signed', 'ICF(s) must be provided to the patient.', 'A patient who is rescreened is not required to sign another ICF unless an updated ICF is', 'available.', '10.1.3.', 'Data Protection', 'Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets', 'that are transferred to the Sponsor will contain the identifier only; patient names or any', 'information which would make the patient identifiable will not be transferred.', 'The patient must be informed that his/her personal study-related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the patient.', 'The patient must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'Alexion will store anonymized data [ie, data that has been anonymized through removal of', 'elements that will identify the individual directly so that the individual is no longer uniquely', 'identifiable] in the study databases for no less than 15 years after the completion of the study', 'or until the purposes of collection and use are attained, after which data will be destroyed.', 'Health authorities and regulatory authorities may retain and utilize such information for the', ""period set forth in applicable law or as duly determined at the relevant regulatory authority's"", 'discretion.', '10.1.4.', 'Dissemination of Clinical Study Data', 'Study-related information and study results may be posted on the US National Institutes of', 'Health website www.clinicaltrials.gov, the EU website www.clinicaltrialsregister.eu/, or other', 'publicly accessible websites as appropriate and in accordance with local regulations.', '10.1.5.', 'Data Quality Assurance', 'All patient data relating to the study will be recorded on printed or electronic CRF unless', 'transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is', 'responsible for verifying that data entries are accurate and correct by physically or', 'electronically signing the CRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the CRF.', 'Page 69 of 109', 'Alexion Confidential']"
69,page_70,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The Investigator must permit study-related monitoring, audits, IRB/IEC review, and', 'regulatory agency inspections and provide direct access to source data documents.', 'The Sponsor or designee is responsible for the data management of this study including', 'quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that data entered', 'into the CRF by authorized site personnel are accurate, complete, and verifiable from source', 'documents; that the safety and rights of patients are being protected; and that the study is', 'being conducted in accordance with the currently approved protocol and any other study', 'agreements, ICH-GCP, and all applicable regulatory requirements. Study monitors will', 'communicate with investigative sites on a regular basis regarding the study and all protocol', 'deviations will be appropriately documented by the Investigator or designee, and study', 'monitors.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study must', 'be retained by the investigator for 5 years after study completion unless local regulations or', 'institutional policies require a longer retention period. No records may be destroyed during', 'the retention period without the written approval of the Sponsor. No records may be', 'transferred to another location or party without written notification to the Sponsor.', '10.1.6.', 'Source Documents', 'Source documents provide evidence for the existence of the patient and substantiate the', 'integrity of the data collected. Source documents are filed at the investigative site.', 'The Investigator or designee will prepare and maintain adequate and accurate source', 'documents (medical records, ECGs, AE and concomitant medication reporting, and raw data', 'collection forms) designed to record all observations and other pertinent data for each patient.', 'Data entered in the eCRF that are transcribed from source documents must be consistent with', 'the source documents or the discrepancies must be explained. The Investigator may need to', 'request previous medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', '10.1.7.', 'Study and Site Closure', 'The Sponsor reserves the right to close the study site or terminate the study at any time for any', 'reason at their sole discretion. A study site is considered closed when all required documents and', 'study supplies have been collected and a study-site closure visit has been performed.', 'The Investigator may initiate study-site closure at any time, provided there is reasonable cause', 'and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the Sponsor or Investigator may include but are', 'not limited to:', 'Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or', ""local health authorities, the Sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of patients by the Investigator', 'Page 70 of 109', 'Alexion Confidential']"
70,page_71,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Discontinuation of further ravulizumab development', '10.1.8.', 'Publication Policy', 'The full terms regarding publication of the results of this study are outlined in the applicable', 'Clinical Study Agreement.', 'Page 71 of 109', 'Alexion Confidential']"
71,page_72,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 10 will be performed by the central laboratory.', 'Protocol-specific requirements for inclusion or exclusion of patients are detailed in Section 5 of', 'the protocol.', 'Additional tests may be performed at any time during the study as determined necessary by the', 'Investigator or required by local regulations.', 'Table 10:', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet count', 'RBC indices:', 'WBC count with', 'RBC count', 'Distribution width', 'differential:', 'Hemoglobin', 'Mean corpuscular volume', 'Neutrophils', 'Hematocrit', 'Mean corpuscular', 'Lymphocytes', 'hemoglobin', 'Monocytes', '% Reticulocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'AST/SGOT', 'Total and direct bilirubin', 'Chemistry', 'C-reactive protein', 'ALT/SGPT', 'Total protein', 'Creatinine', 'Alkaline phosphatase,', 'Albumin', 'Chloride', 'Gamma glutamyltransferase', 'Uric acid', 'Potassium', 'Bicarbonate', 'Sodium', 'Glucose (nonfasting)', 'Coagulation', 'international normalized ratio, partial thromboplastin time, prothrombin time', 'Urine', 'Appearance, color, specific gravity, pH, glucose, protein, leukocyte esterase, blood, ketones,', 'bilirubin, urobilinogen, nitrite, microscopic examination (if blood or protein is abnormal)', 'Other Screening', 'Serum/urine beta-hCG pregnancy test (as needed for patients of child-bearing potential)', 'tests', 'Serum follicle-stimulating hormone test (as needed for patients who consider themselves', 'postmenopausal)', 'HIV-1 and HIV-2 antibodies', 'The results of each test must be entered into the eCRF.', 'Complement', 'Free C5', 'activity', 'Other', 'Antidrug antibodies, AChR antibody', 'Abbreviations: AChR = acetylcholine receptor; ALT = alanine aminotransferase; AST = aspartate aminotransferase;', 'BUN = blood urea nitrogen; C5 = complement component 5; eCRF = electronic case report form; hCG = human', 'chorionic gonadotropin; HIV-1 = human immunodeficiency virus type 1; HIV-2 = human immunodeficiency virus', 'type 2; RBC = red blood cells; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic', 'pyruvic transaminase; WBC = white blood cells.', 'Page 72 of 109', 'Alexion Confidential']"
72,page_73,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '10.3.1.', 'Adverse Event', 'Adverse Event Definition', 'An AE is any untoward medical occurrence in a patient administered a pharmaceutical product and', 'which does not necessarily have a causal relationship with this treatment. An AE can therefore be any', 'unfavorable or unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally', 'associated with the use of a medicinal product, whether or not considered related to the medicinal', 'product.', 'Events Meeting the Adverse Event Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety', 'assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from', 'baseline, considered clinically significant in the medical and scientific judgment of the Investigator (ie,', 'not related to progression of underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an increase in', 'frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study intervention administration even though it may have', 'been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be reported as an AE', 'or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms,', 'and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the', 'definition of an AE or SAE.', 'Events NOT Meeting the Adverse Event Definition', 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the', 'procedure is the AE. Situations in which an untoward medical occurrence did not occur (eg,', 'hospitalization for elective surgery if planned before the signing the ICF, admissions for social reasons', 'or for convenience).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the', 'start of the study that do not worsen.', 'Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to', 'establish drug effect.', 'A medication error (including intentional misuse, abuse, and overdose of the product) or use other than', 'what is defined in the protocol is not considered an AE unless there is an untoward medical occurrence', 'as a result of a medication error.', 'Cases of pregnancy that occur during maternal or paternal exposure to study drug are to be reported', 'within 24 hours of Investigator/site awareness. Data on fetal outcome and breastfeeding will be', 'collected for regulatory reporting and safety evaluation.', 'Page 73 of 109', 'Alexion Confidential']"
73,page_74,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.2.', 'Serious Adverse Event', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions', 'are met (eg, hospitalization for signs/symptoms of the disease under study, death due to', 'progression of disease).', 'A serious adverse event is defined as any untoward medical occurrence that, at any dose:', 'Results in death', 'Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the participant was at', 'risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused', 'death, if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the patient has been detained (usually involving at least an', 'overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have', ""been appropriate in the physician's office or outpatient setting. Complications that occur during"", 'hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the', 'event is serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the AE should', 'be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not', 'considered an AE.', 'Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct normal life functions."", 'This definition is not intended to include experiences of relatively minor medical significance such as', 'uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle)', 'which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.', '1. Is a congenital anomaly/birth defect', '2. Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in', 'other situations such as important medical events that may not be immediately life-threatening or result in', 'death or hospitalization but may jeopardize the participant or may require medical or surgical intervention', 'to prevent one of the other outcomes listed in the above definition. These events should usually be', 'considered serious.', '10.3.3.', 'Suspected Unexpected Serious Adverse Reactions', 'Suspected Unexpected Serious Adverse Reactions Definition', 'Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the IB', 'and that the Investigator identifies as related to study drug or procedure. The US 21CFR312.32 and EU', 'Clinical Trial Directive 2001/20/EC and the associated detailed guidance documents or national', 'regulatory requirements in participating countries require the reporting of SUSARs. Alexion has', 'procedures that will be followed for the recording and expedited reporting of SUSARs that are consistent', 'with global regulations and the associated detailed guidance documents. Suspected unexpected serious', 'adverse reactions will be reported to the national competent authority and IRBs/IECs where applicable.', 'Page 74 of 109', 'Alexion Confidential']"
74,page_75,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.4.', 'Recording and Follow-Up of Adverse Event and/or Serious Adverse Event', 'Adverse Event and Serious Adverse Event Recording', 'When an AE or SAE occurs, it is the responsibility of the Investigator to review all documentation', '(eg, hospital progress notes, laboratory reports, and diagnostics reports) related to the event. The', 'Investigator will then record all relevant AE/SAE information in the CRF.', ""It is not acceptable for the Investigator to send photocopies of the patient's medical records to Alexion"", 'or designee in lieu of completion of the AE/SAE report. If applicable, additional information such as', 'relevant medical records, should be submitted with a signed SAE cover page to Alexion Global', 'Pharmacovigilance (GPV) via ClinicalSAE@alexion.com or via Facsimile: + 1.203.439.9347. In this', 'case, all patient identifiers, with the exception of the patient number, will be redacted on the copies of', 'the medical records before sending to GPV.', 'The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or', 'other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will', 'be documented as the AE or SAE.', 'Assessment of Event Severity', 'The Investigator will make an assessment of intensity for each AE and SAE reported during the study and', 'assign it to 1 of the following categories from National Cancer Institute Common Terminology Criteria for', 'Adverse Events (CTCAE) v5.0, published 27 Nov 2017. Each CTCAE term is a Lowest Level Term (LLT)', 'per MedDRA. Each LLT will be coded to a MedDRA Preferred Term:', 'Grade 1: Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated)', 'Grade 2: Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate', 'instrumental ADL)', 'Grade 3: Severe (severe or medically significant, but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL)', 'Grade 4: Life-threatening (urgent intervention indicated)', 'Grade 5: Fatal (death related to AE)', 'Any change in the severity of an AE should be documented based on specific guidelines in the eCRF', 'Completion Guidelines.', 'Severity and seriousness must be differentiated: severity describes the intensity of an AE, while the term', 'seriousness refers to an AE that has met specific criteria for an SAE as described above.', 'Assessment of Causality', 'The Investigator is obligated to assess the relationship between the study drug and each occurrence', 'of each AE or SAE. An Investigator causality assessment must be provided for all AEs (both', 'nonserious and serious). This assessment must be recorded in the eCRF and on any additional', 'forms, as appropriate. The definitions for the causality assessments are as follows:', 'Not related (unrelated)', 'Related: Temporal relationship to the study drug. Other conditions (concurrent illness,', 'concurrent medication reaction, or progression/expression of disease state) do not appear', 'to explain the event; the event corresponds with the known pharmaceutical profile;', 'improvement on discontinuation; reappearance on rechallenge.', 'Adverse Event Recording', 'The Investigator will use clinical judgment to determine the relationship to the study drug.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as', 'well as the temporal relationship of the event to study drug administration will be considered and', 'investigated.', 'Page 75 of 109', 'Alexion Confidential']"
75,page_76,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Adverse Event and Serious Adverse Event Recording', 'The expectedness and reporting criteria of an SAE will be determined by the Sponsor, based on', 'the Reference Safety Document. The Investigator will also consult the IB in his/her assessment.', 'There may be situations in which an SAE has occurred and the Investigator has minimal', 'information to include in the initial report to Alexion or designee. However, it is very important', 'that the Investigator always makes an assessment of causality for every event before the', 'initial transmission of the SAE data to Alexion GPV.', 'The Investigator may change his/her opinion of causality in light of follow-up information and', 'send a SAE follow-up report with the updated causality assessment.', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements.', 'Follow-up of Adverse Events and Serious Adverse Events', 'The Investigator is obligated to perform or arrange for the conduct of supplemental measurements', 'and/or evaluations as medically indicated or as requested by Alexion or designee to elucidate the', 'nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory', 'tests or investigations, histopathological examinations, or consultation with other health care', 'professionals.', 'If a patient dies during participation in the study or during a recognized follow-up period, the', 'Investigator will provide Alexion or designee with a copy of any postmortem findings including', 'histopathology, if available.', 'The site will enter new or updated SAE data into the electronic system as soon as it becomes', 'available, but no later than 24 hours. The Investigator will submit any updated SAE data to the GPV', 'within 24 hours of awareness of the information.', '10.3.5.', 'Reporting of Serious Adverse Events', 'Serious Adverse Event Reporting to Alexion or Designee via the RAVE Safety Gateway', 'All SAEs must be reported to Alexion GPV within 24 hours of the Investigator or site staff awareness.', 'These timelines for reporting SAE information to the Sponsor need to be followed for the initial SAE report', 'and for all follow-up SAE information.', 'The Investigator or designee must record the SAE data in the eCRF and verify the accuracy of the', 'information with corresponding source documents. The SAE report should be submitted electronically via', 'the RAVE Safety Gateway.', 'In the event that either the electronic data capture (EDC) or the RAVE Safety Gateway is unavailable at the', 'site(s), the SAE must be reported on the paper SAE Contingency Form accompanied by an Investigator', 'signed cover page. Facsimile transmission or email may be used in the event of electronic submission', 'failure.', 'For all SAEs, the Investigator must provide the following:', 'Appropriate and requested follow-up information in the time frame detailed below', 'Causality of the SAE(s)', 'Treatment of/intervention for the SAE(s)', 'Outcome of the SAE(s)', 'Supporting medical records and laboratory/diagnostic information', 'The primary mechanism for reporting an SAE to Alexion or designee will be the RAVE Safety', 'Gateway.', 'If the electronic system is unavailable at the time that the Investigator or site becomes aware of an', 'SAE, the site will use the paper Contingency Form for SAE reporting via facsimile or email.', 'Facsimile transmission or email may be used in the event of electronic submission failure.', 'Email: clinicalsae@alexion.com', 'Facsimile: + 1.203.439.9347', 'Page 76 of 109', 'Alexion Confidential']"
76,page_77,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Serious Adverse Event Reporting to Alexion or Designee via the RAVE Safety Gateway', 'As soon as the EDC becomes available, the data should be entered in the eCRF and forwarded to', 'Alexion GPV via the RAVE Safety Gateway.', 'When further information becomes available, the eCRF should be updated with the new', 'information and an updated SAE report should be submitted to Alexion GPV via the RAVE Safety', 'Gateway.', 'After the study is completed at a given site, the EDC will be taken offline to prevent the entry of', 'new data or changes to existing data.', 'If', 'a site identifies a new SAE from a study patient or receives updated data on a previously', 'reported SAE after the electronic data collection tool has been taken offline, then the site', 'can', 'report this information on a paper SAE form to Alexion GPV.', 'SAE Reporting to Alexion or Designee via Paper Contingency Case Report Form', 'If applicable, additional information such as relevant medical records should be submitted to', 'Alexion GPV via the email address or facsimile number noted above.', 'All paper forms and follow-up information submitted to the Sponsor outside of the RAVE Safety', 'Gateway (eg, discharge summary) should be kept in the appropriate section of the study file.', 'Page 77 of 109', 'Alexion Confidential']"
77,page_78,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '10.4.1.', 'Contraception Guidance', 'Before receiving study drug, female patients who consider themselves to be postmenopausal', 'must provide evidence of menopause based on a combination of amenorrhea for at least 1 year', 'and increased serum follicle-stimulating hormone level (> 30 IU/L).', 'Patients of childbearing potential must use a highly effective or acceptable method of', 'contraception (as defined below) starting at Screening and continuing for at least 8 months after', 'the last dose of study drug.', 'Highly effective contraceptive methods include:', '1. Hormonal contraception associated with inhibition of ovulation', '2. Intrauterine device', '3. Intrauterine hormone-releasing system', '4. Bilateral tubal occlusion', '5.', ""Vasectomized partner provided that the partner is the patient's sole sexual partner"", '6. Sexual abstinence defined as refraining from heterosexual intercourse during the entire', 'period of risk associated with the study drug treatment; reliability of sexual abstinence', 'needs to be evaluated in relation to the duration of the clinical study and the preferred and', 'usual lifestyle of the patient', 'Acceptable contraceptive methods include:', '7. A combination of male condom with either cap, diaphragm, or sponge with spermicide', '(double barrier methods)', 'The above-listed method(s) of contraception chosen for an individual patient can be determined', ""by the Investigator with consideration for the patient's medical history and concomitant"", 'medications.', 'Patients with a spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or', 'partner must agree to use double barrier contraception (male condom plus appropriate barrier', 'method for the female partner) while on treatment and for at least 8 months after the last dose of', 'study drug. Double barrier contraception is required even with documented medical assessment', 'of surgical success of a vasectomy.', 'Male patients must not donate sperm and female patients must not donate ova while on treatment', 'and for at least 8 months after the last dose of study drug.', '10.4.2.', 'Pregnancy Testing', 'Patients of childbearing potential should only be included after a menstrual period and a negative', 'highly sensitive serum pregnancy test.', 'Additional pregnancy testing should be performed per the time points specified in the SoA', '(Section 1.3).', 'Page 78 of 109', 'Alexion Confidential']"
78,page_79,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is', 'otherwise suspected.', '10.4.3.', 'Collection and Reporting of Pregnancy Information', 'No studies of ALXN1210 have been conducted in pregnant women. Pregnant or nursing female', 'patients are excluded from the study. Patients enrolled in the study, and a spouse or partner, will', 'use a highly effective or acceptable method of contraception.', 'In the event of a pregnancy event, pregnancy data will be collected during this study for all', 'patients and a female spouse/partner of male patients. Exposure during pregnancy (also referred', 'to as exposure in utero) can be the result of either maternal exposure or transmission of drug', 'product via semen following paternal exposure. For all Alexion products, both in development or', 'postapproval, exposure during pregnancy must be recorded and the pregnancy followed until the', 'outcome of the pregnancy is known (ie, spontaneous miscarriage, elective termination, normal', 'birth, or congenital abnormality), even if the patient discontinues study drug or withdraws from', 'the study.', ""If a female patient or a patient's female partner becomes pregnant during the conduct of this"", 'study, the Investigator must submit the ""Pregnancy Reporting and Outcome/Breastfeeding"" form', 'to Alexion GPV via facsimile or email (Section 10.3). When the outcome of the pregnancy', 'becomes known, the form should be updated and submitted to Alexion GPV. If additional', 'follow-up is required, the Investigator will be requested to provide the information.', 'Exposure of an infant to an Alexion product during breastfeeding must also be reported (via the', '""Pregnancy Reporting and Outcome Form/Breastfeeding"" form) and any AEs experienced by the', 'infant must be reported to Alexion GPV or designee via email or facsimile (Section 10.3).', 'Pregnancy in itself is not regarded as an AE unless there is a suspicion that the investigational', 'product may have interfered with the effectiveness of a contraceptive medication. However,', 'complications of pregnancy and abnormal outcomes of pregnancy are AEs and may meet the', 'criteria for an SAE (eg, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise,', 'neonatal death, or congenital anomaly). Elective abortions without complications should not be', 'reported as AEs.', 'Page 79 of 109', 'Alexion Confidential']"
79,page_80,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.5.', 'Appendix 5: Management of Potential IInfusion-Associated Adverse', 'Events During Study Drug Administration', 'Intravenous and infusion-associated reactions are a potential risk with the use of mAbs; these', 'reactions can be nonimmune or immune-mediated (eg, hypersensitivity reactions). Signs and', 'symptoms may include headache, fever, facial flushing, pruritus, myalgia, nausea, chest', 'tightness, dyspnea, vomiting, erythema, abdominal discomfort, diaphoresis, shivers,', 'hypertension, lightheadedness, hypotension, palpitations, and somnolence. Signs and symptoms', 'of hypersensitivity or allergic reactions may include hives, swollen face, eyelids, lips, or tongue,', 'or trouble with breathing.', 'All administration-, IV-, and infusion-associated reactions will be reported to the Investigator or', 'qualified designee (Section 8.3). The Investigator or qualified designee are responsible for', 'detecting, documenting, and recording events that meet the definition of AE or SAE and remain', 'responsible for following up events that are serious, considered related to the study drug, or', 'study procedures; or that caused the patient to discontinue the study drug (Section 7).', 'Definitions and procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are', 'outlined in Section 10.3 (Appendix 3).', 'Patients who experience a reaction during the administration of study drug should be treated', 'according to institutional guidelines.', 'Patients who experience a severe reaction during administration of study drug resulting in', 'discontinuation of study drug should undergo all scheduled safety, PK, and PD evaluations', 'required by the protocol. The Sponsor must be notified within 24 hours of any infusion reaction', 'requiring interruption or discontinuation of study drug. All AEs that may indicate an', 'infusion-related response will be graded according to the CTCAE v5.0 or higher.', 'If anaphylaxis occurs according to the criteria listed below, then administration of SC', 'epinephrine (1/1000, 0.3 mL to 0.5 mL, or equivalent) should be considered. In the case of', 'bronchospasm, treatment with an inhaled beta agonist also should be considered. Patients', 'administered an antihistamine for the treatment or prevention of an infusion reaction should be', 'given appropriate warnings about drowsiness and impairment of driving ability before being', 'discharged from the center.', 'Page 80 of 109', 'Alexion Confidential']"
80,page_81,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Clinical Criteria for Diagnosing Anaphylaxis:', 'Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled:', '(1) Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both', '(eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula), and at least 1 of the following:', 'a.', 'Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow', '(PEF), hypoxemia)', 'b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope,', 'incontinence)', '(2) Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes', 'to several hours):', 'a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips/tongue/uvula)', 'b. Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEF, hypoxemia)', 'c.', 'Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)', 'd.', 'Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)', '(3) Reduced BP after exposure to known allergen for that patient (minutes to several hours):', ""a. Systolic BP of less than 90 mmHg or greater than 30% decrease from that patient's baseline"", 'Abbreviations: BP = blood pressure; PEF = peak expiratory flow.', 'Source: Sampson, 2006', 'Page 81 of 109', 'Alexion Confidential']"
81,page_82,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.6.', 'Appendix 6: Myasthenia Gravis Activities of Daily Living Profile', 'To be completed by Study Site', 'Study Number: ALXN1210-MG-306 Subject ID:', 'Date Completed:', 'MG Activities of Daily Living (MG-ADL) profile', 'Score', 'Grade', '0', '1', '2', '3', '(0,1,2 or 3)', 'Normal', 'Intermittent slurring', 'Constant slurring', 'Difficult to', '1. Talking', 'or nasal, but can', 'understand', 'or nasal speech', 'be understood', 'speech', '2. Chewing', 'Normal', 'Fatigue with', 'Fatigue with', 'Gastric tube', 'solid food', 'soft food', '3. Swallowing', 'Rare episode', 'Frequent choking', 'Normal', 'of choking', 'necessitating', 'Gastric tube', 'changes in diet', 'Shortness of', 'Shortness of breath', 'Ventilator', '4. Breathing', 'Normal', 'breath', 'with exertion', 'at rest', 'dependence', '5. Impairment of', 'Extra effort, but', 'Cannot do', 'Rest periods', 'ability to brush', 'None', 'no rest periods', 'one of these', 'needed', 'teeth or comb hair', 'needed', 'functions', '6. Impairment of', 'Mild, sometimes', 'Moderate,', 'None', 'Severe, requires', 'ability to arise', 'uses arms', 'from a chair', 'always uses arms', 'assistance', 'Occurs,', '7. Double vision', 'None', 'Daily,', 'Constant', 'but not daily', 'but not constant', 'Occurs, but', 'Daily, but', '8. Eyelid droop', 'None', 'Constant', 'not daily', 'not constant', 'MG-ADL score', 'total (items 1-8)', '=', 'Evaluator Signature:', 'Date:', '¬© 1997 UT Southwestern Medical Center, Dallas', 'MG-ADL United States/English', 'MG-ADL_AUU1.1_eng-UBori.docx', 'Page 82 of 109', 'Alexion Confidential']"
82,page_83,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.7.', 'Appendix 7: Quantitative Myasthenia Gravis Score for Disease', 'Severity', 'To be completed by Study Site', 'Study Number:', 'ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Time Completed:', 'Was any Anticholinesterase Medication taken within 10 hours of assessment?', 'No', 'Yes; If yes, please record please record time of last dose:', 'N/A (patient is not on acetylcholinesterase therapy)', 'QMG form', 'Test Item', 'None', 'Mild', 'Moderate', 'Severe', 'Score', 'Grade', '0', '1', '2', '3', 'Raw Scale', 'Doublevision on lateral gaze', '61', '11-60', '1-10', 'Spontaneous', 'Rightor left (circle one), secs', 'Ptosis (upward gaze)', '61', '11-60', '1-10', 'Spontaneous', 'Facial muscles', 'Normal lid', 'Complete, weak,', 'Complete, without', 'Incomplete', 'closure', 'some resistance', 'resistance', 'Swallowing 4 oz water', 'Normal', 'Minimal coughing', 'Severe coughing/chokin', 'Cannot swallow', '(1/2cup)', 'or throat clearing', 'or nasal regurgitation', '(testnot', 'attempted)', 'Speech after counting aloud', 'None at 50', 'Dysarthria at', 'Dysarthria at', 'Dysarthria at 9', 'from 1 to 50 (onset of', '30-49', '10-29', 'dysarthria)', 'Right arm outstretched (90', '240', '90-239', '10-89', '0-9', 'degrees sitting), seconds', 'Left arm outstretched (90', '240', '90-239', '10-89', '0-9', 'degrees sitting), seconds', 'Forced Vital Capacity', '> 80', '65-79', '50-64', '<50', 'Rt-hand grip, kg', 'Men', '> 45', '15-44', '5-14', '0-4', 'Women', '> 30', '10-29', '5-9', '0-4', 'Lt-handgrip,kg', 'Men', '35', '15-34', '5-14', '0-4', 'Women', '> 25', '10-24', '5-9', '0-4', 'Head lifted (45 degrees', '120', '30-119', '1-29', '0', 'supine), seconds', 'Rightleg outstzetched (45', '100', '31-99', '1-30', '0', 'degrees supine), seconds', 'Leftleg outstretched (45', '100', '31-99', '1-30', '0', 'degrees supine), seconds', 'TOTAL QMG SCORE :', 'Evaluator Signature:', 'Date:', '¬© 1997 UT Southwestern Medical Center, Dallas', 'QMG United States/English - Original version', 'QMG_AU2.O_eng-uBori.doex', 'Page 83 of 109', 'Alexion Confidential']"
83,page_84,"['Protocol', 'ALXN1210-MG-30 Amendment 2', '10.8.', 'Appendix 8: Myasthenia Gravis Composite Scale', 'To be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Time Completed:', 'MG Composite Scale', 'Results', 'Ptosis, upward gaze', '> 45 seconds', '11 - 45 seconds', '1 10 seconds', 'Immediate', 'Obtain results from QMG:', '(physician examination)', '= 0', '= 1', '= 2', '= 3', 'Double vision on', '> 45 seconds', '11 45 seconds', '1 10 seconds', 'Immediate', 'Obtain results from QMG:', 'lateral', '0', '=', '= 3', '4', 'gaze. left or right', '(physician examination)', 'Eve closure', 'Normal = 0', 'Mild weakness', 'Moderate weakness', 'Severe weakness', 'Obtain results from QMG:', '(physician examination)', '(can be forced open', '(can be forced open easily)', '(unable to keep eyes', 'with', '= 1', 'closed) = 2', 'effort) = 0', 'Talking', 'Normal = 0', 'Intermittent', 'Constant slurring or', 'Difficult to', 'Obtain results from MG-ADL:', '(patient history)', 'slurring', 'nasal but', 'understand speech', 'or nasal speech =', 'can be understood', '= 6', '2', '=4', 'Chewing', 'Normal = 0', 'Fatigue with solid', 'Fatigue with soft food', 'Gastric tube = 6', 'Obtain results from MG-ADL:', '(patient history)', 'food = 2', '4', 'Swallowing', 'Normal = 0', 'Rare episode of', 'Frequent trouble', 'Gastric tube = 6', 'Obtain results from MG-ADL:', '(patient history)', 'choking or', 'swallowing', 'trouble', 'e.g. necessitating changes in', 'swallowing = 2', 'diet 5', 'Breathing', 'Normal = 0', 'Shortness of', 'Shortness of breath at', 'Ventilator', 'Obtain results from MG-ADL:', '(thought to be caused by', 'breath', 'rest = 4', 'dependence = 9', 'MG)', 'with exertion = 2', 'Neck flexion or', 'Normal = 0', 'Mild weakness', 'Moderate weakness', 'Severe weakness', 'extension (weakest)', '1', '(i.e. -50% weak. 7-15%)', '=4', '(physician examination)', '=3', 'Shoulder abduction', 'Normal = 0', 'Mild weakness', 'Moderate weakness', 'Severe weakness', '(physician examination)', '2', '(i.e. -50% weak. +/- 15%)', '5', '=4', 'Hip flexion', 'Normal = 0', 'Mild weakness', 'Moderate weakness', 'Severe weakness', '(physician examination)', '2', '(i.e. -50% weak, +/-15%)', '5', '=4', 'Please note that ""moderate weakness"" for neck and limb items should be construed as weakness that equals roughly 50% +/-15% of expected', 'normal strength Any weakness milder than that would be ""mild"" and any weakness more severe than that would be classified as ""severe""', 'Total Score', 'Evaluator Signature should be the signature of the individual (PI or Neurologist) completing the following assessments: Neck flexion or', 'extension, Shoulder abduction and Hip flexion .Note: If individual transcribing items from MG-ADL and QMG (items 1-7) differs from', 'evaluator, ensure individual appropriately initials here:', 'Evaluator Signature:', 'Date:', 'Permission granted for use from Ted Burns, MD, University of Virginia.', 'Page 84 of 109', 'Alexion Confidential']"
84,page_85,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.9.', 'Appendix 9: Euro Quality of Life Questionnaire', 'EQ-5D-5L', 'Header to be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Completed by:', 'Patient', 'Health Questionnaire', 'English version for the USA', 'gott', 'USA (English) ¬© 2009 EuroQol Group EQ-60‚Ñ¢ is a trade mark of the EuroQol Group', 'Page 85 of 109', 'Alexion Confidential']"
85,page_86,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 9: Euro Quality of Life Questionnaire (Continued)', 'Under each heading, please check the ONE box that best describes your health TODAY.', 'MOBILITY', 'I have no problems walking', 'I have slight problems walking', 'I have moderate problems walking', 'I have severe problems walking', 'I am unable to walk', 'SELF-CARE', 'I have no problems washing or dressing myself', 'I have slight problems washing or dressing myself', 'I have moderate problems washing or dressing myself', 'I have severe problems washing or dressing myself', 'I am unable to wash or dress myself', 'USUAL ACTIVITIES (e.g. work, study, housework, family or', 'leisure activities)', 'I have no problems doing my usual activities', 'I have slight problems doing my usual activities', 'all', 'I have moderate problems doing my usual activities', 'I have severe problems doing my usual activities', 'I am unable to do my usual activities', 'PAIN / DISCOMFORT', 'I have no pain or discomfort', 'I have slight pain or discomfort', 'I have moderate pain or discomfort', 'I have severe pain or discomfort', 'I have extreme pain or discomfort', 'ANXIETY / DEPRESSION', 'I am not anxious or depressed', 'I am slightly anxious or depressed', 'I am moderately anxious or depressed', 'I am severely anxious or depressed', 'I am extremely anxious or depressed', '2', 'USA (English) c 2009 EuroQol Group EQ-5DTH is a trade mark of the EuroQol Group', 'Page 86 of 109', 'Alexion Confidential']"
86,page_87,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 9: Euro Quality of Life Questionnaire (Continued)', 'The best health', 'you can imagine', 'We would like to know how good or bad your health is TODAY.', '100', 'This scale is numbered from 0 to 100.', '95', '100 means the best health you can imagine.', '90', '0 means the worst health you can imagine.', '85', 'Mark an X on the scale to indicate how your health is TODAY.', '80', 'Now, please write the number you marked on the scale in the box', '75', 'below.', '70', '65', '60', '55', 'YOUR HEALTH TODAY =', '50', '45', '40', '35', '30', '25', '20', '15', '10', '5', '0', 'The worst health', 'you can imagine', '3', 'USA (English) ¬© 2009 EuroQol Group EQ-5DTH is a trade mark of the EuroQol Group', 'Page 87 of 109', 'Alexion Confidential']"
87,page_88,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.10.', 'Appendix 10: Myasthenia Gravis Quality-of-Life 15r Scale', 'Header to be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Completed by:', 'Patient', 'Please indicate how true', 'each statement has been', 'Not at all', 'Somewhat', 'Very much', '(over the past few weeks).', '0', '1', '2', '1. I am frustrated by my MG', '2. I have trouble with my eyes because', 'of my MG (e.g. double vision)', '3. I have trouble eating because of MG', '4. I have limited my social activity', 'because of my MG', '5. My MG limits my ability to enjoy', 'hobbies and fun activities', '6. I have trouble meeting the needs of', 'my family because of my MG', '7. I have to make plans around my', 'MG', '8. I am bothered by limitations in', 'performing my work (include work at', 'home) because of my MG.', '9. I have difficulty speaking due to MG', '10. I have lost some personal', 'independence because of my MG (e.g.', 'driving, shopping, running errands)', '11. I am depressed about my MG', '12. I have trouble walking due to MG', '13. I have trouble getting around public', 'places because of my MG', '14. I feel overwhelmed by my MG', '15. I have trouble performing my', 'personal grooming needs due to MG', 'Total MGOOL-R score', 'Page 88 of 109', 'Alexion Confidential']"
88,page_89,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.11.', 'Appendix 11: Neurology Quality of Life Fatigue', 'Header to be completed by Study Sibe', 'Study Number ALXN1210-MG-306', 'Neuro-QOL Item Bauk v1.0 -Fatigue', 'Subject ID', 'Fatigue', 'Data Complated', 'Please respond to each question or statement by marking one box per row.', 'Completed by', 'Patient', 'In the past 7 days', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'I felt exhausted', '1', '2', '3', '4', '5', 'I felt that I had no energy', '1', '2', '3', '4', '5', 'I felt fatigued', '1', '2', '3', '4', '5', 'NOFTGOS', 'I was too tired to do my household chores.', '1', '2', '3', '4', '5', 'I was too tired to leave the house', '1', '2', '3', '4', '5', 'I was frustrated by being too tired to do', 'the things I wanted to do', '1', '2', '3', '4', '5', 'NOFTOMA', 'I felt tired', '1', '2', '3', '4', '5', 'I had to limit my social activity because I', 'was tired', '1', '2', '3', '4', '5', 'I needed help doing my usual activities', 'because of my fatigue', '1', '11th', '3', '4', '5', 'I needed to sleep during the day', '1', '2', '3', '4', '5', 'I had trouble starting things because I was', 'too tired', '1', '2', '3', '4', 'S', 'I had trouble finishing things because I', 'was too tired', '1', '11th', '3', '4', '5', 'I was too tired to take a short walk', '1', '2', '3', '4', '5', 'I was too tired to eat.', '1', '2', '3', '4', '5', 'I was so tired that I needed to rest during', 'the day', '1', '2', '3', '4', '5', 'I felt weak all over', '1', '2', '3', '4', 'S', 'C2008-2013 David Cella and the PROMIS Health Organization on behalf of the National Institute for Neurological', 'Disorders and Stroke (NINDS). Used with permission.', 'English', 'Page 1 of 2', 'November 4, 2014', 'Page 89 of 109', 'Alexion Confidential']"
89,page_90,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 11: Neurology Quality of Life Fatigue (Continued)', 'Neuro-QOL Item Bank v1.0-Fatigue', 'In the past 7 days', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'I needed help doing my usual activities', 'NQFTG17', 'because of weakness', '1', '2', '3', '4', '5', 'I had to limit my social activity because I', 'NQFTG18', 'was physically weak', '1', '2', '3', '4', '5', 'I had to force myself to get up and do', 'NQFTG20', 'things because I was physically too weak.', '1', '2', '3', '4', '5', 'Page 90 of 109', 'Alexion Confidential']"
90,page_91,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.12.', 'Appendix 12: Myasthenia Gravis Foundation of America Clinical', 'Classification', 'MGFA Clinical Classification', 'Class I: Any ocular muscle weakness; may have weakness of eye closure. All other muscle', 'strength is normal.', 'Class II: Mild weakness affecting muscles other than ocular muscles; may also have ocular', 'muscle weakness of any severity.', 'A. IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser', 'involvement of oropharyngeal muscles.', 'B. IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have', 'lesser or equal involvement of limb, axial muscles, or both.', 'Class III: Moderate weakness affecting muscles other than ocular muscles; may also have ocular', 'muscle weakness of any severity.', 'A. IIIa. Predominantly affecting limb, axial muscles, or both. May also have lesser', 'involvement of oropharyngeal muscles.', 'B. IIIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have', 'lesser or equal involvement of limb, axial muscles, or both.', 'Class IV: Severe weakness affecting muscles other than ocular muscles; may also have ocular', 'muscle weakness of any severity.', 'A. IVa. Predominantly affecting limb, axial muscles, or both. May also have lesser', 'involvement of oropharyngeal muscles.', 'B. IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have', 'lesser or equal involvement of limb, axial muscles, or both.', 'Class V: Defined as intubation, with or without mechanical ventilation, except when employed', 'during routine postoperative management. The use of a feeding tube without intubation places', 'the patient in class IVb.', 'Page 91 of 109', 'Alexion Confidential']"
91,page_92,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.13.', 'Appendix 13: Myasthenia Gravis Foundation of America Post-', 'Interventional Status', 'Note that a modified version of Change in Status (excludes ""Exacerbation"" and ""Died of MG"")', 'is used in this protocol (see Section 8.1.9).', 'MGFA Post-intervention Status (MGFA-PIS)', 'Complete Stable', 'The patient has had no symptoms or signs of MG for at least 1 year and has received no therapy', 'Remission (CSR) for MG during that time. There is no weakness of any muscle on careful examination by', 'someone skilled in the evaluation of neuromuscular disease. Isolated weakness of eyelid closure', 'is accepted.', 'Pharmacologic', 'The same criteria as for CSR except that the patient continues to take some form of therapy for', 'Remission (PR)', 'MG. Patients taking cholinesterase inhibitors are excluded from this category because their use', 'suggests the presence of weakness.', 'Minimal', 'The patient has no symptoms of functional limitations from MG but has some weakness on', 'Manifestations', 'examination of some muscles. This class recognizes that some patients who otherwise meet the', '(MM)', 'definition of CSR or PR do have weakness that is only detectable by careful examination.', 'MM-0', 'The patient has received no MG treatment for at least 1 year.', 'MM-1', 'The patient continues to receive some form of immunosuppression but no cholinesterase', 'inhibitors or other symptomatic therapy.', 'MM-2', 'The patient has received only low-dose cholinesterase inhibitors (<120 mg pyridostigmine/day)', 'for at least 1 year.', 'MM-3', 'The patient has received cholinesterase inhibitors or other symptomatic therapy and some form', 'of immunosuppression during the past year.', 'Change in Status', 'Improved (I)', 'A substantial decrease in pretreatment clinical manifestations or a sustained substantial', 'reduction in MG medications as defined in the protocol. In prospective studies, this should', 'be', 'defined as a specific decrease in QMG score.', 'Unchanged (U)', 'No substantial change in pretreatment clinical manifestations or reduction in MG medications', 'as defined in the protocol. In prospective studies, this should be defined in terms of a maximum', 'change in QMG score.', 'Worse (W)', 'A substantial increase in pretreatment clinical manifestations or a substantial increase in MG', 'medications as defined in the protocol. In prospective studies, this should be defined as a', 'specific increase in QMG score.', 'Exacerbation (E)', 'Patients who have fulfilled criteria of CSR, PR, or MM but subsequently developed clinical', 'findings greater than permitted by these criteria.', 'Died of MG (D of Patients who died of MG, of complications of MG therapy, or within 30 days after thymectomy.', 'MG)', 'List the cause (see Morbidity and Mortality table).', 'Page 92 of 109', 'Alexion Confidential']"
92,page_93,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.14.', 'Appendix 14: Columbia-Suicide Severity Rating Scale -', 'Baseline/Screening (Version 1/14/09)', 'Page 1 of 3', 'To be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Completed by:', 'Evaluator (initials):', 'COLUMBIA-SUICIDE SEVERITY', 'RATING SCALE', '(C-SSRS)', 'Baseline/Screening Version', 'Version 1/14/09', 'Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.;', 'Burke, A.; Oquendo, M.; Mann, J.', 'Disclaimer:', 'This scale is intended to be used by individuals who have received training in its administration The questions contained in', 'the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of suicidal', 'ideation or behavior depends on the judgment of the individual administering the scale.', 'Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History Form.', 'developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders', '(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A.,', 'Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First', '[Ed.] Standardized Evaluation in Clinical Practice, pp. 103 - 130, 2003.)', 'For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New', 'York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu', '¬© 2008 The Research Foundation for Mental Hygiene, Inc.', 'C-SSRS Baseline Screening - United States/English Mapi.', 'C-SSRS-BasalineScreening_AU5.1_eng-USor.doc', 'Page 93 of 109', 'Alexion Confidential']"
93,page_94,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 14: Columbia-Suicide Severity Rating Scale - Baseline/Screening (Continued)', 'SUICIDAL IDEATION', 'Ask questions 1 and 2. If `both are negative, proceed to ""Suicidal Behavior"" section. If the answer to', 'Lifetime: Time', 'Past', 'question 2 is ""yes"", ask questions 3, 4 and 5. If the answer to question 1 and/or 2 is ""yes"", complete', 'He/She Felt', 'Most Suicidal', 'Months', '""Intensity of ""deation"" section below.', '1. Wish to be Dead', 'Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.', 'Yes', 'No', 'Yes', 'No', 'Have you wished you were dead or wished you could go to sleep and not wake up?', 'If yes, describe:', '2. Non-Specific Active Suicidal Thoughts', 'General non-specific thoughts of wanting to end one\'s life/commit suicide (e.g., ""I\'ve thought about killing myself"") without thoughts', 'Yes', 'No', 'Yes', 'No', 'of ways to kill oneself/associated methods, intent, or plan during the assessment period', 'Have you actually had any thoughts of killing yourself?', 'If yes, describe:', '3. Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act', 'Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different than', 'a', 'Yes', 'No', 'Yes', 'No', 'specific plan with time, place or method details worked out (e.g. thought of method to kill self but not a specific plan). Includes person', 'who would say, ""I thought about taking an overdose but 1 never made a specific plan as to when, where or how 1 would actually do', 'it. and 1 would never go through with it.', 'Have you been thinking about how you might do this?', 'If yes, describe:', '4. Active Suicidal Ideation with Some Intent to Act, without Specific Plan', 'Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to ""Thave the', 'SE', 'Yes', 'No', 'Yes', 'No', 'thoughts but 1 definitely will not do anything about them.', 'Have you had these thoughts and had some intention of acting on them?', 'If yes, describe:', '5. Active Suicidal Ideation with Specific Plan and Intent', 'Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.', 'Yes', 'No', 'Yes', 'No', 'Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?', 'If yes, describe:', 'INTENSITY OF IDEATION', '88', 'The following features should be rated with respect to the most severe type of ideation (i.e., 1-5 from above, with 1 being', 'the least severe and 5 being the most severe). Ask about time he/she was feeling the most suicidal.', 'Lifetime', 'Most Severe Ideation:', 'Most', 'Most', 'Type (1-5)', 'Description of Ideation', 'Severe', 'Severe', 'Past X Months - Most Severe Ideation:', 'Type . (1-5)', 'Description of Ideation', 'Frequency', 'How many times have you had these thoughts?', '(1) Less than once a week Once aweek\\ (3) 2-5 times in week (4) Daily or almost daily (5) Many times each day', '-', '-', 'Duration', 'When you have the thoughts how long do they last?', '(1) Fleeting few seconds or minutes', '(4) 4-8 hours/most of day', '-', '-', '(2) Less than 1 hour/some of the time', '(5) More than 8 hours/persistent or continuous', '(3) 1-4 hours/a lot of time', 'Controllability', 'Could/can you stop thinking about killing yourself or wanting to die if you want to?', '(1) Easily able to control thoughts', '(4) Can control thoughts with a lot of difficulty', '-', '-', '(2) Can control thoughts with little difficulty', '(5) Unable to control thoughts', '(3) Can control thoughts with some difficulty', '(0) Does not attempt to control thoughts', 'Deterrents', 'Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to', 'die or acting on thoughts of committing suicide?', '(1) Deterrents definitely stopped you from attempting suicide', '(4) Deterrents most likely did not stop you', '-', '-', '(2) Deterrents probably stopped you', '(5) Deterrents definitely did not stop you', '(3) Uncertain that deterrents stopped you', '(0) Does not apply', 'Reasons for Ideation', 'What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain', ""or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were"", 'feeling) or was it to get attention, revenge or a reaction from others? Or both?', '(1) Completely to get attention, revenge or a reaction from others', ""(4) Mostly to end or stop the pain (you couldn't go on"", '(2) Mostly to get attention, revenge or a reaction from others', 'living with the pain or how you were feeling)', '(3) Equally to get attention, revenge or a reaction from others', ""(5) Completely to end or stop the pain (you couldn't go on"", 'and to end/stop the pain', 'living with the pain or how you were feeling)', '(0) Does not apply', 'c 2008 Research Foundation for Mental Hygiene, Inc.', 'C-SSRS-Baseline/Screening (Version 1/14/09)', 'Page of 2', 'Page 94 of 109', 'Alexion Confidential']"
94,page_95,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 14: Columbia-Suicide Severity Rating Scale - Baseline/Screening (Continued)', 'SUICIDAL BEHAVIOR', 'Past', '(Check all that apply, so long as these are separate events; must ask about all types)', 'Lifetime', 'Years', 'Actual Attempt:', 'Yes', 'No', 'Yes', 'No', 'A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill', 'oneself. Intent does not have to be 100% If there is any intent/desire to die associated with the act, then it can be considered an actual suicide', 'attempt. There does not have to be any injury or harm, just the potential for injury or harm If person pulls trigger while gun is in', 'mouth but gun is broken so no injury results, this is considered an attempt.', 'Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances. For example,', 'a', 'highly lethal act that is clearly not an accident so no other intent but suicide can be inferred (e.g., gunshot to head, jumping from window', 'of', 'a', 'high floor/story). Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred', 'Have you made a suicide attempt?', 'Have you done anything to harm yourself?', 'Total # of', 'Total # of', 'Have you done anything dangerous where you could have died?', 'Attempts', 'Attempts', 'What did you do?', 'Did you', 'as a way to end your life?', 'Did you want to die (even a little) when you', '?', 'Were you trying to end your life when you', '?', 'Or Did you think it was possible you could have died from', ',', 'Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, feel better,', 'get sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)', 'If yes, describe:', 'Yes No', 'Yes', 'No', 'Has subject engaged in Non-Suicidal Self-Injurious Behavior?', 'Interrupted Attempt:', 'Y', 'Yes', 'No', 'Yes', 'No', 'When the person is interrupted (by an outside circumistance) from starting the potentially self-injurious act (if not for that, chual attempt would', 'have occurred).', 'Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt rather than an interrupted', 'attempt. Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger. Once', 'they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge.', 'Hanging: Person has noose around neck but has not yet started to hang is stopped from doing so.', 'Total # of', 'Total # of', 'Has there been a time when you started to do something to end your life but someone or something stopped you before', 'interrupted', 'interrupted', 'you actually did anything?', 'If yes, describe:', 'Aborted Attempt:', 'Yes', 'No', 'Yes', 'No', 'When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-', 'destructive behavior. Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by', 'something else.', 'Has there been a time when you started to do something to try to end your life but you stopped yourself before you', 'Total # of', 'Total # of', 'actually did anything?', 'aborted', 'aborted', 'If yes, describe:', 'Preparatory Acts or Behavior:', 'jo', 'Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought, such as', ""assembling a specific method (e.g., buying pills, purchasing a gm or preparing for one's death by suicide (e.g., giving things away, writing a"", 'Yes', 'No', 'Yes', 'No', 'suicide note).', 'Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills,', 'getting a gun, giving valuables away or wrining suicide note)?', 'If yes, describe:', 'Suicidal Behavior:', 'Yes', 'No', 'Yes', 'No', 'Suicidal behavior was present during the assessment period?', 'Answer for Actual Attempts Only', 'Most Recent', 'Most Lethal', 'Initial First', 'Attempt', 'Attempt', 'Attempt', 'Date:', 'Date:', 'Date:', 'Actual Lethality/Medical Damage:', 'Enter Code', 'Enter Code', 'Enter Code', '0. No physical damage or very minor physical damage (e.g., surface scratches).', '1. Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains).', '2. Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree', 'burns; bleeding of major vessel).', '3. Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes', 'intact; third-degree burns less than 20% of body, extensive blood loss but can recover, major fractures).', '4. Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree', 'burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area).', '5. Death', 'Potential Lethality: Only Answer if Actual Lethality=0', 'Enter Code', 'Enter Code', 'Enter Code', 'Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had', 'potential for very serious lethality: put gun in mouth and pulled the trigger but gum fails to fire so no medical damage; laying', 'on train tracks with oncoming train but pulled away before run over).', '0 = Behavior not likely to result in injury', '1 = Behavior likely to result in injury but not likely to cause death', '2 = Behavior likely to result in death despite available medical care', 'c 2008 Research Foundation for Mental Hygione, Inc', 'C-SSRS-Baseline/Screening (Version 1/14/09)', 'Page of 2', 'Page 95 of 109', 'Alexion Confidential']"
95,page_96,"['Protocol', 'ALXN1210-MG-30‚Ç¨ Amendment 2', '10.15.', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last', 'Visit (Version 1/14/09)', 'To be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Completed by:', 'Evaluator (initials):', 'COLUMBIA-SUICIDE SEVERITY', 'RATING SCALE', '(C-SSRS)', 'Since Last Visit', 'Version 1/14/09', 'Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.;', 'Burke, A.; Oquendo, M.; Mamu, J.', 'Disclaimer:', 'This scale is intended to be used by individuals who have received training in its administration. The questions contained in', 'the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of suicidal', 'ideation or behavior depends on the judgment of the individual administering the scale.', 'Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History Form,', 'developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders', '(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A.,', 'Halberstam B. & Mann J J, Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First', '[Ed.] Standardized Evaluation in Clinical Practice, pp. 103-130,2003.)', 'For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New', 'York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu', '¬© 2008 The Research Foundation for Mental Hygiene, Inc.', 'C-SSRS Since Last Visit United States/English - Mapl.', 'Page 96 of 109', 'Alexion Confidential']"
96,page_97,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last Visit (Continued)', 'SUICIDAL IDEATION', 'Ask questions 1 and 2. If both are negative, proceed to ""Suicidal Behavior"" section. If the answer to question 2 is ""yes"",', 'Since Last', 'ask questions 3, 4 and 5. If the answer to question 1 and/or 2 is ""yes"", complete ""Intensity of ""deation\' section below.', 'Visit', '1. Wish to be Dead', 'Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.', 'Yes', 'No', 'Have you wished you were dead or wished you could go to sleep and not wake up?', 'If yes, describe:', '2. Non-Specific Active Suicidal Thoughts', 'General, non-specific thoughts of wanting to end one\'s life/commit suicide (e.g., ""T\'ve thought about killing myself"" without thoughts of ways to kill', 'Yes', 'No', 'oneself/associated methods, intent, or plan during the assessment period', 'Have you actually had any thoughts of krilling yourself?', 'If yes, describe:', '3. Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act', 'Subject endorses thoughts of suicide and has thought of at least one method during the assessment period This is different than a specific plan with time,', 'Yes', 'No', 'place or method details worked out (e.g., thought of method to kill self but not a specific plan). Includes person who would say, ""I thought about taking an', 'overdose but 1 never made a specific plan as to when, where or how 1 would actually do it. and 1 would never go through with it.', 'Have you been thinking about how you might do this?', 'If yes, describe:', '4. Active Suicidal Ideation with Some Intent to Act, without Specific Plan', 'Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposedito Lhave the thoughts but I', 'Yes', 'No', 'definitely will not do anything about them.', 'Have you had these thoughts and had some intention of acting on them?', 'If yes, describe:', '5. Active Suicidal Ideation with Specific Plan and Intent', 'Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.', 'Yes', 'No', 'Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?', 'If yes, describe:', 'INTENSITY OF IDEATION', 'gott', 'The following features should be rated with respect to the most severe type of ideation (i.e., 1-5 from above, with 1 being the least severe', 'and 5 being the most severe).', 'Most', 'Most Severe Ideation:', 'Severe', 'Type # (1-5)', 'Description of Ideation', 'Frequency', 'How many times have you had these thoughts', '-', '(1) Less than once a week', 'Once a week (3) 2-5 times in week (4) Daily or almost daily (5) Many times each day', 'Duration', 'When you have the thoughts, how long do they last?', '(1) Fleeting few seconds or minites', '(4) 4-8 hours/most of day', '-', '(2) Less than 1 hour/some of the time', '(5) More than 8 hours/persistent or continuous', '(3) 1-4 hours/a lot of time', 'Controllability', 'Could/can you stop thinking about killing yourself or wanting to die if you want to?', '(1) Easily able to control thoughts', '(4) Can control thoughts with a lot of difficulty', '-', '(2) Can control thoughts with little difficulty', '(5) Unable to control thoughts', '(3) Can control thoughts with some difficulty', '(0) Does not attempt to control thoughts', 'Deterrents', 'Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on', 'thoughts of committing suicide?', '(1) Deterrents definitely stopped you from attempting suicide', '(4) Deterrents most likely did not stop you', '(2) Deterrents probably stopped you', '(5) Deterrents definitely did not stop you', '(3) Uncertain that deterrents stopped you', '(0) Does not apply', 'Reasons for Ideation', 'What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way', ""you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention,"", 'revenge or a reaction from others? Or both?', '(1) Completely to get attention, revenge or a reaction from others', ""(4) Mostly to end or stop the pain (you couldn't go on"", '(2) Mostly to get attention, revenge or a reaction from others', 'living with the pain or how you were feeling)', '(3) Equally to get attention, revenge or a reaction from others', ""(5) Completely to end or stop the pain (you couldn't go on"", 'and to end/stop the pain', 'living with the pain or how you were feeling)', '(0) Does not apply', 'c 2008 Research Foundation for Mental Hygione, Inc.', 'C-SSRS-Since Last Visit (Version 1/14/09)', 'Page of2', 'Page 97 of 109', 'Alexion Confidential']"
97,page_98,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last Visit (Continued)', 'SUICIDAL BEHAVIOR', 'Since Last', '(Check all that apply, so long as these are separate events; must ask about all types)', 'Visit', 'Actual Attempt:', 'A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill oneself Intent', 'Yes', 'No', 'does not have to be 100% If there is any intent/desire to die associated with the act, then it can be considered an actual suicide attempt. There does', 'not', 'have to be any injury or harm, just the potential for injury or harm If person pulls trigger while gun is in mouth but gun is broken so no injury results,', 'this is considered an attempt.', 'Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances. For example, a highly', 'lethal act that is clearly not an accident 50 no other intent but suicide can be inferred (e.g., gunshot to head, jumping from window of a high floor/story).', 'Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred', 'Have you made a suicide attempt?', 'Have you done anything to harm yourself?', 'Have you done anything dangerous where you could have died?', 'Total of', 'What did you do?', 'Attempts', 'Did you', 'as a way to end your life?', 'Did you want to die (even a little) when you', '?', 'Were you trying to end your life when you', '?', 'Or did you think it was possible you could have died from', '?', 'Or', 'did you do it purely for other reasons/without ANY intention of killing yourself (like to relieve stress, feel better, get', 'sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)', 'If yes, describe:', 'Yes', 'No', 'Has subject engaged in Non-Suicidal Self-Injurious Behavior?', 'Interrupted Attempt:', 'South', 'When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, actual attempt would have', 'Yes', 'No', 'occurred).', 'Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt rather than an interrupted attempt', 'Shooting Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger. Once they pull the trigger,', 'even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around', 'neck but has not yet started to hang is stopped from doing so.', 'Total of', 'Has there been a time when you started to do something to end your life but someone or something stopped you before you', 'interrupted', 'actually did anything?', 'If fyes, describe:', 'Aborted Attempt:', 'Yes', 'No', 'When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-destructive behavior.', 'Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by something else.', 'Has there been a time when you started to do something to (try to end your life but you stopped yourself before you', 'actually did anything?', 'Total of', 'If Tyes, describe:', 'your', 'aborted', 'Preparatory Acts or Behavior:', 'Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought, such as assembling a', 'Yes', 'No', 'specific method (e.g., buying pills, purchasing a gun) or ""preparing for one\'s death by suicide (e.g., giving things away, writing a suicide note).', 'Have you taken any steps towards making suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun,', 'giving valuables away or writing a suicide note)?', 'If yes, describe:', 'Suicidal Behavior:', 'Yes', 'No', 'Suicidal behavior was present during the assessment period?', 'Suicide:', 'Yes No', 'Answer for Actual Attempts Only', 'Most Lethal', 'Attempt', 'Date:', 'Actual Lethality/Medical Damage:', 'Enter Code', '0. No physical damage or very minor physical damage (e.g., surface scratches).', '1. Minor physical damage (eg., lethargic speech; first-degree burns; mild bleeding; sprains).', '2.', 'Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel).', '3. Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes intact; third-degree burns', 'less than 20% of body; extensive blood loss but can recover; major fractures).', '4. Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree burns over 20% of body;', 'extensive blood loss with unstable vital signs; major damage to a vital area).', '5. Death', 'Potential Lethality: Only Answer if Actual Lethality=0', 'Enter Code', 'Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had potential for very serious', 'lethality. put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with oncoming train but pulled away', 'before run over).', '0 = Behavior not likely to result in injury', '1 = Behavior likely to result in injury but not likely to cause death', '2 = Behavior likely to result in death despite available medical care', 'o 2008 Research Foundation for Mental Hygione, Inc.', 'C-SSRS-Since Last Visit (Version 1/14/09)', 'Page of 2', 'Page 98 of 109', 'Alexion Confidential']"
98,page_99,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.16.', 'Appendix 16: Statistical Considerations', '10.16.1. Additional Details on Sample Size Determination', 'The power calculations were based on the longitudinal change from baseline in MG-ADL total', 'score observed in REGAIN (Study ECU-MG-301). The treatment effect (difference between', 'the eculizumab and the placebo arms in mean change (95% CI) from baseline to Week 6 for', 'MG-ADL) was estimated to be - -1.9 (-3.27, -0.55) and the estimated common standard', 'deviation was 3.7. Based on these parameter estimates and the assumption that ALXN1210-', 'MG-306 study will provide similar results, a total of N = 160 patients is required to ensure at', 'least 90% power to reject the null hypothesis of no treatment effect for MG-ADL at the', 'Type I error rate = 5% (2-sided) based on a t-statistic for two independent samples. A', 'simulation-based approach was also adopted to independently verify the sample size calculation', 'in which a large number of virtual datasets were generated with a total of 160 patients', '(equally distributed between two arms) each having a longitudinal profile of change in MG-', 'ADL and baseline MG-ADL score generated according to the treatment-specific variance-', 'covariance structure obtained from REGAIN database. The empirical power was calculated', 'by the proportion of times these virtual trials rejected the null hypothesis based on the', 'MMRM model described above.', '10.16.2. Additional Details on Sensitivity Analysis for Primary Endpoint', 'To assess the credibility of the primary analysis, the following sensitivity analyses are planned,', 'based on assumptions that are unfavorable enough to the ravulizumab group to constitute a', 'convincing stress test of the primary analysis.', '10.16.2.1. Placebo-based Sensitivity Analysis', 'The placebo-based sensitivity analysis will consider the MNAR mechanism for the missing data,', 'where it will be assumed that patients who discontinue early from the ravulizumab group will', 'follow the trajectory of outcomes similar to the one in the placebo group after discontinuation of', 'ravulizumab, taking into account observed values prior to discontinuation (Little, 1996);', '(Ratitch, 2013). Patients discontinuing early from placebo will be assumed to have unobserved', 'outcomes similar to placebo patients who remain on their randomized treatment. The assumption', 'that the efficacy profiles of dropouts after discontinuation of ravulizumab are similar to those of', 'patients in the placebo group provides an estimand of efficacy attributable to patients in the', 'ravulizumab group if received through the time point of interest, while limiting efficacy after', 'early discontinuation to that of the placebo group.', '10.16.2.2. Tipping Point Sensitivity Analysis', 'An additional sensitivity analysis will be performed based on the delta-adjusted stress testing', 'method (tipping point analysis). This approach assumes that patients who discontinue from the', 'active treatment experience worsening defined by a prespecified adjustment (delta) in the', 'primary efficacy endpoint compared with the observed efficacy score of patients that continue', ""the study to next visit (O'Kelley, 2014). Since a negative change in QMG total score indicates"", 'improvement, the prespecified value of delta will be a non-negative fixed quantity. For each', 'value of delta, the treatment effect will be determined and the value of delta for which the', 'Page 99 of 109', 'Alexion Confidential']"
99,page_100,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'nominal 2-sided p-value crosses 0.05, will be considered as the ""tipping point\' in the sense that', 'the positive conclusion drawn from the primary analysis is reversed when patients who drop out', 'are assumed to experience this fixed worsening after the discontinuation visit. After such a', 'tipping point is determined, clinical judgment will be applied as to the plausibility of the', 'assumptions underlying this tipping point. This methodology is expected to inform of what it', 'would take to overturn study conclusions based on varying assumptions about missing data. A', 'value of delta as zero will be considered equivalent to the primary analysis.', 'Page 100 of 109', 'Alexion Confidential']"
100,page_101,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.17.', 'Appendix 17: Abbreviations', 'Table 11:', 'List of Abbreviations and Definitions of Terms', 'AChR', 'acetylcholine receptor', 'AChR Ab', 'acetylcholine receptor antibody', 'ADA', 'antidrug antibody', 'ADL', 'activities of daily living', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'aHUS', 'atypical hemolytic uremic syndrome', 'Alexion', 'Alexion Pharmaceuticals, Inc.; the Sponsor', 'AST', 'aspartate aminotransferase', 'AZA', 'azathioprine', 'BP', 'blood pressure', 'BUN', 'blood urea nitrogen', 'C5', 'complement component 5', 'C5b-9', 'terminal complement complex', 'CFR', 'Code of Federal Regulations', 'CIOMS', 'Council for International Organizations of Medical Sciences', 'CRF', 'case report form', 'CFR', 'Code of Federal Regulations', 'C-SSRS', 'Columbia Suicide Severity Rating Scale', 'CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events', 'CY', 'cyclophosphamide', 'CYC', 'cyclosporine', 'EC', 'Ethics Committee', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'EOS', 'End of Study', 'EQ-5D-5L', 'Euro Quality of Life', 'ET', 'Early Termination', 'EU', 'European Union', 'FDA', '(US) Food and Drug Administration', 'Page 101 of 109', 'Alexion Confidential']"
101,page_102,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 11:', 'List of Abbreviations and Definitions of Terms (Continued)', 'GCP', 'Good Clinical Practice', 'gMG', 'generalized myasthenia gravis', 'GPV', 'Global Pharmacovigilance', 'HIV', 'human immunodeficiency virus', 'IB', ""Investigator's Brochure"", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use', 'IEC', 'Independent Ethics Committee', 'IRB', 'Institutional Review Board', 'IRT', 'interactive response technology', 'IST', 'immunosuppressant therapy', 'IV', 'intravenous(ly)', 'IVIg', 'intravenous immunoglobulin', 'mAb', 'monoclonal antibody', 'MAC', 'membrane attack complex', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MG', 'myasthenia gravis', 'MG-ADL', 'Myasthenia Gravis Activities of Daily Living profile', 'MGC', 'Myasthenia Gravis Composite score', 'MGFA', 'Myasthenia Gravis Foundation of America', 'MGFA-PIS', 'Myasthenia Gravis Foundation of America Post-Intervention Status', 'MG-QoL15r', 'Revised Myasthenia Gravis Quality of Life 15-item scale', 'MM', 'minimal manifestation', 'MMF', 'mycophenolate mofetil', 'MMRM', 'Mixed-effects Model with Repeated Measures', 'MNAR', 'Missing Not At Random', 'MTX', 'methotrexate', 'N meningitidis', 'Neisseria meningitidis', 'NCI-CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events', 'Neuro-QOL', 'Neurological Quality of Life', 'NMJ', 'neuromuscular junction', 'Page 102 of 109', 'Alexion Confidential']"
102,page_103,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 11:', 'List of Abbreviations and Definitions of Terms (Continued)', 'OLE', 'Open-Label Extension', 'oMG', 'ocular myasthenia gravis', 'PD', 'pharmacodynamic(s)', 'PE', 'plasma exchange', 'PIS', 'post-intervention status', 'PP', 'plasmapheresis', 'PK', 'pharmacokinetic(s)', 'PNH', 'paroxysmal nocturnal hemoglobinuria', 'PPS', 'Per protocol set', 'Q2W', 'every 2 weeks', 'Q8W', 'every 8 weeks', 'QMG', 'Quantitative Myasthenia Gravis score for disease severity', 'QoL', 'quality of life', 'QT', 'interval between the start of the Q wave and the end of the T wave in', 'an ECG', 'QTc', 'corrected QT interval', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SC', 'subcutaneous', 'SO2', 'oxygen saturation', 'SoA', 'Schedule of Activities', 'SOC', 'system organ class', 'SUSAR', 'suspected unexpected serious adverse reaction', 'TAC', 'tacrolimus', 'TEAE', 'treatment-emergent adverse event', 'TESAE', 'treatment-emergent serious adverse event', 'Page 103 of 109', 'Alexion Confidential']"
103,page_104,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.18.', 'Appendix 18: Protocol Amendment History', 'Amendment 1 (11 Dec 2018)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment', 'To change duration of safety follow-up after last dose; add additional details on assessments,', 'align pregnancy and clinical laboratory testing frequency with infusions; change supplemental', 'dosing recommendations and sample collection when rescue therapy is provided; and update', 'adverse event and pregnancy/contraception language.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.1: Synopsis; Section 4.1:', 'Patients will be followed for safety for', 'A 24-week follow-up in', 'Overall Design; Section 7.1:', '8 weeks after last dose of study drug.', 'patients is not feasible as', 'Discontinuation of Study', 'safety data would likely be', 'Intervention; Section 8.3.1: Time', 'confounded by new', 'Period and Frequency for Collecting', 'treatments.', 'Adverse Event and SAE Information', 'To align with duration of', 'safety follow-up for other', 'ravulizumab programs.', 'Section 1.3: Schedule of Activities', 'Changed terminology of targeted', 'To align with terminology', 'physical examination to abbreviated', 'for physical examination.', 'physical examination throughout', 'protocol.', 'To ensure appropriate C-', 'Clarification that C-SSRS', 'SSRS versions are', 'Baseline/Screening Version assessment', 'administered.', 'will occur on Day 1 and C-SSRS Since', 'Last Visit Version assessment will', 'occur on subsequent indicated visits.', 'Added reference to section detailing', 'To precisely specify', 'assigned evaluator for assessment', 'appropriate evaluator for', 'instruments.', 'each assessment instrument.', 'Frequency of Clinical Lab Test and', 'To align with infusion visits', 'Pregnancy Test assessments reduced', 'and reduce burden on', 'and aligned with infusion visits.', 'patients.', 'Clarified PK/PD and ADA sample', 'To ensure PK/PD and ADA', 'collection should occur in the event of', 'analyses are performed', 'Clinical Deterioration.', 'consistently across events if', 'Clinical Deterioration occurs.', 'Section 4.2.2: Unscheduled Visits', 'Specified that efforts will be made to', 'To ensure data is associated', 'map unscheduled visit data with the', 'with the appropriate visit.', 'appropriate visit in the eCRF.', 'Section 4.2.3: Properly Trained', 'Removed EQ-5D-5L and MG-QOL15r', 'To clarify as these', 'Clinical Evaluator', 'from section as these instruments are', 'assessments are completed', 'completed by patients.', 'by patients.', 'Section 4.2.4: Responsibilities for', 'Removed EQ-5D-5L and MG-QOL15r', 'To clarify as assessments are', 'Myasthenia Gravis Assessments', 'from Myasthenia Gravis Assessments', 'completed by the patient.', 'and Responsibilities table.', 'Page 104 of 109', 'Alexion Confidential']"
104,page_105,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 6.1: Study Drugs', 'Updated Table 6 to indicate volumes', 'To ensure proper preparation', 'Administered', 'needed for ravulizumab, placebo, and', 'of placebo and ravulizumab', 'diluent.', 'doses.', 'Section 6.2.4: Accountability', 'Updated details for study drug', 'To ensure proper', 'accountability to reflect use of', 'accountability of study drug', 'interactive response technology (IRT)', 'while using IRT.', 'and study monitors.', 'Section 6.2.5: Handling and Disposal', 'Provided details for study drug handling', 'To provide additional details', 'and disposal.', 'on proper handling and', 'disposal of study drug.', 'Section 6.5.1.4: Plasma', 'Updated timing and dosing levels for', 'To ensure proper and', 'Exchange/Plasmapheresis/Intravenous', 'supplemental study drug administration', 'consistent dosing of', 'Immunoglobulin', 'when PE/PP or IVIg rescue therapy is', 'supplemental study drug', 'provided.', 'following PE/PP or IVIg.', 'Section 8.1.1: Hospitalization', 'Updated definition of hospitalization.', 'To ensure admission to', 'facility overnight is collected', 'as hospitalization.', 'Section 8.1.2: Clinical Deterioration', 'Section 10.2 (Appendix 2) referenced in', 'To align with Section 10.2', 'clinical laboratory tests.', '(Appendix 2): Clinical', 'laboratory tests.', 'MG Crisis or Clinical Deterioration', 'Visit changed to Clinical Deterioration', 'To provide consistency with', 'Visit.', 'Clinical Deterioration', 'criteria.', 'Section 8.2.5.1: Columbia-Suicidal', 'Updated to detail the C-SSRS will be', 'To align with other sections', 'Severity Rating Scale', 'administered by the Investigator or a', 'of the protocol indicating the', 'properly trained designee.', 'Investigator or a properly', 'trained designee will', 'administer the assessment.', 'Section 8.3.1: Time Period and', 'Updated language on submission of', 'To align with current', 'Frequency for Collecting Adverse', 'SAE data.', 'practices.', 'Event and SAE Information', 'Section 8.3.4: Regulatory Reporting', 'Added language on reporting of', 'To align with regulatory', 'Requirements for Serious Adverse', 'SUSARs.', 'feedback on ravulizumab', 'Events', 'program.', 'Section 8.3.5: Pregnancy; Section 1.3:', 'Updated to indicate that serum', 'To align with Table 1 and', 'Schedule of Activities', 'pregnancy testing will occur at', 'Table 2 of Schedule of', 'Screening and at the End of Study.', 'Activities.', 'Section 10.2 (Appendix 2): Clinical', 'Added serum follicle stimulating', 'To fix inconsistencies', 'Laboratory Tests', 'hormone and urine creatinine testing.', 'between protocol sections', 'Removed D-dimer and free hemoglobin', 'and remove D-dimer and free', 'testing.', 'hemoglobin assessment.', 'Section 10.3.4 (Appendix 3):', 'Updated to clarify that the expectedness', 'To ensure Reference Safety', 'Recording and Follow-Up of Adverse', 'and reporting criteria of an SAE will be', 'Document is used when', 'Event and/or Serious Adverse Event', 'based on the Reference Safety', 'recording an AE.', 'Document.', 'Section 10.4.1 (Appendix 4):', 'Updated to indicate that male patients', 'To align with current', 'Contraception Guidance', 'must not donate sperm and female', 'Alexion language.', 'patients must not donate ova while on', 'treatment and for at least 8 months after', 'the last dose of study drug.', 'Section 10.4.3 (Appendix 4):', 'Updated language on collection and', 'To align with current', 'Collection and Reporting of', 'reporting of pregnancy information.', 'Alexion language.', 'Pregnancy Information', 'Page 105 of 109', 'Alexion Confidential']"
105,page_106,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.5 (Appendix 5):', 'Updated to indicate CTCAE v5.0 or', 'To align with proper CTCAE', 'Management of Potential Infusion-', 'higher will be used to grade an infusion-', 'version planned for use.', 'Associated Adverse Events During', 'related response.', 'Study Drug Administration', 'Throughout', 'Minor editorial and document', 'As these changes are minor,', 'formatting revisions have been made', 'they have not been', 'throughout the document.', 'summarized.', 'Abbreviations: ADA = antidrug antibody; AE = adverse event; C-SSRS = Columbia Suicide Severity Rating Scale;', 'CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; eCRF = electronic case', 'report file; EQ-5D-5L = Euro Quality of Life; IRT = interactive response technology; IVIg = intravenous', 'immunoglobulin; MG = myasthenia gravis; MG-QoL15r = Revised Myasthenia Gravis Quality of Life 15-item', 'scale; PD = pharmacodynamic; PE = plasma exchange; PK = pharmacokinetic; PP = plasmapheresis; SAE = serious', 'adverse event; SUSAR = suspected unexpected serious adverse reaction', 'Page 106 of 109', 'Alexion Confidential']"
106,page_107,"['Protocol', 'ALXN1210-MG-306 Amendment 2', '11.', 'REFERENCES', 'Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials.', 'Muscle Nerve. 2012;45(6):909-917.', 'Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53-72.', 'Burns TM, Conaway M, Sanders DB. The MG Composite: A valid and reliable outcome', 'measure for myasthenia gravis. Neurology. 2010;74(18): 1434-1440.', 'Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-', 'QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle &', 'Nerve. 2016;54(6):1015-1022.', 'Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in', 'patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.', 'Cella D. Measuring Quality of Life in Neurological Disorders; Final Report of the Neuro-QOL', 'Study September 2010. 2010 2010. Report No.', 'Cetin H, Fulop G, Zach H, Auff E, Zimprich F. Epidemiology of myasthenia gravis in Austria:', 'rising prevalence in an ageing society. Wien Klin Wochenschr. 2012;124(21-22):763-768.', 'Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn:', 'distinct from the FcRn-IgG interaction. Biochemistry. 2006;45(15):4983-4990', 'Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a', 'Danish population based study. Journal of Neurology, Neurosurgery &amp; Psychiatry.', '1998;64(1):78-8', 'Dalakas MC. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA.', '2004;291:2367-2375.', 'Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients', 'with treatment refractory myasthenia gravis. Muscle & Nerve. 2018;58(1):99-105.', 'Fang F, Sveinsson O, Thormar G, et al. The autoimmune spectrum of myasthenia gravis: a', 'Swedish population-based study. Journal of internal medicine. 2015;277(5):594-604', 'Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant,', 'humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary', 'artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100(25):2499-2506', 'Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical', 'trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst.', '2011;16(2):84-91.', 'Page 107 of 109', 'Alexion Confidential']"
107,page_108,"['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Ha JC, Richman DP. Myasthenia gravis and related disorders: Pathology and molecular', 'pathogenesis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.', '2015;1852(4):651-657.', 'Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide', 'epidemiologic study. Neurology. 2009;73(2):150-151.', ""Howard JF, Freimer M, O'Brien F, Wang JJ, Collins SR, Kissel JT. QMG and MG-ADL"", 'correlations: Study of eculizumab treatment of myasthenia gravis. Muscle & Nerve.', '2017;56(2):328-330.', 'Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared', 'to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research.', '2013;22(7):1717-1727.', 'Keshavjee S, Davis RD, Zamora MR, de PM, Patterson GA. A randomized, placebo-controlled', 'trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human', 'beings. J Thorac Cardiovasc Surg. 2005;129(2):423-428.', 'Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis', 'pathogenesis. Expert Rev Clin Immunol. 2008;4(1):43-52', 'Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to', 'thrombopoietin. Blood. 2001;98(12):3241-3248.', 'Little R, Yau L. Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs. Biometrics.', '1996;52(4): 1324-1333.', ""O'Kelley M RB. Clinical trials with missing data: a guide for practitioners. Statistics in Practice."", 'Statistics in Practice. 1 ed. Chichester, West Sussex, UK: John Wiley & Sons, Ltd; 2014. p. 257-', '368.', 'Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.', 'Drugs Today (Barc ). 2005;41(3):165-170.', 'Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial', 'validity and internal consistency findings from three multisite studies with adolescents and', 'adults. Am J Psychiatry. 2011;168(12):1266-1277.', ""Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to"", 'statistical analysis using pattern mixture models. Pharmaceutical Statistics. 2013;12(6):337-347.', 'Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of', 'immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia', 'gravis. J Neuropathol Exp Neurol. 1978;37(2):212-223.', 'Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and', 'management of anaphylaxis: summary report--Second National Institute of Allergy and', 'Page 108 of 109', 'Alexion Confidential']"
108,page_109,"['Protocol', 'ALXN1210-MG-30 Amendment 2', 'Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol.', '2006;117(2):391-397.', 'Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis.', '2014;15(4):167-178.', 'Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients.', 'Yale J Biol Med. 2013;86(2):255-260.', 'Page 109 of 109', 'Alexion Confidential']"
